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Abstract 
 
Inhaled medication is standard therapy in asthma and COPD. However the 
amount of drug reaching the lung is influenced by several factors including aerosol 
particle size and upper airway morphology. While smaller sized aerosol particles may 
be transported to the small airways there is still a need to examine the systemic risk and 
efficacy associated with small particle aerosols. On one hand small particles can be 
transported to the lung periphery (small airways) where they can reduce small airways 
dysfunction. On the other hand small particles can increase plasma concentrations of 
the drug worsening systemic side effects. Aerosol particle size determines deposition 
throughout the whole of the respiratory tract including the upper airway and by altering 
aerosol delivery characteristics it is possible to avoid deposition in the upper airway. 
This thesis set out to investigate how to improve drug deposition in the lung by 
controlling aerosol delivery characteristics mainly particle size and flow rate and 
investigate how the filtering effects of the upper airway can be overcome.  
The specific aims of this thesis were: 
 To quantify aerosol deposition in the upper airway both in vitro and in vivo with 
the hope of using in vitro techniques to predict what happens in vivo.  
 Explore how aerosol particle size effects lung deposition and pulmonary 
bioavailability through pharmacokinetics.  
 Investigate and evaluate novel tests of small and large airways function and see 
if these can detect physiological improvement following inhalation of small (1.5 
µm) particles and large (6 µm) particles.   
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In vitro tests on upper airway models somewhat predicted what happens in vivo. The 
increasing effect of both particle size and flow rate was shown to increase upper 
airway deposition. Tests of respiratory function and inflammation demonstrated 
greater between test variability than routine tests of lung function and warrant further 
evaluation. Improvements in small and large airway function were not associated 
with the deposition of small and large aerosol particles following one off dosing of an 
inhaled corticosteroid fluticasone propionate and a link between these tests and 
aerosol particle size warrants further investigation. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Factors affecting aerosol particle deposition in the lungs  
An aerosol is a suspension of solid particles or liquid droplets in air (Newman 
and Clarke, 1983). The term ‘deposition’ refers to the mean probability of an inspired 
particle being deposited in the respiratory tract by collection on airway surfaces 
(Heyder et al, 1986). Drug particle size is the primary physical factor governing the 
site of deposition of the inhaled medication (Dolovich, 2000). The transport of 
particles onto airway surfaces is governed by inertial impaction, gravitational 
sedimentation and Brownian diffusion (Heyder et al, 1986). These are the main 
physical processes governing the deposition of inhaled drug particles (Biddiscombe 
et al, 2003). Inertial impaction affects larger particles when the transporting airstream 
is fast, changing in direction, or turbulent as in the oropharynx and bifurcations 
between airway generations. Inertial deposition occurs predominantly in the nose, 
mouth, pharynx, larynx and large conducting airways (> 2 mm in diameter). The 
cross sectional area of these regions is small and the flow of air is high. The total 
cross sectional area of the peripheral airways is large and the flow is low. 
Gravitational sedimentation is a time dependent process where aerosol particles 
settle under the effect of gravity during tidal breathing and breath-holding. It occurs 
mainly in the peripheral airways (≤ 2 mm in diameter) and alveoli. The low flows in 
peripheral airways allow time for small particles to sediment and large particles rarely 
reach this region (Newman and Clarke, 1983). Brownian diffusion is of less 
relevance for therapeutic aerosols in the micron size range.     
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Figure 1.1: Physical processes that determine aerosol drug deposition throughout respiratory tract  
 
Aerosol particle size is usually described by its mass median aerodynamic 
diameter (MMAD). Half of the aerosol mass is contained in particles smaller and half 
of the aerosol mass in particles larger than the MMAD. Particles of 1 - 8 µm may be 
deposited by impaction and sedimentation in large and small airways and alveoli 
while particles <1 µm may not be deposited but exhaled like an insoluble gas 
(Newman and Clarke, 1983). The respirable portion of the aerosol dose is contained 
within particles between 2 to 6 µm which is considered the ideal size range for 
inhalation throughout the airways (Biddiscombe et al, 2003; Usmani et al, 2005). As 
the MMAD becomes > 2 µm aerosol deposition in the oropharynx and large 
conducting airways increases and less aerosol is exhaled or reaches the lung 
periphery (Foord et al, 1978; Lippmann and Albert, 1969). Most aerosol particles 
greater than 8 µm in diameter will impact above the level of the larynx and will not 
reach the lung (Swift, 1980). The dominant process for deposition in the upper 
airways (mouth and throat) has been cited as inertial impaction (Rudolf et al, 1990; 
Stahlhofen et al, 1989; Yu et al, 1981). Aerosol deposition in this region is highly 
affected by inter-subject and to a lesser extent intra-subject geometric configuration 
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(Grgic et al, 2004). In vitro studies to determine extra-thoracic aerosol deposition use 
realistic models developed from medical imaging performed in patients. In vitro 
studies allow for more detailed analysis by introducing greater control over relevant 
variables (Zhang et al, 2007) such as breathing patterns and inter-subject variability 
associated with morphological factors (Heyder et al, 1975). Several factors affect 
aerosol deposition in the upper airway (Finlay, 2001) including properties of the 
aerosol material (DeHaan and Finlay, 2001) generation times of the sprayed aerosol 
(Longest et al, 2009) and electrostatic charge forces of particles (Ali et al, 2009). 
Factors affecting the location of aerosol deposition and are summarized in table 1.1 
(below).  
 
Table 1.1: Overview of factors affecting therapeutic aerosol deposition in the lung  
Mode of inhalation Aerosol characteristics Subject characteristics 
Inspiratory flow Particle size Gender 
Inspiratory volume Particle shape Upper airway morphology 
Breath-hold at end inspiration Particle density Intra-thoracic airway morphology 
Tidal breathing Hygroscopic / hydrophobic Airway obstruction 
Starting lung volume Electrical charge Disease 
 Inertial impaction Mechanisms of mucociliary clearance 
 Gravitational sedimentation  
 Brownian diffusion  
 Humidity  
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1.2 Obstructive lung disease  
Obstructive lung disease is defined by airflow limitation that results from 
airway obstruction and includes asthma and chronic obstructive pulmonary disease 
(COPD).  
 
1.2.1 Asthma 
The Global Initiative for Asthma (GINA) (2015) defines asthma as a chronic 
inflammatory disorder of the airways in which many cells and cellular elements play 
a role. This chronic inflammation is associated with airway hyperresponsiveness that 
leads to recurrent episodes of wheezing, breathlessness, chest tightness, and 
coughing, particularly at night or in the early morning. These episodes are usually 
associated with widespread, but variable, airflow obstruction within the lung that is 
often reversible either spontaneously or with treatment.  
 
In asthma, several pathological changes occur. Smooth muscle mass and 
airway wall thickening increase in both the large and small airways. Mucous 
metaplasia occurs in the large and small airways and there is hypertrophy of 
submucosal glands. There is an increase in cellular infiltrate (CD3
+, CD4
+, 
eosinophils, and mast cells) and cytokine expression (Th2 profile- IL-4, IL-5, IL-13, 
and RANTES (Regulated on Activation Normal T Cell Expressed and Secreted)). 
The airway epithelium becomes fragile and denuded while the subepithelial 
basement membrane thickens. There is increased large airway wall vascularity and 
diffuse excess matrix deposition within this region. Post mortem studies have 
revealed hyperinflation, airway plugs, with little or no emphysema.  
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There are many risk factors for the development of asthma which include 
early life sensitization to aeroallergens, presence of atopic dermatitis or allergic 
rhinitis, maternal smoking during pregnancy, children's environmental exposure to 
tobacco smoke, lower respiratory tract infections, and exposure to air pollutants 
(Arruda et al, 2005). Asthma often presents at a young age as recurrent episodes of 
airflow limitation (of varying frequency and intensity) which becomes recognized as a 
chronic pattern of reversible airflow limitation (Braman et al, 1991). The reversal of 
airflow limitation can be minimal or halted in some patients due to airway remodeling. 
Symptoms typically increase with exposure to allergens and triggers, such as viral 
upper respiratory infections, pollen, dust mites, animal dander, environmental 
irritants (most commonly tobacco smoke), cold air, and physical exertion (GINA, 
2015).  
 
In the UK, 5.4 million people are currently receiving treatment for asthma 
which equates to 1 in every 12 adults and 1 in every 11 children (NHS, UK). Asthma 
in adults is more common in women than men (NHS, UK). The severity of the 
disease is graded as either intermittent, mild persistent, moderate persistent or 
severe persistent depending on day time symptoms, night time symptoms, and lung 
function peak expiratory flow (PEF) and forced expiratory volume in one second 
(FEV1). Asthma severity classification also involves the severity of the underlying 
disease and its responsiveness to treatment (Bousquet et al, 2007).  
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1.2.2 COPD 
COPD is a complex multifaceted disease characterized by airway and 
systemic inflammation, progressive airflow limitation, oxidative stress, skeletal 
muscle dysfunction, cardiovascular disease, and exacerbations. COPD 
encompasses pathological changes in four lung compartments (large and small 
airways, parenchyma, and pulmonary vasculature). These changes are variably 
present in individuals with this disease (O’Shaughnessy et al, 1997; Peinado et al, 
1999; Rennard, 1999; Rodriguez-Roisin and MacNee, 1998; Saetta et al, 1998).  
 
Smooth muscle mass and airway wall thickening increase in larger and small 
airways. Mucous metaplasia occurs in the large and small airways and there is 
hypertrophy of the submucosal glands (increased mucous to serous acini ratio). 
There is an increase in cellular infiltrate (CD3+, CD8+, neutrophils, and 
macrophages) and cytokine expression (TNF-α, IL-8 and LTB4). Large airway wall 
vascularity is not known to change and there is diffuse excess matrix deposition 
within the smaller airways. In contrast to asthma, in COPD most of the pathologic 
changes are found in smaller airways, where there is also fibrosis, resulting in 
obliterative bronchiolitis (Barnes, 2000).  
 
COPD typically presents itself in late adulthood (Foreman et al, 2011) and 
cigarette smoking is the primary cause of COPD in the UK (Meldrum et al, 2005). 
However at-risk factors may also be involved such as environmental air pollution and 
respiratory infections (Chung, 2006). The symptoms of COPD include progressive 
dyspnea, chronic cough, and sputum production. The symptoms result in significant 
morbidity and deterioration in the quality of life of this disease group (Ferrer et al, 
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1997; Seemungal et al, 1998). As of 2000, the prevalence rates of COPD in the UK 
seemed to have peaked in men but were continuing to rise in women (Soriano et al 
2000).  
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2015) 
aims to raise awareness of and improve prevention and treatment of COPD. The 
GOLD guidelines (2015) are an international collaborative evidence based guideline 
for COPD diagnosis and management. In their description of levels of evidence there 
are four categories (A,B,C and D).  Categories A and B include sources of evidence 
from randomized controlled trials from rich and limited bodies of data respectively. 
Categories C and D include sources of evidence from nonrandomized and 
observational studies and a panel consensus judgement respectively.  
 
The categorization of COPD severity described by GOLD is based on the 
individual’s symptoms and the degree of airflow limitation as measured by FEV1 and 
the forced vital capacity (FVC) (Chung, 2006). There are four described stages 
including: mild (Stage 1, FEV1 / FVC <70%, FEV1 >80% predicted), moderate (Stage 
II, 50%< FEV1 <80% predicted), severe (Stage III, 30%< FEV1 <50% predicted), and 
very severe (Stage IV, <30% predicted).  
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2015) 
states that COPD is a preventable and treatable disease. However unlike asthma, 
airflow limitation is progressive and only partially reversible. This progressive decline 
in airflow limitation is variable in the response to inhaled therapy.  
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1.3 Inhaled therapy in asthma and COPD 
The inhaled route is the logical means of treating respiratory disease because 
drugs are delivered directly to the lungs. The development of new therapeutic drugs 
and delivery devices has come a long way since the first commercially available 
products. The advantage of targeting specific drugs for particular diseases is well 
recognized. Inhaled aerosolized drugs have a quicker onset of action and smaller 
doses can be used to minimize the systemic side effects associated with larger oral 
or intravenous doses.  
 
1.3.1 Bronchodilators 
The main bronchodilators includes; β2-adrenoceptor agonists, inhaled 
muscarinic antagonists and theophylline. 
 
1.3.1.1 β2-adrenoceptor agonists 
Pharmacodynamically, β2-agonists work on β2-adrenergic receptors which are 
G-protein-coupled receptors. The β2-adrenergic receptor is a large molecule of 413 
amino acids (Opt’ Holt, 2007). These receptors are expressed in airway smooth 
muscle, epithelial cells, endothelial cells, type II pneumocytes and mast cells 
(Johnson, 2006). The β2-adrenergic receptors are found in increasing density with 
increasing airway generations towards the alveoli (Johnson, 1998). This is where β2-
agonists should be deposited to achieve effective bronchodilation (Ebina et al, 1990). 
β2-adrenoceptors are also widely expressed on resident and structural cells of the 
lung and on the leukocytes that traffic through the lung (Carstairs et al, 1985; Mak et 
al, 1996).  
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These drugs induce bronchodilation by causing extended relaxation of airway 
smooth muscle (Johnson and Rennard, 2001) by β2-adrenoceptor mediated 
activation of adenylate cyclase which increases the concentration of intracellular 
cyclic adenosine monophosphate (Bartolome, 2008; Lulich et al, 1988). This cyclic 
nucleotide increases protein kinase A activation, which phosphorylates downstream 
protein modulators (Giembycz and Raeburn, 1991). Protein kinase A 
phosphorylation targets include myosin light chain kinase and myosin light chain 
(MLC) phosphatase (Yang et al, 2007). Protein kinase A phosphorylation of these 
enzymes has been suggested to reduce MLC activity and relax muscle tone 
(Giembycz and Newton, 2006). The activation of this signal transduction pathway 
can result in inhibition of phosphoinositol hydrolysis, reduced intracellular calcium, 
and activation of large conductance potassium channels in which the latter is 
important for the bronchodilation response (Jones et al, 1990).  
 
Other benefits of β2-agonists include mast cell stabilization (Barnes, 1998), 
reduced extravasation of proteins in the airways (Broadley, 2006) and improvement 
of mucociliary dysfunction by increasing mucus clearance (Agusti, 2005).  
 
1.3.1.2 Inhaled muscarinic antagonists 
Inhaled muscarinic receptor antagonists work by inhibiting muscarinic 
acetylcholine receptors on the bronchial airways, which lead to muscle relaxation, 
bronchodilation and improved lung function. The therapeutic efficacy is derived from 
the reversal of vagally mediated bronchoconstriction, by blocking muscarinic 
receptors on airway smooth muscle, which is an important reversible component of 
airflow obstruction in patients with COPD.  In general, the anticholinergic drugs are 
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not as efficacious compared to the β2-agonists as bronchodilator agents. Anti-
cholinergics prevent the cholinergic reflex component of bronchoconstriction, 
whereas in contrast, β2-agonists inhibit all bronchoconstrictor mechanisms. Hence, 
anticholinergics tend only to be used as add-on bronchodilator treatment in 
asthmatics that remain uncontrolled on other inhaled therapy. 
 
1.3.2 Corticosteroids  
Corticosteroids belong to the family of 21-carbon steroid nuclear hormones 
(Adelroth et al, 1990). Corticosteroids are able to freely diffuse from the circulation 
across the cell membrane to initiate their pharmacological effects. These effects are 
mediated via reversible binding to type II glucocorticoid receptors that are localized 
to the cytoplasm. Glucocorticoid receptors are widely distributed within the human 
lung with the greatest levels of expression in airway epithelial cells and bronchial 
vascular endothelial cells (Adcock et al, 1996). The binding of the corticosteroid to 
the glucocorticoid receptor causes a conformational change in the receptor and loss 
of its chaperone proteins and its nuclear localization (Chung et al, 2009). A drug 
receptor complex is formed which regulates directly or indirectly the transcription of 
certain genes (Barnes, 1998). The stimulation of gene transcription (transactivation) 
correlates with several negative side effects whereas repression of transcription 
factors (transrepression) results in positive anti-inflammatory effects (Schacke et al, 
2004). The positive effects of corticosteroids include the reduction in the expression 
of inflammatory cytokines, their receptors, adhesion molecules and other disease-
inducing mediators (Dirkje et al, 2008) which are activated by pro-inflammatory 
transcription factors such as nuclear factor KB and activator protein 1 (Barnes et al, 
2004).  
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Inhaled corticosteroids (ICS’s) also suppress the pro-inflammatory activity of 
airway epithelial and smooth muscle cells (Barnes, 1996). The goal of ICS’s is to 
produce long-lasting therapeutic effects at the site of action while minimizing the oral 
bioavailability and systemic side effects by rapid clearance of absorbed drug 
(Winkler et al, 2004).  
 
1.4 Bronchodilators and corticosteroids in asthma and COPD 
Bronchial inflammation in asthma was first recognized in the 1980’s 
(Bousquet et al, 1990; Drazen et al, 1987; Kirby et al, 1987). Current guidelines 
recommend ICS’s as the first line control medication in the treatment of asthma. This 
is because they are the most efficacious mono-therapy currently available for optimal 
asthma management and this has been demonstrated by both short- and long- term 
studies (Postma et al, 2008). ICS’s control symptoms, improve hyperresponsiveness 
and lung function, reduce the number of exacerbations and improve health status in 
most patients irrespective of the severity of their disease (Barnes 2006). Despite 
their benefits, the majority of patients with asthma still need β2-agonists for symptom 
relief and control. The use of long acting β2-agonists (LABA’s) in asthma started in 
the 1990’s with the expectation of increased compliance and a decline in mortality 
and morbidity (Erdinç, 2011).  
 
Acute symptoms respond rapidly to bronchodilators and a stepwise approach 
to asthma management is recommended according to symptom severity and control 
(British Thoracic Society, Scottish Intercollegiate Guidelines Network, 2008). There 
is sufficient evidence to suggest that asthmatic patients treated with a single inhaler 
containing an ICS plus a LABA experience fewer asthmatic exacerbations than 
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similar patients treated with ICS’s alone (Hirst et al, 2010). Combination therapy has 
been found to be the most effective treatment for asthma (Bateman et al, 2004; 
Bjermer et al, 2003; Greening et al, 1994).  
 
The harmful effects of LABA’s in patients with asthma have previously been 
investigated. This includes severe asthma exacerbations requiring hospitalization, 
life-threatening exacerbations requiring intubations and asthma-related death 
(Martinez, 2005). 
 
COPD is treated primarily with bronchodilator therapy even though airflow 
limitation is largely irreversible due to fixed structural damage in the lungs (Agusti, 
2005). Commonly used bronchodilator drugs other than β2-agonists include 
anticholinergics and methylxanthines (Barnes, 2000; Ferguson, 2000). Inhaled 
muscarinic antagonists are frequently used bronchodilators for COPD and are also 
licensed for asthma. The main goals of bronchodilator drugs in COPD are to prevent 
exacerbation, achieve symptom relief, improve pulmonary function and, in the long 
term, enhance the quality of life (Çelik et al, 1998).  
 
However, bronchodilators are effective only on the reversible component of 
airflow obstruction, which is limited in COPD by definition. Antimuscarinic drugs 
approved for the treatment of COPD include ipratropium bromide, oxitropium 
bromide and tiotropium bromide. A number of Long-Acting Muscarinic Antagonists 
(LAMAs) are being developed as mono- or combination therapy with existing or 
novel β2-agonists for the treatment of COPD (Cazzola and Page, 2013).  
Monotherapy with bronchodilators (LABA or LAMA) are first line therapy in the GOLD 
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guidelines (2009). According to the current GOLD (2015) guidelines bronchodilators 
should be used in preference to LABA and ICS combinations.  
 
Tiotropium (Spiriva, Boehringer Ingelheim), a long-acting inhaled 
anticholinergic bronchodilator, improves lung function, quality of life, and exercise 
endurance and reduces exacerbations in patients with COPD (Bateman et al, 2010; 
Cooper et al, 2013;  Tashkin et al, 2008; Vogelmeier et al, 2011). Tiotropium is 
approved and marketed as a dry-powder formulation delivered by means of the 
HandiHaler® inhalation device (18  μg) and as an aqueous solution delivered by 
means of the Respimat inhaler (at a dose of 5 μg) in many countries.  
 
ICS therapy was introduced for the treatment of COPD after asthma although 
its effectiveness is less evident than its effect in asthma (Chung et al, 2009). The use 
of ICS’s as mono-therapy is not recommended (Park et al, 2012) as they do not 
effectively relieve dyspnea or improve lung function compared to LABA’s. Clinical 
guidelines recommend the use of ICS’s as add-on therapy to long-acting 
bronchodilators in symptomatic patients with severe airflow limitation (defined as an 
FEV1 <50% predicted) or with two or more exacerbations a year irrespective of FEV1 
value (GOLD, 2009).  
 
1.5 Orally administered therapies  
Despite the predominance of inhaled therapies for the treatment of asthma 
and COPD it is important to mention orally administered drugs which can benefit 
some selected patients as an add-on therapy to their main treatment. 
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1.5.1 Theophylline 
Oral theophylline was mainly used as an add-on therapy to bronchodilator 
treatment, but due to its narrow therapeutic index and adverse effect profile, together 
with the availability of safer and more effective alternatives, theophylline is now 
infrequently used in patients with asthma.  Theophylline inhibits phosphodiesterases 
in airway smooth muscle cells, which increases intracellular cyclic AMP and this 
leads to a bronchodilator effect. However, the doses required for bronchodilator 
activity commonly cause adverse effects, which are mainly a consequence of direct 
phosphodiesterase inhibition. Theophylline is normally administered as an oral slow-
release formulation either once or twice a day which results in steady plasma 
concentrations.  
 
1.5.2 Anti-leukotrienes 
Leukotriene pathway inhibitors are a group of compounds that alter the 
pathophysiologic effects of leukotrienes derived from the 5-lipoxygenation of 
arachidonic acid. Two classes of agents are available: inhibitors of the 5-
lipoxygenase enzyme (zileuton) and cysteinyl-leukotriene receptor type-1 
antagonists (montelukast, zafirlukast and pranlukast) (Polosa, 2007). These agents 
predominantly act on the inflammatory mediators produced by mast cells in asthma, 
and also to a lesser extent on mediators produced by eosinophils.  Anti-leukotriene 
treatments may be useful as add-on therapy in selected mild asthmatic patients on 
low-dose ICS, although they  are less efficacious than add-on therapy with LABA.  
They are usually given orally once or twice a day. 
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1.6 Inhaled therapeutic aerosol deposition 
Several commercially available inhaler devices exist for the delivery of 
bronchodilators and corticosteroids. These include pressurized metered dose 
inhalers (pMDI’s), dry powder inhalers (DPI’s), soft mist inhalers (SMI’s) and 
nebulizers. Metered dose aerosols are formulated as either suspensions of fine drug 
crystals or as drug solutions mixed with propellants. These propellants have a high 
vapor pressure and once the device is actuated a dose is released with rapid, initial 
vaporization of the propellant and the drug is inhaled. Dry powder inhalers are a 
convenient alternative delivery system to pMDI's. Several DPI designs have been 
developed where the drug is stored either in a capsule, a dosing disk, a blister or a 
drug reservoir prior to delivery, but all depend on the inspiratory effort of the patient 
to lift the powder into the inhaled airstream. Some devices, such as the Rotahaler® 
(GlaxoSmithKline, UK) and the  Cyclohaler® / Aerolizer® (ISF, Italy; Novartis, 
Switzerland), are known as single dose systems where a  capsule is placed within 
the device then rapid inhalation disperses the powder into the inhaled airstream. 
Other devices, such as the DiskusTM / AccuhalerTM (GlaxoSmithKline, UK), use a 
long foil strip containing multiple doses of drug enclosed within blisters. The 
Turbuhaler® (AstraZeneca, Sweden) is a multi-dose device that contains a reservoir 
of drug from which metered doses are inhaled. Soft mist inhalers such as Respimat® 
(Boehringer Ingelheim) do  not contain propellants or powder. Instead a metered 
dose of drug solution is forced through precisely engineered nozzles producing fine 
jets of liquid that collide to  generate a soft mist.  Nebulizers use either compressed 
gas flow or ultrasonic vibrations to generate the aerosols from drug solution. 
Nebulizers can be used with a mouthpiece or face-mask and require minimal patient 
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effort and coordination. All of these delivery devices produce polydisperse aerosols 
generating particles over a wide size range.  
 
Published clinical studies in patients using two-dimensional gamma-
scintigraphy have consistently shown reduced lung deposition of radiolabelled 
therapeutic aerosols (figures 1.2 and 1.3). This is because the aerosols used in 
these studies were polydisperse aerosols containing a wide range of particle sizes. 
These studies involved the in-direct radiolabelling of aerosol drug formulations with 
the short-lived gamma-emitting radionuclide technetium-99m pertechnetate (99TcO4
-
). Validation tests were performed on the aerosol particle size distribution before and 
after radiolabelling to demonstrate that the radionuclide had no effect on size 
distribution. The results from these studies demonstrated that the amount of ex-
actuated dose of corticosteroid that reached the lungs ranged from 11.2% (Newman 
et al, 2000) for beclomethasone (pMDI and volumatic chamber) to 62.8% (Sebti et al, 
2006) for budesonide (DPI). The dose that impacted on the extra-thoracic airway 
which is referred to in the literature as the oropharynx and includes the mouth, 
throat, esophageal, and stomach ranged from 4.2% (Newman et al, 2001) for 
beclomethasone (pMDI and volumatic chamber) to 71.9% (Newman et al, 2000) for 
budesonide (DPI). The dose that didn’t enter the respiratory tract (waste) ranged 
from 7% to 84% (Newman et al, 2001).  
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Similiarly, for β2-agonists, the ex-actuator dose that reached the lungs ranged 
from 28.3% to 64.1% (Bhavna et al, 2009) for micronized and nano-particle 
salbutamol sulphate (DPI). The dose that impacted on the oropharynx ranged from 
25.3% to 58.4% (Bhavna et al, 2009) for the same medication. The dose that didn’t 
enter the respiratory tract (waste) ranged from 10.8% (Bhavna et al, 2009) to 17% 
(Walker, 2001) in these studies. 
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Figure 1.2: Percentage deposition of ICS’s in human studies 
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From these studies the highest deposition was reported for nano-particle 
salbutamol sulphate (64.1%) delivered as DPI. In this study by Bhavna et al (2009), 
the mean particle size was 60.71 ± 35.99 nm and was measured by liquid anti-
solvent precipitation followed by a spray-drying technique. While deposition was 
greater for the nano-particle salbutamol sulphate this would result in increased blood 
concentrations of the drug due to the small particle size. In these types of studies it 
would be advantageous to perform additional gamma-scintigraphy at later intervals 
to see if the drug is retained within the lungs.  
 
Monodisperse aerosols are designed to deliver a drug mass with a narrow 
particle size distribution. This gives these aerosols greater discriminative power over 
polydisperse aerosols when exploring differences due to particle size effects 
(Usmani et al, 2005). The use of monodisperse aerosols make it possible to 
accurately explore concepts of aerosol particle behaviour within the human airways 
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Figure 1.3: Percentage deposition of SABA's and LABA's in human studies  
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particularly since they have a geometric standard deviation of <1.22 (Morrow, 1981). 
As part of their study, Usmani et al (2005) investigated the effect of particle size on 
lung deposition in asthmatics using 3 separate radiolabelled salbutamol 
monodisperse aerosols. Lung deposition was 46%, oropharynx deposition was 
42.6%, and waste was 6.6% for 6 µm (MMAD) aerosols. Lung deposition was 51%, 
oropharynx deposition was 30.6%, and waste was 13.7% for 3µm (MMAD) aerosols. 
Lung deposition was 56.3%, oropharynx deposition was 14.6%, and waste was 
25.7% for 1.5 µm (MMAD) aerosols. As particle size became smaller lung deposition 
increased and oropharyngeal deposition decreased. Similarly, Heyder et al (1986) 
looked at a series of mono-sized radiolabelled particles and found laryngeal 
deposition in adults increased with particle size from 15% for 5 µm to 84% for 15 µm.  
 
1.7 Physiological tests and therapeutic response 
Historically, forced spirometry has been used as the main measurement of 
lung function and therapeutic response to inhaled medication in asthma and COPD 
patients. However, spirometry does not always detect abnormalities in mild disease 
(Barnes et al, 2010). The production of new extra- and super- fine drug formulations 
designed to target the small peripheral airways, highlights the need for sensitive 
respiratory function tests that can distinguish large and small airway changes in 
these conditions. Extra- and super- fine formulations produce aerosol particles <1 
µm (and <100 nm) in diameter (Acerbi, 2007). Several studies have addressed the 
pathological events that occur in the small airways in asthma and COPD but no 
biomarker or functional parameter has been widely accepted as the hallmark of small 
airway involvement (Contoli et al, 2010).  
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Many asthma and COPD patients perform other routine respiratory function 
tests including airways resistance, lung volumes, and transfer factor for carbon 
monoxide. Spirometry is the most widely used test for monitoring airway obstruction. 
The main parameters measured include FEV1, FVC, FEV1 / FVC and PEF. It is 
widely recognised that FEV1 does not provide comprehensive evaluation of the 
whole bronchial tree (Contoli et al, 2010). In particular, it does not properly reflect 
small airway abnormalities specifically, but does reflect cross-sectional area of the 
lung (Cosio et al, 1978; Kraft et al, 2006). There is intra- and intersubject variability in 
PEF which also does not reflect small airway obstruction.  Since the introduction of 
flow-volume curves many have used maximal mid-expiratory flow between 75% - 
25% of the FVC (MMEF75/25) as a parameter of small airway calibre. The MMEF75/25 
is the average expiratory flow over the middle half of the FVC. Additionally, others 
have used maximal expiratory flows when 75%, 50%, or 25% of the FVC remains to 
be exhaled as parameters of small airway calibre.  However, there is significant intra- 
and intersubject variability which is further influenced by large airway obstruction, 
volume changes, and dynamic airway compression during forced expiratory 
breathing manoeuvres. These parameters have not been shown to correlate with 
small airway inflammation observed from lung biopsies through bronchoscopy 
(Sutherland et al, 2004) and the literature supporting their validity is not conclusive 
as conflicting results have been presented (Contoli et al, 2010). Therefore there is a 
need to look beyond spirometry as this test offers little information in regard to the 
small airways. 
 
Several physiological parameters have been used to characterise gas 
trapping in the lung which may provide more information on small airway changes. 
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This includes the FVC measured during spirometry, and functional residual capacity 
(FRC), residual volume (RV), and the ratio of residual volume to total lung capacity 
(RV:TLC). Inhaled therapeutic drugs targeted to small airways may reduce gas 
trapping thus increase the FVC and normalising the FRC, RV, and RV: TLC ratio. 
Airways resistance and conductance (with or without correction for lung volume) 
have also been shown to improve in response to therapeutic aerosols but these 
reflect large airway changes mainly. There are no parameters measured during 
transfer factor for carbon monoxide (TLCO) that reflect small airway changes. 
However, β2-adrenoceptor agonists may increase vital capacity and corticosteroids 
may increase airway lumen diameter through a reduction in inflammation thus 
improving TLCO.  
 
Routine lung function tests are limited in their capacity to differentiate between 
subtle abnormalities in airway physiology within the large and small airways. 
Specialist respiratory function tests that can determine large and small airway 
changes include the multi-breath nitrogen washout, impulse oscillometry and multiple 
flow exhaled nitric oxide.  
 
The multi-breath nitrogen washout test provides a specific measure of large 
(conducting) and small (acinar) airway indices that are sensitive to changes caused 
by disease. The parameters that are obtained include Scond and Sacin which represent 
ventilation heterogeneity in the conducting and acinar (respiratory) airways which 
increase in airway obstruction. The lung clearance index (LCI) is defined as the 
cumulative expired volume divided by FRC which also increases with airway 
obstruction and hyperinflation. Verbanck et al (1999) investigated acinar airway 
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involvement and the effect of salbutamol in asthma for comparison to COPD 
patients. The asthma group had a more elevated baseline Sacin compared to COPD 
group while Scond was elevated in both groups. After salbutamol treatment both Sacin 
and Scond were partially reduced in the asthmatic group.  In the COPD group Scond 
was reduced but Sacin didn’t change. This reflects the involvement of both large and 
small airways in asthma and the partial reversibility of large airways sometimes 
observed in COPD. Gustafsson (2007) found LCI, Sacin, and spirometry (but not 
Scond) to improve in asthmatic children after receiving nebulised salbutamol. Similarly 
in another study in adult asthmatics, Verbanck et al (2003) found that Sacin and FEV1 
(but not Scond) improved after treatment with salbutamol.  
 
The impulse oscillometry system (IOS) is a method of the forced oscillation 
technique which can evaluate respiratory resistance and reactance at various 
oscillatory frequencies to determine respiratory system mechanics not accessible by 
spirometry alone (Hellinckx et al, 2001; Pride, 1992). IOS is an effort independent 
test that reflects the overall respiratory system including the properties of the thorax 
(Williamson et al, 2010). Recent studies suggest that IOS can detect airway 
abnormalities better than spirometry in adult asthma (Houghton et al, 2007; Mansur 
et al, 2008; Park et al, 2007) and COPD (Borrill et al, 2005; Borrill et al, 2007). Vink 
et al (2003) found that primarily resistance (and to some degree reactance) 
parameters were significantly correlated with the ‘gold standard’ FEV1 and that the 
sensitivity of resistance and reactance to β2-agonists was best at low frequencies (5 
– 15 Hz) in asthmatic children. In a recent study, Hiroyuki et al (2009) found that 
resistance and the reactance area improved following treatment with pranlukast (a 
leukotriene receptor antagonist) combined with salmeterol / fluticasone. Spirometry 
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could not detect changes in small airway calibre observed in this asthmatic study. 
Similarly, Borrill et al (2007) found that IOS (and airway conductance) parameters 
were more sensitive to airway changes than FEV1 which remained stable in COPD 
patients treated with tiotropium and salmeterol.  
 
Small airways and lung parenchyma are the predominant sites of 
inflammation in COPD (Hogg et al, 2004) but in asthma the large airways are also 
affected. Nitric oxide (NO) is biosynthesized endogenously from L-arginine and 
oxygen by various isoforms of the enzyme NO synthase. NO has numerous 
biological effects in asthma and COPD. NO is produced by resident cells (e.g. airway 
epithelial cells, airway and circulatory endothelial cells, and trafficking inflammatory 
cells) in all airways and alveoli (Barnes et al, 2010). By measuring fractional exhaled 
NO (FENO) at multiple flow rates the alveolar (CalvNO) and bronchial fraction 
(J’awNO) of exhaled NO can be obtained. In this simplified two compartment model of 
airway NO, CalvNO represents a small airways and distal alveolar compartment while 
J’awNO represents a maximal flux of NO from the large airway compartment (airway 
generations 1 - 16). High levels of FENO are suggestive of asthma and have been 
demonstrated in adult asthmatics (Smith et al, 2004). Elevated FENO acts as a good 
predictor of treatment response to ICS’s (Smith et al, 2005). There is evidence that 
FENO decreases after treatment with ICS (Radomski et al, 1990) and this reduction 
can be fast and dose-dependant (Jones et al, 2002; Kharitonov et al, 1996; 
Kharitonov et al, 2002; Lim et al, 1999). While much of the literature focuses on 
corticosteroid response, Papi et al (2000) found that higher levels of FENO occur in 
COPD with greater degrees of bronchodilator reversibility and sputum eosinophilia. 
49 
 
Papi et al (2000) did not measure CalvNO and J’awNO. Brindicci et al (2005) found 
that COPD was associated with an elevated NO concentration for CalvNO.  
 
1.8 Research statement  
Clinical studies (in vivo) investigating polydisperse aerosol deposition has 
revealed mixed deposition patterns throughout the respiratory tract. Studies have 
demonstrated that the amount of ex-actuated aerosol that reaches the lungs can be 
minimal while the amount that deposits in the upper (extra-thoracic) airway can be 
high. The experimental use of monodisperse aerosols can increase our 
understanding of the effects of aerosol particle size on both lung and upper airway 
deposition. The respiratory function tests that are currently routinely performed may 
not be sensitive enough to assess the clinical response to inhaled poly- and 
monodisperse therapeutic aerosols targeted to different regions of the lung 
(particularly when the administered dose is low). The sensitivity of more specialist 
respiratory function tests should be able to discriminate where clinical improvement 
takes place in the lungs and increase our understanding of the pathophysiological 
differences between asthma and COPD.  
 
1.9 Research hypotheses  
 The deposition of inhaled aerosols in the lungs is influenced by the extra-thoracic 
airway and in vitro techniques can be used to help determine what happens in 
vivo.  
 Clinical changes in respiratory function are related to the effects of aerosol 
particle size and their deposition distribution throughout the airways. Therefore 
parameters of small and large airways disease and inflammation are associated 
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with a response to the deposition of small, intermediate, and large (1.5, 3, and 6 
µm MMAD) therapeutic aerosol particles. 
 Pharmacokinetics can be also used to investigate the effects of aerosol particle 
size on lung deposition and systemic uptake.  
 The pathophysiological differences between asthma and COPD are better 
reflected in parameters of small and large airways disease and inflammation than 
parameters obtained from routinely performed respiratory function tests.  
 
1.10 Aims 
1. Investigate how upper airway deposition is influenced by aerosol particle size, 
flow rate, and flow direction (inspiratory and expiratory) and observe  if in vitro 
experiments using realistic models can predict what happen in vivo in patients. 
2. Measure changes in parameters of small and large airways disease and 
inflammation in asthma patients treated with poly- and monodisperse aerosols 
and relate changes to aerosol particle size.  
3. Investigate how aerosol particle size affects drug deposition in the lung through 
pharmacokinetics.  
4. Perform routine and specialist respiratory function tests in healthy volunteers, 
healthy smokers, asthmatics, and COPD patients to evaluate parameters of lung 
physiology and inflammation.  
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CHAPTER 2: METHODS 
 
This next Chapter details the methods and materials used in each study in the 
successive Chapters. The methods and materials used to generate and deliver 
aerosols used in both the patient and model studies are described here, together 
with the approaches used to quantify aerosol deposition.  
 
The following studies investigated the deposition of therapeutic monodisperse 
aerosols within the lung and specifically the upper airway using two-dimensional 
gamma-scintigraphy and also, the bioavailability of inhaled aerosols using 
pharmacokinetic methods in mild-moderate asthmatics.  
 
A central theme to the patient studies in the successive Chapters involved 
looking at parameters of respiratory function and inflammation, their change in 
response to mono- and polydisperse inhaled aerosols, how these parameters 
differed between patient groups, and how they changed with time. These are 
described in detail in this Chapter. 
 
2.1 Aerosol deposition in upper airway models (Chapter 3)  
 
2.1.1 Equipment for upper airway model study 
 Aerosol Delivery System (Clinical Bio-Engineering, Royal Brompton Hospital). 
 Spinning-Top Aerosol Generator, Mark II, Research Engineers Ltd., London, UK. 
 Aerodynamic Particle Sizer (model 3310 with 3302 100:1 Diluter), TSI Inc., St. 
Paul, Minnesota, USA. 
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 Suction pump, Platon, UK.  
 Double headed gamma camera, Philips Forte (Philips Healthcare), Eindhoven, 
Netherlands. 
 High resolution collimator. 
 HERMES software, Hermes Medical Solution, Stockholm, Sweden.  
 Resin cast of simplified upper airway geometry.  
 4 identical silicone upper airway models constructed from resin cast.  
 Salbutamol sulphate, GlaxoSmithKline, Hertfordshire, UK. 
 Technetium pertechnetate (99mTcO4
-), Mallinckrodt, Radiopharmacy Services, 
Middlesex Hospital, Middlesex, UK.   
 Polyoxyethylenlaurylether, Brij® 35P solution, Sigma-Aldrich, Dorset, UK. 
 1,2,3-propanetriol, BDH Prolabo, VWR International Ltd, Leicestershire, UK. 
 Spiroguard bacterial / viral filters, Air Safety Limited, Lancashire, UK.  
 Ethanol, Sigma-Aldrich, Dorset, UK. 
 Sterile water, Baxter, Northampton, UK.  
 
2.1.1.1 The spinning-top aerosol generator (STAG) & aerosol delivery system 
The aerosol delivery system (Biddiscombe et al, 2003), incorporating the 
STAG, was developed at the Royal Brompton Hospital as a tool for delivering 
monodisperse aerosols to subjects in a controlled manner for the investigation of 
drug delivery to the lungs. The STAG has been used in 3 studies described in this 
thesis. Its mode of operation and main components are the same in all these studies 
but the applications are different. Here the principle of operation and the main 
components of the aerosol delivery system are described.  The system is further 
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described in sections 2.1.2, 2.2.2 and 2.8.2 where the relevant operating conditions 
are outlined.  
 
The STAG is a type of nebuliser that can be used to generate monodisperse 
aerosols by feeding drug solution to the flat upper surface of a top spinning at very 
high speeds. See figure 2.1 (a) below. The liquid spreads to the edge of the disc-like 
upper surface where it accumulates until the centrifugal force acting upon it exceeds 
the retaining force of surface tension. The liquid is expelled tangentially, and forms 
rings of spherical droplets of two sizes known as primary and secondary droplets.  
The aerosol particle size can be controlled by varying the rotational speed of the top. 
 
 The STAG’s main components are the steel top, a stator support assembly, 
and a liquid feed needle assembly. Compressed air is used to drive the top and 
provide a “cushion” of air to support it while it is spinning to allow very high speeds to 
be obtained. A control unit housing air pressure regulators allows manual control of 
the rotational speed of the top and generates an exhaust flow to remove unwanted 
aerosol droplets. The control unit also contains a digital speed indicator to provide 
feedback of the rotational speed of the disc. 
 
The STAG forms part of the Aerosol Delivery System which incorporates a 
purpose-built Perspex tank (aerosol chamber) to house the STAG and accumulate 
the aerosol prior to inhalation or sampling. See figure 2.1 (b) below. An outlet leads 
from the front of the aerosol chamber to a four-way inflatable balloon valve system 
(Hans Rudolph Inc., K.C., MO., USA) and a mouthpiece by which subjects may 
inhale the generated aerosol. A pneumotachograph with Fleisch flow transducer 
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head senses the inhalation flow of the patients, and controls the opening and closing 
of balloon valves. 
 
 
 
 
 
 
 
 
a) 
 
 
 
 
 
 
 
 
b) 
 
Figure 2.1: The principle of operation of the STAG (a) and the aerosol delivery system (b) 
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2.1.2 Experimental procedure for upper airway model studies 
Realistic models of the upper airway were constructed at the University 
Hospital UZ Brussels. Mouth and throat images from computed tomography in five 
healthy non-smoking adults were selected for this purpose. The best images were 
deemed representative of a healthy adult mouth and throat and were from an adult 
male (Brouns 2007).  
 
These images were then used to create a real life model of the upper airway. 
This model was made out of hard resin and was used in the development of four 
identical silicone models (figure 2.2). An L-shaped container was developed to act as 
a template. This was filled halfway to the top with clay. The resin model was laid 
down sideways so that the whole length of one side of the model was in contact with 
the clay. The model was gently squeezed into the clay up to halfway along its mid-
sagittal plane. Afterwards, mould making silicone rubber was poured into the 
container and left to solidify for 24 hours. This process was repeated to create the 
other half of the upper airway model. Each model had the same internal geometric 
configuration. Figure 2.2 displays one half of the silicone rubber model (on the right).  
Within each model, four compartments were defined (oral cavity, pharyngeal, 
laryngeal, and trachea). These compartments formed the four regions of interest 
(ROIs).  
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Figure 2.2: Resin model of upper airway based on CT images (left) and one half of a silicone model 
(right) 
 
For the experiments, the inner surfaces of the models were coated with a 
mucus-like solution to replicate phlegm in the human respiratory tract. This consisted 
of polyoxyethylenlaurylether (2.5 g) sonicated in ethanol (20 mls) and mixed with 
1,2,3-propanetriol (79.2 mls). The model had two outlets, one at the beginning of the 
oral cavity and the other at the base of the trachea. At one outlet the model was 
connected to the aerosol chamber and at the other outlet to a suction pump. The 
suction pump withdrew the aerosol out of the aerosol chamber and through the 
model onto a low resistance total trap filter.  
 
The orientation of the model and its attachment to the aerosol chamber and 
the suction pump depended on which experimental mode was studied. During the 
inspiratory mode the outlet at the oral cavity was attached to the inhalation port of 
the aerosol chamber while the outlet at the trachea was attached to the suction 
pump. During the expiratory mode the outlet at the trachea was attached to the 
oral cavity 
pharynx 
larynx 
trachea 
Resin model used to 
construct upper airway 
models 
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inhalation port of the aerosol chamber while the outlet at the oral cavity was attached 
to the suction pump (see figure 2.3 below). The models had to be in a similar 
position during both modes in respect of gravity. This meant that during the 
expiratory mode an additional attachment with a 90° bend had to be used to connect 
the aerosol chamber to the outlet at the trachea. Figure 2.3 displays the 
experimental set up for both experimental modes.  
 
  
Figure 2.3: Experimental set up for inspiratory and expiratory modes 
 
The experiments were aimed at obtaining deposition data for two 
monodisperse aerosols of micron sized particles (3 and 6 μm), at two flow rates (30 
and 60 L/min), and at two flow directions (inspiratory and expiratory).  
 
 Before each experiment a fresh aerosol solution was prepared by sonicating 
salbutamol sulphate (100 mg) in ethanol (25 mls) and sterile water (2 mls) and 
radiolabelling with 300 MBq of 99mTcO4
-. Lead shielding was used during this 
airway  
model  
 
airway  
model  
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process. The radiolabelling process has previously been described by Usmani et al 
(2004). The aerosol solution was contained within a sterile 50 ml syringe and fed to 
the STAG at a constant rate using a syringe driver. The needle was securely 
positioned vertically above the conical spinning top. The spinning velocity of the top 
was set to 1500 or 600 revolutions per second to generate monodisperse aerosols of 
either 3 or 6 μm respectively (geometric standard deviation (GSD) <1.22).  
 
The STAG is enclosed within an airtight chamber which connects to an 
inhalation port via a 4-way balloon valve system (Section 2.1.1.1). The aerosols 
consisted of dry spherical particles of uniform size which remained stable for up to 
six minutes after production (Biddiscombe et al, 2003). Before each experiment the 
aerosol particle size and mass concentration was verified using the Aerosol Particle 
Sizer (APS) to ensure they were within the specified range. The APS measured 
aerosol mass median aerodynamic diameter (MMAD) and drug concentration in near 
real time. 
 
Each aerosol was drawn through the model at the target flow rate for 4 
minutes which allowed sufficient aerosol deposition in the model to be detectable by 
gamma- scintigraphy. Three tests were performed for the smaller sized particle, low 
flow combination (3 μm at 30L/min) and for the larger sized particle, high flow 
combination (6 μm at 60 L/min). Four tests were performed for the two intermediary 
combinations of smaller sized particle at high flow (3 μm at 60 L/min) and larger 
sized particle at low flow (6 μm at 30 L/min). Aerosol deposition under these 
experimental conditions was expected to vary. Therefore an extra set of 
measurements were performed. 
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During a single experimental run, between 2 and 4 models were used in the 
deposition experiments. Gamma-scintigraphy was performed immediately after the 
models were treated to aerosols. Immediately before imaging the models were 
opened and the two halves placed on a double headed gamma camera with a high 
resolution collimator attached. Images were acquired for 10 minutes. HERMES 
software was used to draw boundary ROIs around both halves of the open models, 
the four compartments (ROIs) within the models, the connecting pieces that attach 
models to the aerosol chamber and suction pump, and the filter. The two halves 
were separated during imaging to reduce attenuation through the cast material.  
 
The radioactive counts within ROIs were used to calculate aerosol deposition 
within the whole upper airway as well as each ROI. The radioactive counts 
measured within each ROI were recorded and corrections were made for both 
background radiation and radioactive decay of the isotope. Deposition within each 
ROI was calculated using equation 1, 2 and 3 below. Figure 2.4 shows aerosol 
deposition in two halves of the same model before and after ROIs boundaries was 
drawn. The models were cleaned with methanol after 72 hours and allowed to dry 
completely before the next experimental run.  
 
Equation 1: Decay Correction of Counts  
Decay corrected ROI counts = (ROI counts at time t)  x   e-kt   
Where  k = 0.693/t1/2   based on a  Half-life 6.02 Hours for  
99mTcO4
- 
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Equation 2: Background Correction 
Background Corrected Counts in ROI = ROI count - [background counts per pixel] x 
ROI pixels  
 
Equation 3: Deposition in Each ROI as a percentage of total cast deposition 
 DROI
 = (Corrected ROI counts / sum of all corrected ROI counts) x 100 
 
Figure 2.4: Gamma-scintigraphic images of an open upper airway model displaying radiolabelled 
aerosol deposition. On the left side image without ROI boundaries drawn. On the right side image with 
ROI boundaries. Circle in image is total trap filter.  
 
2.2 Aerosol deposition in the upper airway of patients 
This section describes the novel analysis of upper airway data from an earlier study 
(Usmani et al, 2005). The data has been re-analyzed in order to compare the patient 
data with the data obtained in the model experiments. 
 
 
oral cavity 
pharyngeal 
laryngeal 
     tracheal 
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2.2.1 Equipment for patient upper airway study 
 Aerosol Delivery System (Clinical Bio-Engineering, Royal Brompton Hospital).  
 Spinning-Top Aerosol Generator, Mark II, Research Engineers Ltd., London, UK. 
 Aerodynamic Particle Sizer (model 3310 with 3302 100:1 Diluter), TSI Inc., St. 
Paul, Minnesota, USA. 
 Suction pump, Platon, UK.  
 Single headed gamma camera, Sopha Medical. 
 High sensitivity parallel-hole collimator.  
 HERMES software, Hermes Medical Solution, London, UK.  
 Salbutamol sulphate powder, GlaxoSmithKline, Hertfordshire, UK. 
 Technetium pertechnetate (99mTcO4
-), Mallinckrodt, Radiopharmacy Services, 
Middlesex Hospital, Middlesex, UK.   
 Ethanol (96% pharmaceutical grade), Martindale, UK. 
 Sterile water, Baxter, Northampton, UK.  
 SafeTway mouthpieces, Vitalograph, Buckingham, UK. 
 Plastic nose clips, Vitalograph, Buckingham, UK.  
 
2.2.2 Experimental procedure for patient studies 
The aerosol solutions consisted of 25 / 50 µg salbutamol sulphate powder 
dissolved in 12.5 mls of ethanol and 1 ml of sterile water. Twenty-five µg was used in 
the production of 1.5 µm, and 50 µg was used for the production of 3 and 6 µm 
monodisperse aerosols. The aerosols were generated using the STAG as for the 
model experiments.  
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Salbutamol sulphate powder was weighed into a lead-shielded scintillation 
vial, into which 5 GBq of technetium pertechnetate (99mTcO4
-) in normal saline, 
eluted from a molybdenum / technetium generator, was added. Lead shielding was 
used at all stages. The solution was made up to a 1 ml volume with sterile water, 
when necessary, and the drug was allowed to completely dissolve before ethanol 
was added. The resulting solution was drawn into a 50 ml syringe and aerosolized in 
the STAG to produce dry and physically stable monodisperse salbutamol aerosols. 
Aerosol particle size, stability, and delivered drug dose were validated prior to the 
start of the study using an APS (Biddiscombe, 2003).  
 
On study days subjects inhaled three 1 L single breaths of aerosol from FRC, 
via the inhalation port and at an inspiratory flow rate of 30 or 60 L/min. Subjects were 
guided by a visual indicator and each inhalation was followed by a 10 second breath-
hold pause. Subjects practiced the inhalation maneuver on room air at the beginning 
of each visit. The volume of air inhaled and the breathing pattern were controlled by 
using a pneumotachograph attached to the electronic control circuit (Clinical Bio-
Engineering, Royal Brompton Hospital).  
 
Immediately after inhalation, subjects were seated upright with their backs 
against a wide field of view gamma camera. Lateral throat images were then 
recorded for 2 minutes. HERMES software was used to draw 4 ROIs on each upper 
airway image (figure 2.5) as in the model experiments. The ROIs were drawn around 
the image with the most radio-activity. The boundary outline was drawn between the 
radioactivity in the upper airway and the point at which the radioactivity decayed to 
background radiation (outside of airway). Deposition within each ROI was calculated 
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as for the models (see above) with the exception there were no corrections 
necessary for filters or connecting pieces. Corrections were made for background 
radiation and radioactive decay of the isotope. 
 
 
 
 
 
 
 
 
Figure 2.5: Gamma-scintigraphic images from patients showing radiolabelled aerosol deposition. 
Boundaries drawn around ROIs. Left to right images following inhalation of 1.5-, 3-, and 6 µm 
monodisperse aerosols at an inspiratory flow of 60 L/min. Square is for background radioactive 
counts.    
 
2.3 Patient Groups 
The two main patient groups studied in the successive Chapters included 
those with asthma and chronic obstructive pulmonary disease (COPD). Within the 
asthma group there were two sub-groups; mild-moderate asthma and severe asthma 
distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009). 
Since the original submission of this thesis (2012) the guidelines have been updated 
(2015). The COPD group included stage I to III patients, classified according to 
severity of airflow limitation (post bronchodilator FEV1), from the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD, 2011). These 
guidelines have been updated (2015) and the classification of severity of airflow 
oral cavity oral cavity 
oral cavity 
pharyngeal 
pharyngeal  
pharyngeal 
laryngeal 
laryngeal 
laryngeal 
tracheal tracheal tracheal 
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limitation remains the same. Two further groups were also studied including healthy 
volunteers and healthy smokers. During the patient studies respiratory function 
parameters were measured from four ‘routinely’ performed tests (spirometry, lung 
volumes, single-breath transfer factor, and airways resistance and conductance) and 
three ‘specialist’ tests (multiple flow exhaled nitric oxide, multi-breath nitrogen 
washout, and impulse oscillometry).  
 
Prior to all tests the subjects had their height and weight measured. Height 
was measured in the standing position without shoes on. Weight was also performed 
standing up and without shoes and any excess clothing on; that is, their coat or 
jacket. Height was recorded in centimetres and weight in kilograms (to one decimal 
point).  
 
All subjects were coached and supervised before and during the tests. All 
tests were performed while seated upright and breathing orally through a low 
resistance filter (bacterial / viral), with the nose occluded. For multi-breath nitrogen 
washout and impulse oscillometry tests an additional mouthpiece was used. In some 
instances an additional mouth piece was used to prevent leaking at the mouth during 
tests using the body plethysmograph. Forced spirometry was performed last to avoid 
inducing bronchoconstriction. Tests were performed in accordance with position 
statements (guidelines) from The American Thoracic Society and European 
Respiratory Society where applicable (MacIntyre et al, 2005; Miller et al, 2005; 
Wagner et al, 2005). Where this was not possible results were either considered 
satisfactory for inclusion or unreliable and excluded based on the operators 
experience and discretion.  
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2.4 Lung physiology 
 
2.4.1 Whole-body plethysmography tests 
Whole-body plethysmography was performed to measure the gas that 
compresses and decompresses in the lungs during breathing. Intra-thoracic gas 
volume and volume change were used to calculate static lung volumes which 
change in the presence of airflow limitation. The intra-thoracic gas volume was used 
to calculate airways resistance which also increases in the presence of airflow 
limitation. Specific airway conductance is the reciprocal of airways resistance and is 
corrected for by the lung volume measured during testing. Specific airway 
conductance is a slightly more robust measurement of airflow limitation and was 
reported in conjunction with airways resistance. Single-breath transfer factor tests 
were performed to measure the overall ability of the lungs to transport atmospheric 
oxygen to the pulmonary blood and the surface area available for gas exchange 
which deteriorates in obstructive lung disease and chronic smoking. Forced 
spirometry measures the severity of airflow limitation in obstructive lung disease.  
 
2.4.2 Equipment and materials  
 Whole-Body Plethysmograph, MasterScreen® Body, Cardinal Health, 
Hoechberg, Germany. 
 Gas cylinder certified to contain approximately 0.28% carbon monoxide, 14% 
helium, 19% oxygen and balance air, calibration and test gas, British Oxygen 
Company, UK. 
 3 litre volume calibration syringe (certified), Cardinal Health, Hoechberg, 
Germany. 
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 Spiroguard bacterial / viral filters, Air Safety Limited, Lancashire, UK.  
 Plastic nose clips, Vitalograph, Buckingham, UK.  
 Flat plastic mouthpieces (for patients who could not maintain a tight seal with 
their lips on bacterial / viral filter), Cardinal Health, Hoechberg, Germany. 
 HemoCue whole blood Hb system, HemoCue Ltd, Derbyshire, UK. 
 HemoCue Hb 201 microcuvettes, HemoCue Ltd, Derbyshire, UK.  
 HemoTrol Normal, quality controls (Hb 11.8 – 12.2 ± 0.6 g/dL).  
 Haemolance (normal flow safety lance), HaeMedic, Ozorkow, Poland.  
 Disposable cleaning wipes, Clinell, GAMA Healthcare, London, UK.  
 
2.4.3 Calibration of equipment 
Prior to all tests, temperature (°C), relative humidity (%), and barometric 
pressure (mmHg) were measured and updated using an ambient unit attached to the 
body plethysmograph (figure 2.6). The new values were then stored. A volume 
calibration was performed according to the three-flow protocol (see appendix A). A 3 
litre volume syringe was used to pump air through the pneumotachograph at 3 
different flow ranges (Range 1: 0 - 1.5 L/s, Range 2: 1.5 - 5 L/s, and Range 3 >5 L/s) 
(see figure 2.7). The volume calibration was saved when the difference between old 
and new corrected values for inspiratory (CorrIN) and expiratory (CorrEX) were 98 - 
102% (figure 2.8). Ambient conditions were updated and the volume calibration was 
repeated prior to the testing of every new patient. These were also updated regularly 
for patients tested throughout the same day.  
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Figure 2.6: Ambient conditions measured by ambient unit  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Three different flow ranges for 3-flow protocol 
 
 
 
 
 
 
 
 
Range 1 
Range 2 
Range 3 
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Figure 2.8: Successfully completed 3-flow protocol 
  
A gas calibration was performed for carbon monoxide (CO) and helium (He) 
using the calibration gas described above. The calibrations were successful when 
the difference between the new and certified gas concentrations (and also old 
calibration) were <1% and when pass result was displayed (figure 2.9). Each time a 
new gas cylinder was connected the certified gas concentrations had to be updated.  
 
 
 
 
 
 
 
 
 
Figure 2.9: Successfully completed gas calibration for single-breath transfer factor tests 
  
 
 Difference between  
old and new   
98 - 102% 
 
% Difference between 
old and new gas 
calibration values  
and calibration result 
(pass: O or fail: X) 
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A body plethysmograph calibration was performed with the chamber door 
closed. The body plethysmography was allowed to stabilise for 3 minutes then 3 
calibration trials were initiated in accordance with the manufacturer’s guidelines:  
Half value calibration (T = Time constant, box tightness) 
Body box calibration (PB = Pressure body, internal box pressure) 
 
For calibrations to be successful the half value period (T calibration) had to be 
between 4 – 7 seconds (figure 2.10) and the pressure body (PB calibration) must 
have remained stable with minimal drift. If calibrations were unsuccessful then they 
were repeated until satisfactory. 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Successfully completed box calibration for lung volumes and airways resistance tests 
 
2.4.4 Performance of lung volumes  
Subjects were seated on the chair within the body plethysmograph and 
performed the tests with the door closed. When subjects began breathing on the 
pneumotachograph they may have started at a volume above or below their actual 
 
Between 4 – 7 seconds 
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functional residual capacity (FRC).  Therefore, after several tidal breaths the start of 
the measurement was readjusted so that recording began at functional residual 
capacity. This prevented underestimation or overestimation of lung volumes. 
Following a period of tidal breathing subjects performed a panting manoeuvre with 
their hands firmly pressed against their cheeks. They panted against the 
pneumotachograph which was occluded (<2 seconds) at FRC. Following the panting 
subjects then inhaled to total lung capacity (TLC), exhaled to residual volume (RV) 
and inhaled again to TLC (figure 2.11). The occlusion at FRC resulted in the 
measurement of intra-thoracic gas volume (ITGV) which was slightly above FRC. 
This was because the pneumotachograph occludes at the beginning of inspiration. 
Therefore ITGV was adjusted to be equal to FRC. Tests were performed until three 
satisfactory and reproducible measurements could be achieved.  
 
Lung volumes and their subdivisions were calculated from the following 
equations: 
RV = mean ITGV – mean ERV (expiratory reserve volume) 
TLC = calculated RV + largest IVC (inspiratory vital capacity) 
Results included RV, TLC, RV: TLC (ratio) and FRC and were expressed in liters (L) 
and percent predicted (% pred).  
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Figure 2.11: Spirogram trace showing measurement of lung volumes and occlusion at FRC 
 
 
2.4.5 Performance of airway resistance  
Airway resistance was measured at a respiratory rate of 30 – 40 small tidal 
breaths per minute and at a target flow rate of -1 - +1 L/s. The two lowest resistance 
measurements were selected from 10 similar measurements (figure 2.12).  
 
 
 
 
 
 
 
 
 
Figure 2.12: Airways resistance measurements 
 
 
0.0  – -1.0 L/s 
(expiration) 
0.0 to – +1.0 L/s 
(inspiration) 
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The results for airway resistance (kPa/L/s) included: 
Expiratory airway resistance (Raw EX)  
The results for specific airway conductance (kPa/L/s/L) included: 
Specific expiratory airway conductance (SGaw EX) 
 
2.4.6 Performance of single-breath transfer factor  
Subjects began tidal breathing and were then instructed to take a small 
inspiratory breath and then exhale to RV. Before RV could be reached the demand 
valve was activated so that as soon as the subject inhaled to TLC they would inspire 
the test gas mixture. At TLC the subject performed a 6 - 10 second breath-hold 
before re-expiring into collection piping for analysis of CO and He concentrations 
(figure 2.13). A minimum of four minutes between measurements was necessary to 
allow for washout of the test gas. If pressure at the pneumotachograph exceeded 3 
kPa during breath-hold this was indicative of a subject leak and the test was 
repeated. The exhalation or discard volume at the end of the breath-hold was set to 
700 mls and did not have to be reduced for any subjects who had reduced lung 
volumes and / or expiratory flows. Three measurements were performed with the two 
lowest being within 10% of the highest result obtained. The mean of the two best 
results were reported after being corrected for the subject’s Hb.  
 
The results included: 
Transfer factor for carbon monoxide corrected for Hb concentration:  
TLCOc (mmol/min/kPa) 
TLCOc (% Pred) 
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Transfer coefficient for carbon monoxide corrected for Hb concentration:  
kCOc (mmol/min/kPa/L) 
kCOc (% Pred)  
Alveolar volume:  
VA (L) 
VA (% Pred) 
 
 
 
 
 
 
 
 
 
Figure 2.13: Spirogram of single-breath transfer factor test measurement  
 
Before performing single-breath transfer factor tests, the accuracy of the 
HemoCue whole blood Hb system was checked with a quality control sample (range 
11.8 - 12.2 .2 ± 0.6 g/dL) before any blood could be sampled. Hemoglobin (Hb) 
samples were taken from the finger. The side of the subject’s fingertip was wiped 
with disposable cleaning wipes and then tissue paper to remove surplus alcohol. The 
skin was then pricked with a haemolance and the blood flow was encouraged by 
gentle massage of the punctured finger. The first few drops were wiped away using 
tissue and then a microcuvette was used to collect a blood sample by capillary flow. 
 
 
 
Inhaling to TLC 
Exhalation to RV 
 
 
 
 
 
Breath-hold 
 
 
 
 
 
Exhaled gas for analysis 
(discard volume) 
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The microcuvette was then inserted into HemoCue whole blood Hb system for 
quantification of hemoglobin (Hb). If the sample was significantly low or high a 
second sample was taken for confirmation. The result was then used to correct 
results from single-breath transfer factor tests.  
 
2.4.7 Performance of forced spirometry 
Spirometry was performed after a period of tidal breathing using the whole 
body plethysmograph. Each subject inhaled to TLC and then performed a maximal 
forced exhalation to RV. At RV the subject then performed a fast maximal inhalation 
to TLC. This completed a single measurement. At least three reproducible results 
were obtained and the best results were selected for both the expiratory and 
inspiratory parts of the measurement. 
 
The results included: 
FEV1, FVC, FEV1 / FVC (ratio), FEV1 / FVC and MMEF75/25 and were expressed in 
liters (L), percent predicted (% pred) and liters/sec (L/s).  
 
2.5 Impulse oscillometry 
This test distinguishes between airflow limitation in the large and small 
airways in obstructive lung disease (Shi et al, 2011). During the measurement sound 
waves are generated by a loudspeaker and superimposed over tidal breathing. The 
airflow at the mouth and sound wave response is then analyzed to calculate the 
various components of resistance to tidal breathing.    
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2.5.1 Equipment and materials  
 Impulse Oscillometry System, Cardinal Health, Hoechberg, Germany. 
 Reference impedance device (for calibration), Cardinal Health, Hoechberg, 
Germany. 
 3 litre volume calibration syringe (certified), Cardinal Health, Hoechberg, 
Germany. 
 Spiroguard bacterial / viral filters, Air Safety Limited, Lancashire, UK.  
 Plastic nose clips, Vitalograph, Buckingham, UK.  
 FreeFlow™ mouthpieces, Cardinal Health, Hoechberg, Germany. 
 
2.5.2 Calibration of the equipment 
Ambient conditions were measured using ambient unit connected to body 
plethysmograph. The values were then input into the oscillometry software. A volume 
calibration was then performed using a 3 litre volume calibration syringe in the flow 
range of 0.0 - 10 L/s (figure 2.14). The volume calibration was saved when the 
difference between old and new corrected values for inspiratory (CorrIN) and 
expiratory (CorrEX) were 98 - 102%. A reference impedance device was then 
attached to the pneumotachograph and the impulse oscillometry program was 
started. The impedance calibration was successful when resistance (R and Rex) 
between 5 - 35 hertz measured 0.20 kPa (figure 2.15). The screen cap on the Y-
adapter (terminal resistance) had to be open for the volume calibration and closed 
during impedance calibration.  
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Figure 2.14: Successfully completed volume calibration  
 
 
 
 
 
 
 
 
Figure 2.15: Successful calibration of respiratory resistance using reference impedance device 
 
2.5.3 Performance of impulse oscillometry 
Prior to measurements each subject was instructed on the use of the 
FreeFlow™ mouthpiece. They had a practice with the mouthpiece keeping their 
tongue under the depressor and lips tightly around the flange. Once the subject was 
confident in the use of the mouthpiece it was then attached to the 
pneumotachograph. Height and weight were added to their profile and then the tests 
 
Difference between  
old and new   
98 - 102% 
All resistance measurements   
(R and Rex) between 
 0 – 35 hertz are 0.20 
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were started. After initial activation of the frequency signals the subject put on a nose 
clip and inserted the mouthpiece into their mouth.  
 
Subjects performed tidal breathing while seated upright with their hands 
supporting their cheeks. Subjects were instructed to keep their shoulders down, 
chest open, eyes closed, and relax. Tidal breathing was performed for ≥ 60 seconds 
with the first 30 seconds allowing the subject to get used to the test.  
 
At the end of each measurement the result was checked and corrected for 
any artefact’s (swallowing etc.). This was done by expanding the display window and 
separating tidal breathing from resistance at 5 hertz (figure 2.16). The volume 
display window was also checked for artifacts at impedance at 5 hertz (figure 2.17). 
The results were then recalculated by highlighting the best sequence of breath(s) 
(figure 2.18). Figure 2.19 displays impedance at 5 hertz after removal of artifacts. 
The measurements were performed 3 times and the average result was used.  
 
 
 
 
 
 
 
 
Figure 2.16: Separation of tidal breathing and resistance at 5 hertz to display artifacts 
 
 
 
Tidal  
Breathing  
Resistance 
at 5 hertz  
Artefacts in resistance at 5 hertz  
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Figure 2.17: Volume display window showing impedance at 5 hertz and artifacts during tidal breathing  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18: Reselection and recalculation of breaths after removal of artifacts  
 
0.0 to 1.0 L/s 
(inspiration) 
 
Peaks in impedance at 5 hertz from 
artefacts  
Impedance at 5 hertz 
during tidal breathing  
Expiration   Inspiration  
Reselection and recalculation over 
several breaths to exclude artefacts  
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Figure 2.19: Volume display window showing impedance at 5 hertz during tidal breathing after 
removal of artifacts  
 
The results for impulse oscillometry included: 
Respiratory resistance (kPa/L/s) 
Expiratory resistance measured at 5 hertz (R5 EX) 
Expiratory resistance measured at 20 hertz (R20 EX) 
Central airways resistance (Rcentral) 
Peripheral airways resistance (Rperipheral) 
 
Respiratory reactance (kPa/L/s) 
Expiratory reactance measured at 5 hertz (X5 EX) 
 
Reactance area (kPa/L) 
Reactance area measured during expiration (AX EX) 
Reactance area for whole-breath (AX) 
 
Resonant frequency (1/L) 
Impedance at 5 hertz during tidal breathing 
after artefacts have been removed  
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2.6 Multi-breath nitrogen washout  
This test is used to assess the non-uniformity of ventilation distribution in the 
lungs (Verbanck et al, 2003). This test distinguishes between ventilation 
heterogeneity arising from the larger and smaller airways in obstructive lung disease.  
 
2.6.1 Equipment and materials  
 Closed “bag in a box system” (inhalation, exhalation bags in a Perspex box). 
 Four-way inflatable balloon valve system (Hans Rudolph Inc., K.C., MO., USA). 
 Non-return valves, Intersurgical Ltd, Wokingham, UK. 
 Nitrogen (N2) analyzer with built-in pneumotachograph for measuring breathing 
flow and vacuum pump, Logan Research Ltd, Rochester UK.  
 Housing unit for needle valve (for measuring N2).  
 Data acquisition card and LabVIEW software, National Instruments, Austin, USA.  
 Laptop computer. 
 Gas cylinder certified to contain approximately 100% oxygen (test gas), British 
Oxygen Company, UK. 
 1 litre calibration syringe (certified), Jaeger, Hoechberg, Germany. 
 Vitalograph bacterial / viral filters, Vitalograph, Buckingham, UK.  
 Plastic nose clips, Vitalograph, Buckingham, UK.  
 TRU-FIT mouthpieces (Amici), Southern Scientific Ltd, Lancing, UK.  
 Suction pump for evacuating inhalation and exhalation (washout) bag. 
 Turbo Pascal DOS software for analysis of results. 
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2.6.2 Calibration of equipment  
 
The N2 analyser was switched on prior to all tests to warm up. The box door 
was briefly opened to refresh the system with room air. The inhalation and exhalation 
(washout) bags were completely deflated by the suction pump. The inhalation bag 
was filled with 100% oxygen and the MBNW LabVIEW program was started. Prior to 
beginning a test the N2 analyser was required to read between 70 - 80% (figure 
2.20). This indicated that ambient conditions existed within the system. A volume 
calibration was then performed using a 1 L syringe after zeroing the volume settings 
in the software (figure 2.21). The 1 L syringe was also used to perform a “syringe 
test”, where the piston was moved in and out several times to simulate a patient 
breathing 1 L tidal breaths to generate a mini washout curve. This also ensured that 
the N2 concentration would drop to <2%.  
 
 
Figure 2.20: N2 display in LabVIEW to check ambient conditions prior to start of test. Upper panel 
displays N2 between -100 – 100%. Lower panel displays N2 in magnified scale.  
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Figure 2.21: Volume calibration using 1 L syringe 
 
2.6.3 Performance of multi-breath nitrogen washout  
The subject was instructed how to use the TRU-FIT mouthpiece so that they 
maintained an air tight seal during the measurements. During the tests tidal 
breathing was performed at an inhalation volume of 1 L. Subjects followed a visual 
display showing their inspiratory volume in near real time as a bar moving up the 
screen. Displayed on this bar was a line representing the 1 L target inhalation 
volume. Before and during the measurements the subjects were encouraged not to 
pause or slow down their breathing at the end of inspiration or expiration. The first 
few inhalations were from room air. During an expiratory breath, the operator 
switched the circuit, using a two-way inflatable balloon system (Hans Rudolph, inc, 
USA), so that the subject’s next and subsequent breaths were of 100% oxygen from 
the inhalation bag. The test was continued until the exhaled N2 concentration had 
fallen to <2%. Three measurements were performed, each separated with a rest 
period to allow pulmonary N2 levels to return to baseline. Figure 2.22 displays a 
typical trace from a subject.  
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Figure 2.22: Trace from multi-breath nitrogen washout test  
 
2.6.4 Procedure for analysis of multi-breath nitrogen washout results 
All results were analyzed using the DOS (Turbo Pascal) software that was 
created for this purpose. Once the file was uploaded any drift in the in the subject’s 
tidal breathing could be spotted and corrected before proceeding. The software next 
requests if the delay time is correct.  Prior to May 2011 this was set at 5 but after this 
date it was set at 2. This was because a new needle valve replaced the original one 
at this time and the length of tubing between the needle valve and analyzer was 
shortened. The delay is the time difference between N2 sampling at the mouth and 
the analyzer.  
 
The ambient N2 concentration was then selected from the last inspiration 
before the subject was switched to oxygen breathing (figure 2.23). The lowest N2 
concentrations were then selected from all inspirations at end inspiration (figure 
2.24). Phase III slopes were then plotted for each exhalation (figure 2.25 shows 
phase III slopes). At the end of this part of the analysis an output file was created for 
Tidal breathing 
during test   
Pulmonary N2 
concentrations 
during test   
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each measurement containing the results (figure 2.26). The parameters in the output 
file were as follows:  
n = breath number 
VDF = Fowler dead space 
VDB = Bohr dead space 
Sn = normalized phase III slope 
FRC = functional residual capacity  
FET = end-tidal N2 concentration 
CM = mean expired concentration 
INVOL = inhalation volume 
EXVOL = exhalation volume 
C_IN = inspiratory N2 concentration  
 
The output file was then copied and pasted into an excel template for the 
second part of the analysis. The FRC closest to 2% was selected for that 
measurement and used to calculate lung turnover (TO). The first exhalation volume 
had to be greater ≥ 1000 mls otherwise the corresponding Sn was deleted. All 
subsequent exhalation volumes between 960 – 1000 mls had the Sn value replaced 
with the Sn value obtained in the first part of the analysis. Any exhalation volumes ≤ 
960 or ≥ 1300 mls had their corresponding Sn values deleted due to under- and over 
estimation of the Sn respectively. Figure 2.27 is an example of the modification to 
the output file during the second part of the analysis. This process was repeated for 
the two remaining results.  
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The three results were used to obtain a fitted mean result.  
The results included: 
Ventilation heterogeneity in the acinar airways (Sacin [/L]) 
Ventilation heterogeneity in the conducting airways (Scond) [/L]) 
Lung clearance index (LCI) 
 
 
Figure 2.23: Selection of ambient N2 from last inspiration of room air 
 
Figure 2.24: Inspirations during test and selection of lowest N2 concentration at end inspiration 
Inspiratory N2 
concentration  
Inspiratory N2 
concentration  
 
Inspiration 
 
Inspiration 
Ambient N2 
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Figure 2.25: Expirations during test and selection of the phase III slopes 
 
 
 
 
Figure 2.26: Output results following first part of MBNW analysis in DOS (Turbo Pascal) 
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Figure 2.27: Modification of output results during second stage of MBNW analysis in excel 
 
 
2.7 Multiple flow exhaled nitric oxide 
This measures exhaled nitric oxide as a biomarker of airway inflammation and 
distinguishes between inflammation arising from the bronchial (large airways) and 
alveolar (small airways) compartments in obstructive lung disease (Kharitonov et al, 
2002). 
 
2.7.1 Equipment and materials  
 Niox®Flex, Aerocrine, Solna, Sweden.  
 Gas cylinder certified to contain approximately 200 parts per billion nitric oxide 
(calibration gas), Air Liquide, Germany. 
 Niox®Flex bacterial / viral filters, Air Safety Limited, Lancashire, UK.  
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2.7.2 Calibration of the equipment 
Gas calibrations were performed every 14 days using gas specified above. 
Before calibrations, the 3 valves on the cylinder regulator were flushed out. The 
breathing handle was then attached to the calibration port on the regulator and the 
gas pressure was fine-tuned (2.9 - 3.1 bar). Gas concentration was measured and 
updated. Prior to each new test the Niox®Flex performed a self-test to detect any 
technical problems. Ambient nitric oxide levels also had to be <200 parts per billion 
(ppb) before testing.  
 
2.7.3 Performance of multiple flow exhaled nitric oxide 
Subjects performed a maximal inhalation followed by controlled exhalation 
through Niox®Flex bacterial / viral filters which were attached to the breathing 
handle. The computer screen has a visual display to help guide exhalation. The tests 
were performed in duplicate at 4 exhalation flow rates (50, 100, 200, and 300 
mls/sec) and no nose clip was needed.  
 
The results for VNO nl/min was plotted against flow rate to provide the 
regression slope and intercept. VNO is the rate of NO exhaled per unit time and 
calculated from the product of NO concentration in nl/L and expiratory flow rate  in 
L/min corrected to body temperature pressure saturated. The slope represents the 
alveolar NO concentration (Calv) and intercept represents bronchial NO flux (J’awNO). 
Fractional exhaled NO at an exhalation flow rate of 50 mls (FENO50) was also 
reported. Units for Calv and FENO50 were ppb and J’awNO was nl/s.  
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2.8 Production of Fluticasone Propionate Monodisperse Aerosols  
 
2.8.1 Equipment  
 Aerosol Delivery system (Clinical Bio-Engineering, Royal Brompton Hospital). 
 Spinning-Top Aerosol Generator, Mark II, Research Engineers Ltd., London, UK. 
 Aerosol Particle Sizer (model 3310 with 3302 100:1 Diluter), TSI Inc., St. Paul, 
Minnesota, USA. 
 Andersen Cascade Impactor, Graseby-Andersen, Smyrna, Georgia, USA.   
 Agilent 1000 High-Performance Liquid Chromatography System with UV 
detection, Agilent Technologies, Berkshire, UK.  
 Micronized Fluticasone Propionate (FP), GlaxoSmithKline, Hertfordshire, UK. 
 Total trap filters, (Filtrete G-200), 3M, St. Paul, USA.  
 2 L volume syringe, Jaeger, Hoechberg, Germany. 
 Ethanol, Sigma-Aldrich, Dorset, UK. 
 Methanol (HPLC grade), Fisons, Loughborough, UK.  
 Sterile distilled water, Baxter, Northampton, UK. 
 Heparinized tubes.  
 Centrifuge, Haraeus Labofuge 200, DJB Labcare, UK. 
 n-Hexane, BDH, VWR International Ltd, Poole, UK.  
 Silicone oil DC 200 / 200, BDH, VWR International Ltd, Poole, UK.  
 HPLC Agilent 1100 system, Agilent Technologies LDA UK Limited. 
 Agilent 1100 Degasser, Biomax 062343. 
 Agilent 1100 Pump, Biomax 062341. 
 Agilent 1100 Autosampler, Biomax 065258. 
 Agilent 1200 Oven, Biomax 501077. 
90 
 
 Agilent 1100 VWD, Biomax 065259 
 Agilent 1100 Control Module, Biomax 066183. 
 
2.8.2 Validation of aerosol particle sizer (APS) determined particle size 
The APS used in these studies assumes that aerosol particles are spherical 
with uniform density. Since this is not true for all aerosols, validation tests of particle 
size and mass concentration were necessary prior to patient studies. The accuracy 
of the APS was crucial in ensuring patients inhale the correct particle size and dose.  
 
The Andersen Cascade Impactor (ACI) is traditionally used to determine 
aerosol particle size and drug mass concentration. This method is the gold standard. 
It was therefore important to compare the same aerosol distributions measured by 
the APS with those measured by the ACI. Each ACI impaction plate was coated with 
a solution of 1% silicone oil in hexane and allowed to dry. This prevented particle 
bounce within the ACI. A volume of 30 mls ethanol (99.8% ethanol, conforming to 
BP, EP and USP standards) was added to 100 mg of fluticasone propionate powder. 
The resulting mixture was placed in a beaker in an Ultrasonic Bath for 5 – 10 
minutes until the initial milky liquid became clear.   
 
Three monodisperse aerosols (1.5, 3 and 6 µm) with a GSD <1.22 were 
generated from the resulting solution using the STAG with the top spinning at 2000, 
1250 and 300 r.p.s. respectively. Figure 2.28 shows three typical STAG-generated 
FP aerosol distributions as measured by the APS. When the APS measured the 
target aerosol particle size and mass concentration the aerosol production was 
stopped. The ACI was immediately attached by connecting the USP inlet (United 
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States Pharmacopeia) to the mouthpiece on the aerosol chamber. The aerosol was 
drawn through the ACI at a suction flow rate of 28 L/min for 2 minutes.  
 
The FP collected on each ACI stage and impaction plate (including the USP 
and base filter) was recovered by carefully washing with a solution of methanol and 
distilled water. High performance liquid chromatography (HPLC, Agilent 1100) was 
performed to calculate aerosol particle size (MMAD) for comparison to the APS. The 
MMAD’s of 3 aerosol distributions were measured by both the ACI and APS and 
were plotted in regression analysis (Figure 2.29). This showed a linear relationship 
between the two instruments for MMAD (r² = 0.99). 
 
Figure 2.28: Typical monodisperse FP distributions for: A 1.5µm; B 3µm; C 6µm as displayed by the 
APS 
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Figure 2.29: Comparison of particle size (MMAD) measured by ACI vs. APS for FP monodisperse 
aerosols with SD error bars (3 replicates) 
 
2.8.3 Validation of aerosol particle sizer (APS) measured concentration mass 
The aerosols were generated as described above. Then in a manner likewise 
to patients inhaling aerosols, quantities of aerosol were drawn through low 
resistance total trap filters using a 2 L volume syringe at spontaneous flows. The 
filters, contained within a specially designed holder, were attached directly to the 
aerosol chamber at the mouthpiece. Three filters were used consecutively per 
aerosol run.  
 
The APS was used methodically to check aerosol particle MMAD and mass 
concentration of the remaining aerosol between each filter test and for up to 7 
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minutes after the aerosol had formed. The FP deposition on each filter was 
recovered and analysed also by HPLC to quantify mass concentration for 
comparison to the APS measurements. The mass concentration decayed as 
expected due to sedimentation of the aerosol in the chamber after aerosol 
production ceased. The mass calculated by the APS was plotted against the mass 
concentration recovered from the filter for each particle size (Figure 2.30). 
 
  
 
Figure 2.30: Regression slopes comparing FP mass concentration obtained through HPLC analysis of 
filters vs. APS for 1.5-, 3-, and 6 μm monodisperse aerosols  
 
Despite the non-spherical nature of the particles a linear relationship existed 
between the APS and the ACI FP particle MMAD’s (Kalsi et al 2011). The APS 
slightly underestimated MMAD as particle size increased. The comparison of mass 
concentration measured by APS and filter collections also showed a linear 
relationship even though there was not a one to one correspondence. These 
measurements were reproducible for each particle size meaning that provided that 
the appropriate corrections factors were used, the APS can be used to give a 
measure of both particles size and mass concentration of a given monodisperse FP 
distribution. The regression slopes were used to extrapolate particle MMAD and 
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mass concentration measured by the ACI to the APS to ensure the correct particle 
size and drug dose was given to patients. 
 
2.9 Pharmacokinetic studies in subjects (Chapter 6)  
Manufacture and preparation of FP solutions for inhalation were performed by 
Hammersmith Medicines Research (HMR, London) and delivered to the Royal 
Brompton Hospital for use within 3 days of manufacture. At each visit participants 
either inhaled FP from a pMDI (250 µg) or 50 µg from 1 of 3 monodisperse aerosols 
(particles sizes 1.5, 3 or 6 µm MMAD, GSD <1.22). The three monodisperse 
aerosols were generated by the STAG and checked by the APS as described above 
in the validation work. Aerosol mass concentration was also measured by the APS to 
ensure the correct dose was inhaled by the subject.  
 
When monodisperse aerosols were inhaled, subjects performed four 
subsequent 2 L inhalations from FRC, via the inhalation port mouthpiece at an 
inspiratory flow rate between 30 and 60 L/min. They were guided by a visual 
indicator and each inhalation was followed by a 10 second breath-hold pause. 
Subjects practiced the inhalation on room air at the beginning of each visit. The 
volume of air inhaled and the breathing pattern were controlled by using a 
pneumotachograph attached to an electronic control circuit. A volumatic spacer was 
used when patients inhaled from a pressurized metered dose inhaler (pMDI).  
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2.9.1 Pharmacokinetic analysis of plasma samples 
A venous indwelling catheter was placed in the forearm for serial blood 
sampling (5 mls) at the beginning of each visit. Samples were taken at baseline and 
at the following times post dosing: 5, 7.5, 12.5, 15, 20, 25, 30, 45 minutes and 1, 1.5, 
2, 3, 4, 6, 8, 12 hours. Samples were collected into heparinized tubes then 
centrifuged within 30 minutes of collection at 40°C and 1,600 g for 10 minutes. The 
supernatant plasma was stored at -70°C prior to transfer to GlaxoSmithKline for 
quantification FP.  
 
Fluticasone propionate was separated from plasma and quantified using 
HPLC. The lower limit of quantification was 10 pg / ml. The following parameters 
were calculated. Maximum plasma concentrations (Cmax) and time of their 
occurrence (tmax) were determined from the observed highest concentration and its 
occurrence, and area under the plasma concentration time-curve (AUC0-12) from 
baseline to the last sampling time (12 hours). All HPLC analysis was performed by 
GlaxoSmithKline, Ware, UK.  
 
 
 
 
 
 
 
 
 
96 
 
CHAPTER 3: AEROSOL DEPOSITION IN THE UPPER AIRWAY  
 
3.1 BACKGROUND 
 
Inhaling drugs in the form of aerosols have advantages over orally 
administered drugs. Aerosolized drugs act faster and can be delivered topically to 
the airways at lower doses, whereas larger oral doses are required for the equivalent 
effect (Newhouse and Dolovich, 1986). However, a good proportion of the inhaled 
drug deposits in the upper airways, which act as a natural barrier to assist in the 
removal of inhaled noxious particles (Bowes and Swift, 1989), but the upper airways 
also trap aerosolized drugs targeted to the lung (Yu et al, 1998). There is great 
interest in trying to minimize the amount of drug depositing in the upper airways, as 
deposition in this region limits the amount of drug entering the lungs to give rise to 
clinical benefit, but also leads to the possibility of local oropharyngeal adverse effects 
as well as presenting drug to the gastrointestinal tract that could be absorbed to give 
rise to systemic side effects (Derendorf et al, 2006).  
 
 Many researchers have investigated both in vitro and in vivo, the passage of 
inhaled aerosols through the upper airways (and oropharynx), and beyond into the 
lungs. In recent years, the use of more ‘human’ like upper airway models has 
become increasingly popular in deposition (Burnell et al, 2007; McRobbie et al, 2003; 
Zhou et al, 2011). These models have been developed based on medical imaging 
performed in healthy subjects and are a step forward from the simplified universal 
induction ports (USP’s) (Nichols et al, 2013; Zhang et al, 2007). The USP’s have 
been used experimentally to mimic the human mouth and throat in cascade impactor 
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studies. As the name suggests they are simple and possess the same internal 
geometry from beginning (entry at mouth) to end (base of throat). These devices 
consist of an inlet throat which typically bends through 90° and attaches at the base 
to a chamber containing a series of partitioned stages (Borgstrom, 1999). After 
dispersal of an inhaler, aerosolized drug particles deposit on these stages depending 
on particle size. Larger particles collect on upper stages while small particles collect 
further towards the base. The USP together with the cascade impactor is supposed 
to mimic the upper airway and lungs in in vitro studies of inhaler performance. The 
rationale for performing in vitro tests is to simulate what occurs in vivo with the hope 
of correlating the findings (Srichana et al, 2000).  
 
Experiments with realistic ‘human-like’ models in the laboratory are simple, 
cost effective, and permit greater control over relevant factors that affect particle 
deposition (Zhang et al, 2007). However, while in vitro tests of inhaler performance 
are important in quality control and product development they are not great 
predictors of in vivo performance (Borgstrom, 1999). More recently a representative 
model of the throat has been developed for the use in cascade impactor studies 
called the ‘Alberta’ Idealized Throat. This model is also based on adult geometry and 
was originally developed by Stapleton et al (2000). Zhang et al (2004) developed a 
‘highly’ idealized mouth-throat which model was developed from investigations of 
particle deposition in curved pipes (Pui et al, 1987). Adult models are not suitable for 
studying aerosol deposition in the pediatric population as geometry of the upper 
airway in children changes with age. The ‘Sophia Anatomical Infant Nose-Throat’ 
(Saint) model was developed by Janssens et al (2001) to study the variables that 
inhibit drug delivery to the lungs in children. In their CFD model studies investigating 
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aerosol transport and deposition in the upper airways, Sosnowski and colleagues 
(2007) showed inertia (the predominant mechanism of deposition in the upper airway 
region influenced larger particles (>3 microns) such that they were deposited in the 
pharyngeal and nasal regions, whereas submicron particles were deposited 
relatively distally in the oropharynx. They did not investigate down to the level of the 
trachea as has been done here. They observed the effect of dynamic mixing of the 
airstreams in inspiration and expiration as influential in determining the relative 
patterns of aerosol deposition. 
 
Previous experimental and simulation studies of aerosol deposition in the 
upper airway during oral breathing have primarily focused on the inspiratory mode. It 
has been presumed that deposition within the oropharyngeal region is a 
consequence of inspiration (Yu et al, 1981). Cheng (2003) reviewed aerosol 
deposition in the upper airway and stated that no such data existed on expiratory 
deposition for particles in the impaction range (>0.5 µm). This lack of experimental 
data may be because most aerosol deposition strategies focus on maximizing 
deposition during inspiration by including an end-inspiratory breath hold. However, 
Usmani et al (2005) reported exhaled fractions of up to 20% for micron sized 
particles even when a breath hold was performed at end-inspiration. Cheng (2003) 
suggested that in the lack of expiratory deposition data, the deposition of micron 
sized particles in the oropharynx during inspiration and expiration is presumed to be 
equal. The National Council on Radiation Protection and Measurements 1997 
document (1997) suggests that expiratory and inspiratory deposition should be 
considered equal in the absence of any other information.  
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Hence, it can be appreciated that quantitative information on upper airway 
deposition is of importance, not only to industrial hygienists and environmental 
scientists interested in the amount of harmful inhaled substances that could reach 
the lungs (Cheng et al, 1997), but also in therapeutic drug delivery as upper airway 
deposition is undesirable as there is minimal therapeutic benefit (Ali et al, 2009).  
 
3.1.1 Aims 
The aims of this Chapter were to: 
 Investigate how aerosol deposition in the upper airway is influenced by 
aerosol particle size and flow rate in a throat model and human subjects.   
 Investigate the effect of flow direction (inspiration and expiration) on aerosol 
deposition in an upper airway model. 
 I also investigated if there were any different patterns of aerosol deposition 
within specific regions in the upper airway (‘regional deposition’) in an 
experimental in vitro set-up and in human asthmatic patients.  
 
3.1.2 Hypotheses 
The main hypothesis to be tested was that the total amount of aerosolized drug 
that deposits in upper airway models should increase as the aerosol particle size and 
inhaled flow rate increase, regardless of the direction of inhaled flow (inspiration and 
expiration).  
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3.2 METHODS 
 
3.2.1 Aerosol deposition in an experimental upper airway model 
Please refer to section 2.1 in the methods Chapter for a detailed account of 
the methodology used in the upper airway model experiments. In the present study, 
total deposition refers to particle collection in the whole upper airway as a 
percentage of the all the aerosol delivered. Regional deposition refers to particle 
collection in a region of interest (ROI) within this airway. ROI deposition represents a 
percentage of the total deposition. There are four distinct adjoining ROIs going from 
superior to inferior (oral cavity, pharynx, larynx, and trachea). The upper airway 
represents airways outside of the chest cavity, however, in this study the upper 
airway includes the trachea. 
 
As stated in the methods (section 2.1.2) three tests were performed for the 
smaller sized particle, low flow combination (3 μm at 30L/min) and for the larger 
sized particle, high flow combination (6 μm at 60 L/min). Four tests were performed 
for the two intermediary combinations of smaller sized particle at high flow (3 μm at 
60 L/min) and larger sized particle at low flow (6 μm at 30 L/min). Aerosol deposition 
under these experimental conditions was expected to vary. Therefore an extra set of 
measurements were performed. 
 
3.2.2 Aerosol deposition in the upper airway in asthmatic subjects 
Please refer to section 2.2 in the methods Chapter for a detailed account of 
methods used in asthmatic subjects. Twelve mild-moderate asthmatic subjects (6 
male: 6 female) with a documented history of reversible asthma were recruited. Each 
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patient provided information regarding their medical history and gave their written 
informed consent. The mean (± SD) spirometry measures for the group were; FEV1 
2.71 L (± 0.74 L), FEV1 % pred 76.8 % (± 11.4 %) and FVC 4.20 L (± 1.07 L).  
 
This study was approved by a local ethics committee. The data used here 
was part of a previous study: A randomized, double-blind, cross-over study to 
determine the effect of particle size of respirable fraction of salbutamol on respiratory 
function and systemic parameters in mild to moderate asthmatics. Information 
relating to the study ID was not available from the Research and Development 
department at the Royal Brompton Hospital (Chelsea, London) or Imperial College 
London. 
 
3.2.3 Statistical analysis 
Data were treated as normally distributed and statistical analysis was performed 
using GraphPad Prism 5 (San Diego, USA). 
 
3.2.3.1 Total deposition within the upper airway model 
Analysis of variance (ANOVA) and Bonferroni (post hoc) tests were performed to 
determine if as significant difference existed between the four combinations of 
aerosol particle size and flow rate: 
 6 µm at 60 L/min 
 6 µm at 30 L/min 
 3 µm at 60 L/min 
 3 µm at 30 L/min 
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The analysis was performed for inspiratory mode and repeated for expiratory mode. 
Differences were considered statistically significant at a p value < 0.05. 
 
3.2.3.2 ROI deposition within the upper airway model 
Analysis of variance (ANOVA) and Bonferroni (post hoc) tests were performed to 
determine if as significant difference existed between the four combinations of 
aerosol particle size and flow rate within each ‘individual’ ROI: 
 Oral cavity   
 Pharyngeal 
 Laryngeal 
 Trachea 
 
For example in the oral cavity and during the inspiratory mode: 
(6 µm at 60 L/min vs. 6 µm at 30 L/min vs.3 µm at 60 L/min vs. 3 µm at 30 L/min) 
The analysis was performed for inspiratory mode and repeated for expiratory mode. 
Differences were considered statistically significant at a p value < 0.05. 
 
3.2.3.3 ROI deposition within the upper airway of asthmatics 
Analysis of variance (ANOVA) and Bonferroni (post hoc) tests were performed to 
determine if as significant difference existed between the three combinations of 
aerosol particle size for a ‘single’ flow rate within each ‘individual’ ROI: 
 Oral cavity   
 Pharyngeal 
 Laryngeal 
 Trachea 
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For example in the oral cavity and at 30 L/min: 
(6 µm vs.3 µm vs. 1.5 µm) 
The analysis was performed for each aerosol particle size inhaled at 30 L/min and 
repeated for 60 L/min. Differences were considered statistically significant at a p 
value < 0.05. 
 
3.2.3.4 Comparison of ROI deposition between models and asthmatics 
T-tests were performed to determine if a significant difference existed between 
matched aerosol particle size and flow rate combinations and within each ‘individual’ 
ROI.  
For example in the trachea and for 6 µm at 30 L/min: 
(models vs. asthmatics) 
Differences were considered statistically significant at a p value < 0.01.  
 
3.3 RESULTS 
 
3.3.1 Total deposition in an upper airway experimental model  
Overall, total aerosol deposition in the experimental upper airway model 
increased when aerosol particle size was the largest and flow rate was high, and 
decreased when aerosol particle size was smaller and flow rate was low, for both 
inhalation flow rate (figure 3.1) and exhalation flow rate (figure 3.2).  
 
3.3.1.1 Total deposition during inspiratory mode 
Examining the inspiratory inhalation mode, total aerosol deposition within the 
experimental upper airway model was 79.8%, 36.4%, 13.0%, and 2.7% for the 6 µm 
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at high flow (60 L/min), 6 µm at low flow (30 L/min), 3 µm at high flow (60 L/min), and 
3 µm at low flow (30 L/min), respectively (table 3.1).  
 
Inspiratory deposition of the 6 µm at high flow was significantly greater than  6 
µm at low flow, 3 µm at high flow, and 3 µm at low flow (p = <0.001) (figure 3.1). 
Deposition of the 6 µm at low flow was significantly greater than 3 µm at high flow (p 
= <0.01), and 3 µm at low flow (p = <0.001), the latter comparison suggesting the 
importance of particle size effect at the same flow rate on total aerosol deposition in 
the upper airway model (figure 3.1).  
 
Only significant comparisons (p<0.05) are shown; all other comparisons are non-
significant.  
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Table 3.1 shows the total and regional percentage deposition in the 
experimental upper airway model during inhalation. Each experiment involved 
delivering a specific particle sized aerosol at a specific flow rate. Data from each 
experiment are reported. The number of repeated experiments was not the same in 
each experimental condition for particle size and flow rate combinations. 
 
Table 3.1: Percentage deposition in upper airway models during inspiratory mode  
Particle size (µm) 6  6  3  3 
Flow rate (L/min) 60  30  60  30 
Total deposition (%) 
Experiment 1  
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
87.5 
 77.9 
88.2 
65.4 
 
 
 
79.8 (10.7) 
37.0 
40.7 
38.6 
45.2 
20.3 
 
36..4 (9.5) 
14.6 
14.1 
18.7 
4.6 
 
13.0 (6.0) 
2.8 
3.2 
2.0 
 
 
 
2.7 (0.6) 
Oral cavity (%) 
Experiment 1 3 
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
 83.0 
  77.3 
 82.0 
81.2 
 
 80.8 (2.5) 
 69.9 
 56.1 
 53.6 
 66.3 
58.8 
 60.9 (6.9) 
 53.7 
 49.8 
 42.1 
 70.0 
 
 53.9 (11.8) 
 43.1 
 34.7 
 47.9 
  
 
 41.9 (6.7) 
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Table 3.1 Continued  
Particle size (µm) 6  6  3  3 
Flow rate (L/min) 60  30  60  30 
Pharyngeal (%) 
Experiment 1  
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
 10.3 
 13.1 
 9.9 
10.8 
 
 
 11.0 (1.5) 
 13.4 
 21.7 
 26.1 
 17.1 
16.7 
 19.0 (4.9) 
 17.2 
 17.5 
 21.1 
 13.3 
 
 17.3 (3.2) 
 17.2 
 24.7 
 15.6 
 
 
 19.2 (4.8) 
Laryngeal (%) 
Experiment 1  
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
 
 3.9 
 5.3 
 2.7 
4.6 
 
 4.1 (1.1) 
 4.7 
 14.4 
 14.8 
 7.2 
14.4 
 11.1 (4.8) 
 13.0 
 13.6 
 18.4 
 9.7 
 
 13.7 (3.6) 
 8.3 
 22.5 
 9.0 
 
 
 13.3 (8.0) 
Trachea (%) 
Experiment 1  
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
 2.9 
 4.4 
 5.5 
3.5 
 
 4.1 (1.1) 
 12.1 
 7.9 
 5.6 
 9.4 
10.0 
 9.0 (2.4) 
 16.1 
 19.1 
 18.5 
 7.0 
 
 15.2 (5.6) 
 31.4 
 18.1 
 27.4 
 
 
 25.6 (6.8) 
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3.3.1.2 Total deposition during expiratory mode 
Examining the expiratory exhalation mode, total deposition within the 
experimental upper airway model was 72.5%, 33.4%, 15.5%, and 3.0% for the 6 µm 
at high flow, 6 µm at low flow, 3 µm at high flow, and 3 µm at low flow, respectively 
(table 3.2).  
 
Expiratory deposition of the 6 µm at high flow was significantly greater than 6 
µm at low flow (p = <0.01), 3 µm at high flow (p = <0.001), and 3 µm at low flow (p = 
<0.001) (figure 3.2). Deposition of the 6 µm at low flow was significantly greater than 
3 µm at low flow (p = <0.05), again suggesting the importance of particle size effect 
at the same flow rate on total aerosol deposition in the upper airway model (figure 
3.2).  
 
3.3.1.3 Total aerosol deposition - Comparison of particle size and inhalation 
mode  
 The larger 6 µm particles gave greater total aerosol deposition than the 
smaller 6 µm particles in both inspiratory and expiratory mode. The combination of a 
larger particle size and higher flow rate (either inhalation or exhalation mode) led to 
the greatest aerosol deposition and conversely, the combination of a smaller particle 
size and slower flow rate (either inhalation or exhalation mode) led to the lowest level 
of aerosol deposition. 
 
The percentage total aerosol deposition in the upper airway models during 
inspiratory and expiratory modes was essentially the same between the inspiratory 
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mode and expiratory mode for each particle size and flow rate combination. 6 µm at 
high flow (60 L/min) 79.8% vs 72.5%, 6 µm at low flow (30 L/min) 36.4% vs. 33.4%, 
3 µm at high flow (60 L/min) 13.0% vs. 15.5%, and 3 µm at low flow (30 L/min) 2.7% 
vs. 3.0%, respectively for inspiratory versus expiratory mode (table 3.1 and table 
3.2).  
.  
 
Only significant comparisons (p<0.05) are shown; all other comparisons are non-
significant.  
 
 Table 3.2 shows the total and regional percentage deposition in the 
experimental upper airway model during exhalation. Each experiment involved a 
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delivering a specific particle sized aerosol at a specific flow rate. Data from each 
experiment are reported. The number of repeated experiments was not the same in 
each experimental condition for particle size and flow rate combinations. 
 
Table 3.2: Percentage deposition in upper airway models during expiratory mode  
Particle size (µm)  6  6  3  3 
Flow rate (L/min)  60  30  60  30 
Total deposition (%) 
Experiment 1  
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
 78.0 
 
 70.4 
 
 69.1 
 
 
 
 
 
 72.5 (4.8) 
 39.5 
 
 40.3 
 
 20.4 
 
  
 
 
 
 33.4 (11.3) 
 21.6 
 28.6 
 3.5 
8.1 
 
 15.5 (11.7) 
 2.6 
 
 1.0 
 
 5.4 
 
 
 
 
 
 3.0 (2.2) 
Oral cavity (%) 
Experiment 1  
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
 21.6 
 
 24.9 
 
 23.4 
 
 
 
 
 
 23.3 (1.7) 
 24.6 
 24.6 
 28.4 
 
 
 25.9 (2.2) 
 22.5 
 20.9 
 50.6 
31.9 
 
 31.5 (13.6) 
 33.0 
 
 29.8 
 
 27.0 
 
 
 
 
 
 29.9 (3.0) 
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Table 3.2 Continued 
Particle size (µm) 6 6 3 3 
Flow rate (L/min) 60 30 60 30 
Pharyngeal (%) 
Experiment 1 
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
73.6 
 
72.7 
 
68.4 
 
 
 
 
 
71.6 (2.8) 
71.4 
 
73.3 
 
61.6 
 
 
 
 
 
68.8 (6.3) 
74.0 
73.1 
44.0 
61.6 
 
63.2 (14.0) 
48.9 
 
63.3 
 
19.7 
 
 
 
 
 
44.0 (22.2) 
Laryngeal (%) 
Experiment 1 
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
2.0 
1.4 
2.7 
 
 
2.1 (0.6) 
2.5 
1.4 
2.8 
 
 
2.2 (0.7) 
2.1 
3.4 
2.2 
3.9 
 
2.9 (0.9) 
4.9 
1.3 
8.7 
 
 
5.0 (3.7) 
Trachea (%) 
Experiment 1 
Experiment 2 
Experiment 3 
Experiment 4 
Experiment 5 
Mean (SD) 
2.8 
0.9 
5.5 
 
 
 
 
3.1 (2.3) 
1.5 
0.8 
7.3 
 
 
 
 
3.2 (3.6) 
1.4 
2.6 
3.3 
2.6 
 
 
2.5 (0.8) 
13.3 
 
5.6 
 
44.6 
 
 
 
 
 
21.1 (20.7) 
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3.3.2 Regional aerosol deposition in an experimental upper airway model 
 
3.3.2.1 ROI deposition during inspiratory mode   
During the inspiratory mode, aerosol deposition was highest in the oral cavity 
when aerosol particle size and flow rate were both high (6 µm at 60 l/min), and 
lowest when aerosol particle size and flow rate were both low (3 µm at 30 l/min) 
(figure 3.3). Oral cavity deposition was  80.8%, 60.9%, 53.9%, and 41.9% for the 6 
µm at high flow (60 L/min), 6 µm at low flow (30 L/min), 3 µm at high flow, and 3 µm 
at low flow, respectively, showing that deposition increased with particle size and 
with flow rate (table 3.1).   
 
Deposition in the oral cavity of the 6 µm at high flow was significantly greater 
than 6 µm at low flow (p = <0.05), 3 µm at high flow (p = <0.01), and 3 µm at low flow 
(p = < 0.001). Deposition of the 6 µm at low flow was significantly greater than 3 µm 
at low flow (p = <0.05), suggesting the importance of particle size effect at the same 
flow rate on regional oral cavity deposition.  
 
The quantity of aerosol deposited within the pharyngeal and laryngeal regions 
was similar irrespective of particle size and flow rate combinations (figure 3.3 and 
table 3.1). However, as the aerosol particle size decreased (3 µm vs 6 µm) and the 
flow rate became slower (30 L/min vs 60 L/min), deposition in these regions slightly 
increased, although there was no statistical difference (figure 3.3).  
 
Deposition within the tracheal region of interest during the inspiratory mode 
was 4.1%, 9.0%, 15.2%, and 25.6% for the 6 µm at high flow, 6 µm at low flow, 3 µm 
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at high flow, and 3 µm at low flow, respectively (table 3.1). As the combination of 
aerosol particle size and flow rate decreased deposition significantly increased; that 
is, a reverse trend on tracheal deposition was seen for each particle size and flow 
rate combination in comparison to oral cavity deposition (figure 3.3).  
 
Tracheal deposition of the 3 µm at low flow was significantly greater than 3 
µm at high flow (p = <0.05), 6 µm at low flow (p = <0.001), and 6 µm at high flow (p = 
<0.001). Deposition of the 3 µm at high flow was significantly greater than 6 µm at 
high flow (p = <0.05), suggesting a particle size effect at the same flow rate on 
tracheal deposition.  
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Only significant comparisons (p<0.05) within each ROI are shown; all other 
comparisons are non-significant.  
3.3.2.2 Regional deposition during expiratory mode 
Examining the  amount of aerosol deposited within each of the 4 ROIs during 
the expiratory mode, there was no statistically significant difference between the  
particle size and flow rate combinations (figure 3.4). During expiration the largest 
amount of deposition occurred in the pharyngeal region, and it was observed within 
this region that as the combination of aerosol particle size and flow rate decreased 
so did deposition. Within the tracheal region the 3 µm particle at low flow (30 L/min) 
notably achieved ~21% deposition (figure 3.4), but this was not statistically 
significant compared to the other particle size and flow rate combinations, which 
each achieved ~3% deposition (Table 3.2)    
 
All comparisons within each ROI were non-significant (p>0.05)  
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3.4 Regional aerosol deposition in the upper airway in asthmatic subjects  
Having undertaken the exploration of particle size and flow rate in our 
experimental upper airway model during inspiratory and expiratory modes, I 
undertook to investigate the effect of particle size and flow rate on regional upper 
airways deposition in human asthmatic subjects. I studied three particle sizes (1.5-, 
3- and 6 µm), which were inhaled at slow and fast inhalation flow rates (30 and 60 
L/min).  Details of the patients and the methodology undertaken in human subjects 
are described in section 2.2 in the methods Chapter.  
 
3.4.1 Flow rate and particle size effects on regional aerosol deposition in the 
upper airway in asthmatic subjects 
At both slow (30 L/min) and fast (60 L/min) inhalation flow rates, overall, the 
greatest deposition was observed in the tracheal region, and lowest levels in the 
pharyngeal region (figure 3.5 and figure 3.6). The percentage of aerosol deposited 
within the pharyngeal regions at both slow and fast inhalation was statistically not 
significantly different for each particle size and flow rate combination, and the same 
was observed for the oral cavity at both flows (figure 3.5 and 3.6).  
 
Particle size influenced percentage of aerosol deposited within the tracheal 
region at high flow as there was significantly less deposition of the 6 µm aerosol 
(23.7 %) compared to the 3 µm (36.4 %) and 1.5 µm (41.9 %) aerosols (p = <0.05 
and p = <0.01 respectively) (figure 3.6). Comparisons between slow and fast flow 
rate in the pharyngeal and tracheal regions did not show any statistically significant 
differences for deposition in these regions of interest for each particle size (table 
3.3). 
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Within the oral cavity region of interest, it was observed that flow rate, as 
opposed to particle size, had the greater influence on the percentage of aerosol 
deposition (table 3.3). Reducing the flow rate from fast to slow significantly increased 
the deposition of the 1.5 µm aerosol from 23.0 % to 30.0 % (p = <0.05) and 3 µm 
aerosol from 19.7 % to 31.1 % (p = <0.01), whereas there was no difference for the 6 
µm aerosol (27.7% vs. 28.3%) (table 3.3). This also suggested that flow rate had a 
greater effect on deposition with the smaller particles. In contrast changing particle 
size for each flow rate did not significantly alter deposition within the oral cavity 
(figure 3.5 and figure 3.6).  
 
Within the laryngeal region, reducing the flow rate from fast to slow 
significantly decreased the deposition of the 1.5 µm aerosol from 22.6 % to 14.1 % 
(p = <0.05) and 3 µm aerosol from 27.5 % to 15.0 % (p = <0.01), whereas there was 
a reduction in deposition for the 6 µm aerosol (30.3% vs. 22.5%) but this was not 
statistically different (table 3.3). 
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Table 3.3: Percentage deposition in the upper airway in asthmatic subjects 
Particle size (µm) 6 6 3 3 1.5 1.5 
Flow rate (L/min) 60 30 60 30 60 30 
Oral cavity (%)   
Subject 1  
Subject 2 
Subject 3 
Subject 4 
Subject 5 
Subject 6  
Subject 7 
Subject 8 
Subject 9 
Subject 10  
Subject 11 
Subject 12 
Mean (SD) 
45.7 
 
19.8 
 
20.8 
 
20.9 
 
18.5 
 
20.5 
 
41.4 
 
38.7 
 
24.8 
 
23.7 
 
24.9 
 
33.1 
 
27.7 (9.5) 
19.5 
32.7 
26.7 
29.0 
24.4 
45.4 
14.2 
40.1 
24.6 
28.1 
22.0 
32.7 
28.3 (8.6) 
14.9 
26.3 
15.0 
22.5 
11.9 
17.6 
13.8 
41.7 
18.0 
24.9 
15.9 
14.2 
19.7 (8.3) 
22.5 
 
25.7 
 
32.9 
 
38.2 
 
38.5 
 
45.7 
 
15.3 
 
 
 
41.8 
 
26.8 
 
19.6 
 
35.4 
 
31.1 (9.8) 
 
20.2 
 
27.7 
 
22.1 
 
21.8 
 
16.9 
 
22.2 
 
21.0 
 
39.2 
 
17.4 
 
 
 
19.0 
 
26.2 
 
23.0 (6.3) 
 
21.9 
 
29.7 
 
40.7 
 
31.8 
 
34.6 
 
29.5 
 
18.1 
 
36.2 
 
46.1 
 
25.7 
 
16.0 
 
30.0 
 
30.0 (8.8) 
 
Pharyngeal (%)   
Subject 1  
Subject 2 
Subject 3 
Subject 4 
Subject 5 
Subject 6  
Subject 7 
Subject 8 
Subject 9 
Subject 10  
Subject 11 
Subject 12 
Mean (SD) 
11.4 
 
33.0 
 
31.4 
 
7.9 
 
17.8 
 
14.7 
 
13.0 
 
18.1 
 
28.6 
 
18.2 
 
17.1 
 
9.0 
 
18.3 (8.4) 
 
17.6 
22.6 
56.9 
6.6 
18.6 
10.7 
6.2 
6.9 
42.7 
14.6 
14.8 
14.8 
19.4 (15.4) 
9.4 
 
13.4 
 
25.0 
 
3.5 
 
24.9 
 
9.3 
 
15.2 
 
12.4 
 
31.2 
 
22.9 
 
13.7 
 
15.1 
 
16.3 (8.0) 
15.3 
 
50.4 
 
19.9 
 
7.4 
 
14.2 
 
12.3 
 
9.4 
 
 
 
14.4 
 
12.5 
 
14.2 
 
11.2 
 
16.5 (11.7) 
7.4 
 
17.5 
 
14.0 
 
5.9 
 
20.8 
 
9.5 
 
10.4 
 
7.6 
 
25.5 
 
 
 
7.7 
 
11.1 
 
12.5 (6.3) 
8.4 
 
37.9 
 
18.4 
 
9.5 
 
13.5 
 
15.3 
 
9.4 
 
19.1 
 
10.8 
 
8.6 
 
11.2 
 
15.4 
 
14.8 (8.2) 
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Table 3.3 Continued 
Particle size (µm) 6 6 3 3 1.5 1.5 
Flow rate (L/min) 60 30 60 30 60 30 
Laryngeal (%)   
Subject 1  
Subject 2 
Subject 3 
Subject 4 
Subject 5 
Subject 6  
Subject 7 
Subject 8 
Subject 9 
Subject 10  
Subject 11 
Subject 12 
Mean (SD) 
18.4 
28.1 
31.4 
29.2 
45.1 
38.8 
12.2 
27.3 
33.8 
33.7 
43.0 
22.7 
30.3 (9.6) 
40.7 
25.4 
7.9 
25.8 
30.1 
16.0 
15.5 
15.2 
18.3 
21.9 
33.5 
20.2 
22.5 (9.1) 
25.2 
35.6 
38.0 
15.6 
28.2 
30.9 
15.5 
12.4 
28.8 
20.2 
46.1 
34.0 
27.5 (10.2) 
19.8 
7.9 
13.9 
15.0 
10.3 
13.3 
9.6 
 
17.0 
17.7 
29.3 
11.6 
15.0 (6.0) 
10.9 
19.5 
21.8 
11.1 
39.0 
30.2 
14.5 
8.5 
34.3 
 
39.8 
19.0 
22.6 (11.5) 
14.4 
13.3 
14.8 
13.8 
17.4 
11.0 
18.0 
7.9 
13.2 
11.8 
16.1 
17.6 
14.1 (3.0) 
Trachea (%)   
Subject 1  
Subject 2 
Subject 3 
Subject 4 
Subject 5 
Subject 6  
Subject 7 
Subject 8 
Subject 9 
Subject 10  
Subject 11 
Subject 12 
Mean (SD) 
24.6 
 
19.2 
 
16.4 
 
42.0 
 
18.7 
 
26.0 
 
33.5 
 
16.0 
 
12.8 
 
24.4 
 
15.6 
 
35.2 
 
23.7 (9.1) 
22.2 
19.4 
8.5 
38.6 
26.9 
27.9 
64.2 
37.8 
14.4 
35.4 
29.7 
32.4 
29.8 (14.2) 
50.4 
24.7 
22.0 
58.4 
35.1 
42.2 
55.5 
33.6 
22.0 
32.0 
24.3 
36.7 
36.4 (12.8) 
42.4 
16.1 
33.3 
39.4 
37.0 
28.6 
65.7 
 
26.8 
42.9 
36.9 
41.8 
37.4 (12.4) 
61.6 
35.3 
42.2 
61.2 
23.3 
38.2 
54.0 
44.6 
22.9 
 
33.6 
43.7 
41.9 (13.2) 
55.4 
19.1 
26.2 
44.9 
34.6 
44.3 
54.5 
36.9 
29.9 
53.9 
56.7 
37.0 
41.1 (12.5) 
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Only significant comparisons (p<0.05) within each ROI are shown; all other 
comparisons are non-significant  
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Only significant comparisons (p<0.05) within each ROI are shown; all other 
comparisons are non-significant. 
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3.5 Comparison between ROI deposition in an experimental models and 
human asthmatic subjects 
Comparisons were made between ROI deposition in asthmatic patients and 
model experiments (for two particle sizes (3 and 6 µm) at slow and fast inspiratory 
flow rates (30 and 60 L/min). 
 
Oral cavity deposition was greater in the experimental upper airway model 
compared to asthmatic subjects for each particle size and flow combination (figure 
3.7). At high flows (60 L/min) there was significantly (p = <0.001) more deposition in 
the model compared to asthmatics for the 6 µm aerosol (80.8% vs. 27.7%) and 3 µm 
aerosol (53.9 % vs.19.7 %). At low flows (30 L/min) there was significantly (p = 
<0.001) more deposition in the model compared to asthmatics only for the 6 µm 
aerosol (60.9% vs. 28.3%), and although a similar trend for the 3 µm aerosol was 
observed 41.9% vs. 31.1%), this was not statistically significant (figure 3.7).  
 
Pharyngeal deposition was similar between both types of studies and was not 
effected by particle size and flow rate conditions. 
 
Laryngeal deposition was greater in the asthmatic subjects than in model for 
all particle size and flow combinations. At high flows there was significantly (p = 
<0.001) more deposition in asthmatics compared to the model for the 6 µm aerosol 
(30.3% vs. 4.1%), and although a similar trend for the 3 µm aerosol was observed 
(27.5% vs. 13.7%), this was not statistically significant (figure 3.7) 
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Tracheal deposition was greater in the asthmatic subjects than in the model 
for all particle size and flow combinations. At high flows there was significantly more 
deposition in asthmatics compared to the model for the 6 µm aerosol (23.7% vs. 
4.1%; p = <0.001)) and the 3 µm aerosol (36.4% vs.15.2 %; p = <0.01)). At low flows 
there was significantly (p = <0.01) more deposition in the asthmatics compared to 
the model for the 6 µm aerosol (29.8% vs. 9.0%), and although a similar trend for the 
3 µm aerosol was observed (37.4% vs. 25.6%), this was not statistically significant 
(figure 3.7).  
  
Only significant comparisons (p<0.01) within each ROI are shown; all other 
comparisons are non-significant  
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3.6 DISCUSSION 
 
 Through the use of an in vitro experimental upper airway model and in vivo 
experiments in human asthmatic subjects, this study has demonstrated that flow rate 
and aerosol particle size both influence total and regional upper airway deposition, 
and that both factors of flow rate and particle size should be considered in 
combination together, and not in isolation, to understand the deposition patterns of 
inhaled aerosols within the upper airways. Importantly, using the model, the data 
showed that airway deposition occurred in the upper airways on exhalation as well 
as on inhalation, and it was observed that the direction of airflow also affected the 
specific aerosol deposition patterns within the different regions of interest. These 
observations may have clinical implications for the toxic or pharmacological local 
effects of inhaled aerosols.   
 
Both in vitro and in vivo approaches in this study observed a trend during 
inspiratory conditions where aerosol deposition improved in the distal tracheal region 
of interest (ROI) as aerosol particle size became smaller (figures 3.3, 3.5 and 3.6), 
which was significant for the experimental model. This deposition pattern in the 
tracheal region was further enhanced when inspiratory flow was reduced from fast to 
slow (figure 3.7). The data shown here within the upper airways were therefore 
consistent with previous results showing that as particle size and flow rate both 
decrease, aerosol deposition overall potentially reaches further distally along the 
airway tree (Usmani, 2005). Usmani and colleagues (2005) showed in asthmatic 
subjects that a 1.5 µm aerosol inhaled slowly resulted in greater aerosol penetration 
along the airway tree in comparison to a larger 6 µm aerosol inhaled at a fast (> 
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60L/min) inhalation flow rate. Indeed, in the experimental model as the distal ROI 
(tracheal) deposition improved with decreasing particle size and flow rate, the 
proximal ROI (oral cavity) deposition decreased (figure 3.7), although this was not 
observed in the asthma patients, for the oral cavity.  
 
In comparison, oral deposition was lower in asthmatics than that observed in 
the experimental model and this clearly could be due to morphological differences 
between the two and mechanisms of aerosol deposition (figure 3.7). The dominant 
mechanism for upper airway deposition has been cited as inertial impaction (Cheng 
et al, 1999; Fadl et al, 2007; Rudolf et al, 1990; Stahlhofen et al, 1989; Yu et al, 
1981; Zhang et al, 2006). Micron (µm) sized particles deposit by inertial impaction as 
they experience rapid changes in trajectory and reach high speeds (Martonen, 
1993). Aerosol deposition increases with increasing particle diameter and flow rate 
because of the strong inertial impaction for particles larger than 1 µm (Mitsakou et al, 
2007). 
 
The preferential oral deposition of larger particles during inhalation compared 
to submicron (<1 micron) particles has been observed in model experiments 
(Ehtezazi et al, 2006) and in computational fluid dynamic (CFD) simulations 
(Sosnowski et al, 2007; Takano et al, 2006). Recently Ehtezazi et al (2009) used 
ultrafine pMDI’s, devices that generate aerosols with a mass median aerodynamic 
diameter of less than 0.83 µm, in seven oropharyngeal models with different internal 
geometry. They found that inhaling ultrafine aerosols via spacers at 30 L/min may 
reduce the effect of oropharyngeal geometry on inhaled aerosol properties; that is, 
smaller particles may be more forgiving of the anatomical structural environment of 
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the oropharynx with respect to deposition. Aerosol deposition in the upper airway is 
affected by inter-subject and to a lesser extent intra-subject geometric configuration 
(Grgic et al, 2004; McRobbie et al, 2003b; McRobbie and Pritchard, 2005; Pritchard 
and McRobbie, 2004; Yu et al, 1979). As a result, high variability in the upper airway 
aerosol deposition can be expected and has been previously observed (Borgstrom et 
al, 2006; Burnell et al, 2007; Grgic et al, 2004; Xi and Longest, 2007). 
  
 In the assessment of the data, the aim was to also to identify similarities and 
disparities between both in vitro and in vivo approaches in order to determine 
whether the experimental upper airway model could predict the behavior of aerosols 
in the human asthmatic upper airways. There were significant differences observed 
between the deposition amounts observed in the in vitro model to the in vivo patients 
in the tracheal and oral cavity ROIs for all particle size and flow combinations except 
the smallest particle (at the slowest inhalation flow (3 micron at 30 L/min). Generally, 
significantly higher tracheal deposition values were observed in the asthma patients 
than determined by the experimental model. However, it is actually highly likely that 
some of the deposition counts were due to radioactivity in the esophagus rather than 
just in the trachea and it was almost impossible to separate them out. Patients were 
instructed to refrain from swallowing during the duration of the image acquisition but 
it is likely that radioactivity was swallowed and resided in the esophagus. However, 
in the pharyngeal and also the laryngeal (except the 6 micron at 60 L/min) 
compartments, there were reasonably similar deposition amounts observed for all 
particle size and flow rates with no significant differences between the experimental 
set up and the patients and potentially, the model could be used to predict 
pharyngeal deposition in human subjects.  
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Model experiments showed that aerosol deposition during expiratory mode 
was very different to that observed during inspiratory mode. Deposition was greatest 
in the pharyngeal region on expiration and not influenced by flow rate or particle size 
(figure 3.4). In contrast, oral cavity deposition was greatest during inspiratory mode 
and larger particles and faster flows gave significantly higher deposition, and this 
would again be explained by their greater momentum and inertial impaction 
compared to the smaller particles at slower flows (figure 3.3). During inhalation, the 
experimental model also showed that the order of aerosol deposition was greatest in 
the oral cavity region and then in the tracheal region, with finally relatively equal 
amounts in pharyngeal and laryngeal region (figure 3.3). In contrast, the human 
study showed that slightly more aerosol deposition occurred in the trachea than in 
the oral cavity, with relatively equal amounts in pharyngeal and laryngeal region 
(figure 3.5 and figure 3.6). In this respect, the experimental model was similar to the 
in vivo state  with respect to which of the four ROIs studied would receive the least 
amount of aerosol (pharyngeal and laryngeal), but the experimental model was 
unable to predict the order of deposition or the ROI that would receive the greatest 
amount of aerosol deposition. Overall, there were more disparities observed 
between the in vitro model and the in vivo study, suggesting that the experimental 
model studied was not an effective surrogate to accurately predict aerosol behavior 
in the upper airways of human diseased subjects. 
 
Total aerosol deposition in the upper airway model, as opposed to ROI 
deposition, was similar for each combination of aerosol particle size (3 and 6 µm) 
and flow rate (30 L/min and 60 L/min) and was unaffected by direction of the flow . A 
clear trend was observed in greater deposition as aerosol particle size and flow rate 
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increased (figure 3.1 and figure 3.2). Both Cheng (2003) and the National Council on 
Radiation Protection and Measurements 1997 document (1997) suggested that 
inspiratory and expiratory deposition should be considered equal in the absence of 
any other information. This study here shows that total deposition during inspiratory 
and expiratory modes was similar but regional lung deposition was very different. 
Total deposition was similar during both modes because the models had a simplified 
internal geometry that remained static during all experiments. All aerosols would 
have travelled through the same oral-pharyngeal curves regardless of flow direction. 
During the inspiratory and expiratory modes aerosol particles were retained in the 
oral and pharyngeal regions respectively. This accounts for differences in  regional 
deposition.  
 
In humans the upper airway internal geometry changes between inspiration 
and expiration. The cross-sectional area increases during inhalation but decreases 
during expiration. This influences the relative sizes of the airway compartments, local 
curvatures, and flow velocity. Therefore it may seem reasonable to expect more 
deposition during expiration than inspiration. Heenan et al (2004) found that local 
deposition can vary within one and the same individual depending on if the tongue 
was pulled back or not. Achieving an optimal anatomical throat has been considered 
crucial in understanding and predicting aerosol transport within the airway tree.  
 
Cheng et al (2001) and Zhang et al (2006) have suggested that experiments 
using a standard USP with cascade impactors largely underestimate deposition in 
the human upper airway. Studies by Stein and Gabrio (2000) and Cheng et al (2001) 
demonstrated using a pMDI that deposition in their mouth and throat models was 
127 
 
greater than deposition in the USP. Borgstrom (1999) stated that in vitro 
measurements of fine-particle dose will be highly dependent on the internal 
geometry of the USP connected to an impactor. The fine particle dose is the amount 
of drug with an aerodynamic diameter of less than 5 µm. Borgstrom (1999) stated 
that this is considerably lower when a model of the human throat is used versus 
when a standard gas inlet is used. Berg (1995) found the fine particle dose of 
budesonide, delivered as a pMDI, was significantly reduced when an upper airway 
model was used compared with a standard USP. Olsson (1995) found the fine 
particle dose of budesonide DPI (Turbohaler) was similar between the upper airway 
model and USP, but the fine particle dose was reduced in the throat model for 
budesonide delivered as a pMDI. This is because the internal geometry of the upper 
airway models is more complex and impaction losses are greater than in a standard 
USP.  
 
Studies by Kim et al (1987), Newman et al (1991), and Fink (2000), have 
demonstrated that a considerable amount of aerosol from a pMDI can deposit in the 
upper airway, up to 80% for pMDI’s and 50% for DPI’s. Pressurized metered dose 
inhalers are used by asthmatics due to their portability and low airflow resistance 
(Ehtezazi et al, 2009). If deposition in the upper airway is underestimated as for the 
USP then deposition in the lung may be overestimated in subjects using pMDI’s. 
Variability in upper airway drug deposition has been shown to cause variability in the 
amount of drug that reaches the lung (Borgstrom et al, 1996).  
 
It may be debated whether understanding the localized deposition of inhaled 
aerosol within specific upper airway ROI will lead to clinical impact. Deposition 
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studies on inhaled aerosols are important for monitoring the behavior of existing and 
future drugs in treating lung diseases. In the field of therapeutic aerosols for 
respiratory therapy incorporating the four upper airway ROIs into subject 
experiments could provide valuable information regarding the deposition of micron 
sized aerosol particles throughout the human respiratory tract (upper and lower 
airways). The side-effects associated with aerosol deposition in the upper airway are 
known. However, the specific site of aerosol deposition within the upper airways may 
not be important since the aerosol particles will be in contact with saliva and mucus 
for transport to the gut after swallowing. The swallowed portion could induce 
unwanted side effects observed in asthmatics using corticosteroids, and oral 
bioavailability is currently ascertained by studying the upper airways as one unit. 
However, high concentrations of inhaled corticosteroids (ICS) may not be removed 
rapidly by saliva and mucus and may induce local upper airway side effects that can 
be localized to their anatomical location (table 3.4). 
  
Importantly, knowing the basic characteristics of the aerosol device (particle 
size and flow) that is being used to deliver the ICS may allow one to predict in an 
individual patient or group of patients the likelihood of getting a ‘site-specific’ side-
effect. For example, one may want to avoid directing ICS to the laryngeal region to 
avoid affects on vocal function and this could potentially be achieved by altering 
particle size and flow rate. Figure 3.7 shows that an ~15% drop in aerosol deposition 
in the laryngeal region is achieved in asthmatic patients when an aerosol of 3 
microns is inhaled at 30 L/min versus an aerosol of 6 microns inhaled at 60 L/min. 
This would need to be shown in a clinical study. 
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Table: 3.4 Side effects induced by local deposition of inhaled corticosteroids by anatomical region 
Inhaled corticosteroid side-effect Upper airway anatomical region 
Mouth ulcers 
Oropharyngeal candidiasis  
Pharyngitis 
Dysphonia 
Reflex cough 
Bronchospasm 
Tracheitis 
Oral cavity 
 
Oropharynx 
 
Pharynx 
 
Larynx 
 
Larynx 
 
Laryngotracheal 
 
Tracheal 
 
 
Collectively the data in this Chapter highlights the often overlooked fact that 
particles can deposit on their way out of the lungs as well as on their way in. The 
model experiments (during expiratory mode) demonstrated that local deposition may 
be increased during expiration because aerosol particles which are exhaled or 
remain airborne deposit in the pharyngeal region. The model experiments 
demonstrated that pharyngeal expiratory deposition was greater than 70.0% while 
inspiratory deposition was under 20.0%. This observation could potentially be utilized 
by engineers designing new aerosol inhalation devices in order to (i) target aerosol 
to selective upper airway regions (and avoid other regions) and (ii) improve the 
efficiency aerosol delivery to the lungs by understanding the relative retention in the 
upper airways with that in the lower airways (lungs).   
 
One possible direct area that may benefit from the need for regional 
anatomical specificity (into four distinct regions of interest) and understanding 
aerosol deposition is that of treating patients with chronic cough (Morice et al, 2015). 
Novel oral treatments in development (such as the current interest in targeting TRP 
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channels in cough) (Bonvini et al, 2015) are often limited by side-effects, and there 
may be a need to produce inhaled formulations of such drugs for efficacy in human 
subjects. By knowing the ideal particle size and flow rate conditions to optimally 
target the laryngeal (cough reflex) region may allow investigators vital information 
during the compound development process.     
 
3.6.1 Limitations of the study  
 The ROI deposition results from model experiments may have differed if less 
simplified models with more realistic internal geometry were used. The four identical 
silicone rubber models were based on a single individual whose upper airway 
morphology was considered representative of most healthy adults (Brouns et al, 
2007). The initial resin cast used to construct the models was based on computed 
tomography images of the upper airway during an end-inspiratory breath hold in the 
supine position. In this position the upper airway internal geometry decreases due to 
gravitational forces but to what degree an end-inspiratory breath hold compensates 
for this is unknown.  
 
Computed tomography was used to obtain the air space within the upper 
airway and was not sensitive to the ROI volume changes. Magnetic resonance 
imaging has provided more information on upper airway anatomy detail (McRobbie 
et al, 2003) and would be sensitive to ROI volume changes. Additionally, inclusion of 
anatomical structures such as soft palate, tongue, uvula, arytenoids, vocal cords, 
laryngeal ventricle, ventricle fold, and cartilaginous rings within the trachea may have 
influenced ROI deposition. While most of these anatomical structures remain static 
during breathing the vocal cords are dynamic. Brancatisano et al (1983) studied the 
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respiratory movements of the vocal cords and found that the widths of the glottal 
opening varied during tidal breathing, with a maximal glottal width of 10.1 ± 5.6 mm 
(mean ± S.E.) and a maximal cross sectional area of 126 ± 8 mm2. Robinson et al 
(2009) stated that the vocal folds can vary in shape during respiration and that the 
consequence of the interaction between the true and false vocal folds during 
respiration is unclear as this can lead to gaps and air spaces within the laryngeal 
compartment. Martonen (1990) suggested incorporating physiological realistic 
laryngeal features in models because older studies by Chan et al (1978) and 
Martonen and Lowe (1983) demonstrated enhanced aerosol particle deposition in 
human laryngeal models. The larynx is a region of maximum flow constriction (Xi et 
al, 2008). If inspiratory pharyngeal deposition is to be investigated the use of a 
simplified model as used here would be adequate as results were similar to human 
subjects.  
 
There are limitations in using two dimensional gamma-scintigraphy. The 
images are taken from two dimensions making it difficult to distinguish the trachea 
from the esophagus in asthmatics. Additionally the outline of the ROI needs to be 
large enough to include all radioactive counts which highly increased the likelihood of 
including radioactivity in the esophagus. This can be reduced by gargling and 
drinking fluids and eating to remove radioactivity in the upper part of the 
gastrointestinal tract. The problems associated with two dimensional imaging can be 
overcome with other imaging techniques. The results reported here for tracheal 
deposition in asthmatics should be interpreted with care.  
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Future research should focus on using realistic upper airway models that 
possess internal geometries specific to the flow direction to be studied. This is 
important as the cross sectional area will be larger during inspiration then expiration. 
Life like anatomical structures should be incorporated to replicate the human upper 
airway. If imaging is used to construct the model a sensitive imaging technique must 
be used. Magnetic resonance imaging has the advantage over CT because there is 
no radiation dose. The radiation dose of CT restricts its use to studies involving 
healthier volunteers as opposed to subjects with clinical indications (McRobbie et al, 
2003).  
 
When repeating such experiments it may be useful to perform extra tests at 
flow rates observed in persons both during inspiration and expiration. This is 
because individuals using inhaled medication inhale and exhale at differing flow 
rates than the fixed flow rates in this study. It may be of interest to perform the 
inhalation tests with and without a volumatic spacer device to see how this impacts 
upper airway aerosol deposition.  
 
3.7 SUMMARY 
 
In summary the data supports the hypotheses that as aerosol particle size 
and flow rate increase so does the total amount of drug depositing in the upper 
airway, while oral and pharyngeal deposition increases during inhalation and 
exhalation respectively. Additionally experiments using upper airway models can be 
used to predict deposition in human subjects during inspiration.  
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 In both asthmatics and models aerosol deposition improved distally in the 
trachea as aerosol particle size became smaller. This deposition was enhanced 
under low inspiratory flow conditions. Therefore as particle size and flow rate 
decreased the amount of aerosol that potentially reaches the lung improves.  
 
The deposition results from model experiments may have differed if more 
realistic models were used. Models should include anatomical structures and internal 
geometry specific to inspiration and expiration.  
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CHAPTER 4: AIRWAY PHYSIOLOGY AND INFLAMMATION IN 
HEALTHY LUNGS AND OBSTRUCTIVE LUNG DISEASE: GROUP 
COMPARISONS 
 
4.1 BACKGROUND 
 
4.1.1 Airways anatomy 
Understanding the structure and function of the normal airways helps in our 
understanding of how obstructive lung diseases alter respiratory function and inhaled 
aerosol (therapeutic and environmental) deposition. Much of what is known about 
airway morphology is based on Weibel’s original work where he measured the 
number, length and width of the airways and Figure 4.1 is based on Weibel’s (1963) 
model of the lung. The thoracic airways start at the trachea (airway generation 0) 
and progressively bifurcate such that each generation of airways becomes smaller in 
diameter and length, down to the level of the alveolar ducts (airway generation 23) 
as described in Ewald Weibel’s seminal paper (Weibel 1963). Large airways are 
airways > 2 mm in diameter (airway generation 0 - 7) and their major constituent are 
the bronchi that contain cartilage and maintain airway patency (Kendrick, 2007). The 
peripheral or small airways are defined as conducting airways ≤ 2 mm in diameter 
(airway generation 7 – 23) and extend from the non-cartilaginous bronchioles to the 
alveolar ducts (James, 2002). In healthy subjects, the greatest amount of resistance 
is found within the large airways (Kendrick, 2007) and the resistance within the small 
airways accounts for 10% of the total resistance to flow (Hogg et al, 1968; Macklem, 
1967). 
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Weibel also described the first 15 - 16 generations constituting the 
‘conducting’ zone involved in transporting inhaled air between the environment and 
gas exchanging regions of the lungs (Weibel 1963). Airway generations 16 – 23 form 
the acinar or ‘respiratory’ zone and are mainly involved in gas exchange. Alveolar 
ducts appear at generations 19 – 22 and generation 23 constitutes the alveolar sacs 
(Kendrick, 2007).  
 
Based on this anatomical model, there is currently much interest in knowing 
whether treating the small airways in patients with asthma and chronic obstructive 
pulmonary disease (COPD) is beneficial (Scichilone 2015; Usmani, 2012; Usmani 
and Barnes 2012; Usmani 2015) and so it is important to understand the extent of 
small airways dysfunction in these patients groups using advanced physiology tools. 
The difficulty is that the small airways have been termed the ‘quiet’ zone as it difficult 
to assess this region in daily clinical practice (Macklem and Mead 1967). 
Understanding airway function and lung mechanics has helped physiologists and 
physicists to develop approaches to assess the ‘silent’ zone (Usmani, 2012c). 
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Figure 4.1: Morphological model of the airways (left) and physiological compartments of the airways 
(right) redrawn from Weibel’s (1963) original work.   
 
4.1.2 Airways function  
The airways narrow with each branching, decreasing from approximately 18 
mm in the trachea to 0.7 mm at generation 14 and 0.3 mm at the alveolar ducts 
(Kendrick, 2007). As the airways narrow there is an increase in the resistance 
(pressure / flow) to airflow within a single airway. Continual branching of the airways 
increases the total cross-sectional area from 2.5 cm2 in the trachea to approximately 
13 cm2 at the 10th generation (1024 airways) with a final cross-sectional area of 
around 300 cm2 in the acinar zone (Kendrick, 2007). Therefore there is a significant 
increase in the surface area available for gas exchange.  
 
In the conducting zone and large airways, air moves by bulk flow and air flow 
is largely turbulent which in turn increases resistance to air flow. Within the small 
airways and particularly within the acinar zone, air moves by diffusion. Small 
conducting airways have a thin wall and offer little resistance to airflow that is 
laminar.  
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4.1.3 Small airways 
Small airway obstruction has little effect on the mechanical properties of the 
lung, particularly if there is collateral ventilation, but it does affect the distribution of 
inspired gas if the air is displaced from one set of air spaces across collateral 
channels to alveoli beyond the obstructed airways (Macklem, 1998). Fresh air will 
enter the unobstructed alveoli, whereas the collateral ventilated spaces will receive 
alveolar gas (Macklem, 1998). Collateral ventilation occurs due to the pores of Kohn 
which appear in alveolar walls of adjacent alveoli. These pores allow transfer of gas 
between alveoli and function to minimize the collapse of lung units if a larger airway 
becomes blocked (Hogg et al, 1969).  
 
Brown et al (1969) placed small and large beads to obstruct small and large 
airways respectively in excised dog and pig lungs. Extensive small airways 
obstruction resulted in little change in total pulmonary resistance. The obstruction of 
high resistance pathways, large airways, increased the total pulmonary resistance by 
double that of small airways obstruction.  The vital capacity was unaffected in both 
small and large airways obstruction due to collateral ventilation. The vital capacity 
was reduced in pig lungs which are deprived of collateral channels. Humans have 
collateral ventilation and small airways obstruction has little effect on lung mechanics 
but it does affect ventilation distribution (Macklem, 1998).  
 
4.1.4 The small and large airways in obstructive lung disease 
The structure of the airways, and hence their function is affected by disease 
(Ranga and Kleinerman, 1978). Different anatomical sites are involved in the 
pathology of asthma and chronic obstructive pulmonary disease (COPD). Asthma is 
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traditionally considered to affect mostly the large airways while COPD affects the 
lung parenchyma. However, it has been shown that both disorders, asthma included, 
involve disease of the small airways and the structural changes in these airways are 
responsible for much of the physiological impairment that occurs (James et al, 1989; 
Moreno et al, 1986; Wiggs et al, 1990). Indeed, although the small airways contribute 
little to airway resistance in healthy individuals, studies using invasive measurement 
of airways resistance have shown that the small airways are a major site of airflow 
limitation in diseased lungs such asthma and COPD (Bates and Suki, 2008; 
Macklem and Mead, 1967; Yanai et al, 1992). Resistance to airflow (which causes 
airflow limitation) varies inversely with the fourth power of the airway radius. A 
decrease in airways radius may be a consequence of the inflammatory processes 
where cells obstruct the airway lumen, the thickness of the submucosa increases, 
fibrosis occurs, smooth muscle mass increases and there is elevated mucus 
secretion. Loss of alveolar attachments in the membranous bronchioles causes 
destabilisation of the airway, premature closing and airflow limitation, and premature 
airway closing has been considered a physiological hallmark and marker signifying 
small airways disease (Burgel, 2011).  
 
Inflammation is the abnormality that contributes to small airway narrowing 
while emphysema is the abnormality most associated with loss of elasticity in 
alveolar attachments (Cosio et al, 1978; Cosio and Guerassimov, 1999; Hogg et al, 
1968; Hogg et al, 2004). Inflammation is largely eosinophilic driven in asthma and 
neutrophilic driven in COPD (Postma et al, 2014).  
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In fatal asthma, inflammation has been demonstrated to increase the cross-
sectional total wall area of both large and small airways compared to healthy controls 
(Carroll et al, 1993). Within the large airways there are ciliated epithelia cells and 
goblet cells which decrease in number along the airway pathway such that goblet 
cells are replaced by Clara cells in the small airways. Goblet cells, mucus secreting 
cells and submucosal secretory cells produce thick mucus that lines all but the 
smallest of conducting airways (Kendrick, 2007). Macklem et al (1970) suggested if 
mucus cannot be eliminated it is quite possible that it could move peripherally 
towards these smaller airways replacing surfactant. The low surface tension of 
surfactant protects the small airways from closing at reduced lung volumes. Mucus 
has a higher surface tension destabilising these airways and causing them to 
collapse. The extent to which mucus adheres to a surface is largely dependent on its 
surface tension (Daviskas and Rubin, 2013) and mucus with a high adhesivity is not 
easily transported by either cilia or cough (King et al, 1989).  
 
COPD is characterised by increased sputum production, hyperplasia of 
mucus glands, and ineffective cough (Macklem et al, 1970) therefore mucus 
production may not be balanced by elimination and its presence will contribute to 
small airway obstruction. Similarly surfactant abnormalities resulting from 
inflammatory exudate or excess mucus production could lead to closure of 
bronchioles and distal airways in asthma (Macklem, 1998).  
 
4.1.5 Airways physiology and assessment 
Physiological assessment of respiratory function is crucial for detecting 
pathological abnormalities in lung function, distinguishing between different disease 
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conditions, classification of disease severity and in the assessment of the response 
to inhaled therapy.  
 
Recently, Pretto et al (2013) cited the main reason why patients were referred 
for hospital based respiratory testing was for follow up of known respiratory disease. 
The two main subcategories of disease were asthma (26%) and COPD (40%). Both 
diseases are the most common obstructed airway disease in the community (Gibson 
and Simpson, 2009) and distinguishing between the two diseases in older patients 
can prove difficult (Sin et al, 2006). Indeed as described, both asthma and COPD 
involve the small airways (a major site of airflow limitation) and historically this 
relatively inaccessible region of the lungs has been termed the ‘quiet’ zone (Macklem 
and Mead 1967). The assessment of diseased distal small airways in day to day 
practice is difficult (Usmani and Barnes 2012) and this perhaps highlights that there 
is a need to develop new approaches for the assessment of these diseases beyond 
routine lung function tests in current practice. 
 
4.1.6 Aims  
The purpose of this cross-sectional study was to compare and contrast 
respiratory tests of large and small airway dysfunction in subgroups of the population 
with and without chronic obstructive lung disease. The tests and results were 
described for five different subject groups (healthy volunteers, healthy smokers, mild-
moderate asthmatics, severe asthmatics, and COPD). The primary aim was to 
determine the extent to which there was small (and large) airways dysfunction 
(physiological and inflammatory measures) in the different subject groups, in order to 
assess the relative importance of the ‘quiet’ zone in each disease. A panel of novel 
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advanced lung physiology tests were utilised to investigate small airways 
dysfunction. The next chapter (chapter 5) assesses the changes in these 
measurements prospectively over 16 months.  
 
4.1.7 Hypothesis 
The main hypothesis to be tested was that small airways dysfunction was 
present in patients with obstructive lung disease to support the current view that 
treating the small airways with inhaled aerosols directed to this region may be of 
benefit. 
 
4.2 METHODS 
 
4.2.1 Subjects and study design 
This was a single centre cross-sectional (Chapter 4) and longitudinal (Chapter 
5) study involving asthmatic and chronic obstructive pulmonary disease (COPD) 
patients and healthy volunteers (including smokers). Subjects were between the 
ages of 18-85 years old, were given a patient information sheet and provided their 
written informed consent. Subjects were interviewed at visit 1 and a medical history 
was documented. Healthy subjects (including smokers) had no history of respiratory 
disease. COPD patients (stages I – III) were classified according to the Global 
Initiative for Chronic Obstructive Lung Disease guidelines (GOLD, 2011). Asthmatics 
(mild, moderate and severe) were classified according to the Global Initiative for 
Asthma diagnostic criteria (GINA, 2009). Patients with lung disease were instructed 
to continue their medications as normal during study.  
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Subjects were free from cardiac, gastrointestinal, hepatic, renal, 
haematological, neurological and psychiatric disease. No subjects reported alcohol, 
drug abuse, or any other condition associated with poor compliance. No females 
were pregnant or breastfeeding during participation. The tests were repeated every 8 
months for a total of 3 study visits. This study was approved by Hounslow and 
Hillingdon Research Ethics Committee. (Study ID: 08/H0709/2) and registered on 
ClinicalTrials.gov (identifier: NCT00677560) and funded and sponsored by Imperial 
College London. Figure 4.2 gives an overview of the study protocol at baseline 
(cross-sectional, Chapter 4) and repeated visits (Chapter 5).  
Figure 4.2: Overview of study protocol 
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4.2.2 Respiratory function tests  
Measurements of respiratory function were performed in the following order and 
as outlined in methods (*indicates advanced / specialist physiological tests that have 
been advocated as indirectly assessing the distal small airway tree): 
1. Multiple flow exhaled nitric oxide 
Parameters measured: FENO50 (ppb), J’awNO [manual] (nl/s), and *CalvNO 
[manual]) (ppb). 
2. Impulse oscillometry 
Parameters measured: *R5 EX (kPa/L/s), R20 EX (kPa/L/s), *R5 - R20 EX 
(kPa/L/s), Rcentral (kPa/L/s), *Rperipheral (kPa/L/s), *X5 EX (kPa/L/s), *AXEX 
(kPa/L), *AX (kPa/L), and fres (1/L) 
3. Multi-breath nitrogen washout  
Parameters measured: *Sacin (/L), Scond (/L), and LCI 
4. Single-breath transfer factor test 
Parameters measured: TLCOc (mmol/min/kPa), TLCOc [% pred], kCOc 
(mmol/min/kPa/L), kCOc [% pred], VA, (L) and VA [% pred]) 
5. Expiratory airways resistance and specific airways conductance  
Parameters measured: Raw EX (kPa/L/s) and SGaw EX (kPa/L/s/L) 
6. Lung volumes  
Parameters measured: TLC (L), TLC [% pred], RV (L), RV [% pred], RV: TLC 
(%), RV: TLC [% pred], FRCpleth, (L) and FRCpleth [% pred] 
7. Forced spirometry 
Parameters measured: FEV1 (L), FEV1 [% pred], FVC (L), FVC [% pred], 
FEV1 / FVC (%), MMEF75/25 (L/s), and MMEF75/25 [% pred] 
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Measurements involving vital capacity manoeuvres (lung volumes, single-
breath transfer factor and forced spirometry) were left until last as they dilate and / or 
constrict the airways. This would influence the results from tests performed during 
near tidal breathing as well as lower exhaled nitric oxide results. Spirometry was the 
very last test to be performed as this test can constrict the airways and reduce vital 
capacities measured during other tests.  
 
4.2.3 Statistical analysis 
The subject number per group was based on feasibility and no statistical 
techniques were used to determine group size. The Kolmogorov-Smirnov test was 
used to determine if data for each respiratory parameter listed in 4.2.2 was normally 
distributed. 
 
 Comparison of the physiological parameters for small airways (CalvNO, Sacin 
and R5-R20 EX, see section 4.2.2) were undertaken as the primary endpoint analysis 
to determine the presence or absence of small airways dysfunction and elicit any 
differences in comparisons undertaken as shown below to address the following 
areas; 
 
To determine differences between healthy lungs and diseased lungs, comparisons 
were made as follows  
Healthy subjects compared with mild-moderate asthma  
Healthy subjects compared with severe asthma 
Healthy subjects compared with COPD  
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To determine differences between disease severity within asthmatics, comparison 
was made as follows  
Mild-moderate asthma compared with severe asthma  
To determine differences between the effect of smoking with diseased lungs and 
healthy lungs, comparisons were made as follows  
Healthy smokers compared with mild-moderate asthma  
Healthy smokers compared with severe asthma 
Healthy smokers compared with COPD  
Healthy smokers compared to healthy subjects  
 
To determine differences between asthma and COPD diseases, comparisons were 
made as follows  
Mild-moderate asthma compared with COPD 
Severe asthma compared with COPD 
 
Parametric tests (one-way analysis of variance (ANOVA) and Bonferroni’s post hoc 
test) and non-parametric tests (Kruskal-Wallis and Dunn’s post hoc test) were 
performed using GraphPad Prism 5 (San Diego, California, USA). Parametric data is 
presented as mean and standard deviation (± SD) and non-parametric data as 
median and interquartile range (± IQR). The differences between groups were 
considered statistically significant at a p value of less than 0.05.  
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4.3 RESULTS 
 
4.3.1 Subject characteristics of each group 
The healthy group consisted of 29 never-smokers with a mean age of 50 
years. The healthy smoking group consisted of 20 current smokers with a mean age 
of 55 years (smoking history ≥ 10 pack years). The mild-moderate asthma group 
consisted of 20 patients with a mean age of 41 years.  The severe asthma group 
consisted of 23 patients with a mean age of 50 years. The COPD group consisted of 
34 patients with a mean age of 66 years. Table 4.1 displays subject’s characteristics 
per group. 
 
The COPD group were older than all asthma and healthy subject groups and 
the healthy smokers were older than mild-moderate asthmatics (p < 0.05). The mild-
moderate asthmatics were taller than COPD group (p < 0.01). Body mass index 
(BMI) and weight were similar across groups, in that there was no significant 
differences observed (Table 4.1).  
 
All asthmatic and COPD patients were in a stable condition (≥ 4 weeks) at 
study visits; that is they had not experienced a disease exacerbation or step-up 
change in treatment or antibiotic prescription. All tests were well tolerated and no 
patients required rescue medication (β2-agonists). No adverse events occurred 
during study visits. Table 4.2 lists the concomitant medications taken per group. As 
clinically expected, the severe asthma patients were mainly treated with oral 
corticosteroids whereas mild-to-moderate patients were predominantly on a short-
acting beat agonist and ICS monotherapy or in combination with LABA. In contrast, 
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COPD patients were primarily treated with either combination ICS/LABA or a long-
acting muscarinic antagonist bronchodilator agent.  
 
Table 4.1: Subject characteristics of each group  
 Healthy  Healthy 
smokers 
Mild-moderate 
asthma 
Severe  
asthma 
COPD 
 
Number 29 20 20 23 34 
 
Male / Female 14 / 15 9 / 11 13 / 7 6 / 17 16 / 18 
 
Age (years) 50 (15) 
d 
55 (10) 
e g  
41 (15) 
i 
50 (14) 
j  
66 (7)  
 
BMI (kg/m
2
) 25.63 (4.80) 23.90 (4.82) 24.90 (4.04) 26.89 (5.64) 25.76 (4.57) 
 
Height (cm) 168.2 (10.7) 167.2 (11.3) 174.3 (10.1) 
i  
168.7 (8.5) 164.4 (8.5) 
 
Weight (kg) 73.05 (17.99) 66.95 (15.55) 76.30 (17.19) 76.00 (13.18) 69.75 (14.04) 
 
Results are presented as mean (± SD) 
 
d 
(p < 0.05 healthy compared with COPD)
 
e 
(p < 0.05 healthy smokers compared with mild-moderate asthma)
 
g 
(p < 0.05 healthy smokers compared with COPD)
 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
j 
(p < 0.05 severe asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
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Table 4.2: Proportion of patients receiving concomitant medications by drug class  
    
Drug class and dosage  Mild-moderate 
asthma 
Severe  
asthma 
COPD 
 
ICS’s    
BDP (100 µg) 3 (15)  2 (6) 
BUD (200 µg)   1 (3) 
FP (125 – 500 µg) 1 (5) 1 (4)  
OCS’s    
Prednisolone (3 – 40 mg) 1 (5)  17 (71) 1 (3) 
SABA’s    
Salbutamol (100 µg) 18 (90) 17 (71) 13 (38) 
Salbutamol nebules (5 mg)  1 (4)   
Terbutaline sulphate (0.5 mg)   1 (3) 
Subcutaneous terbutaline (10 mg / 24 hrs)  1 (4)  
LABA’s    
Formoterol (12 µg)   1 (3) 
Salmeterol (50 µg)  1 (4)  
Oral LABA’s    
Bambuterol (20 mg)  1 (4)  
Combined (ICS’s / LABA’s)    
BDP / FOR (100 / 6 µg)   1 (3) 
BUD / FOR (100 / 6 – 400 / 12 µg) 4 (20) 13 (54) 10 (29) 
FLU / SAL (250 / 25 – 500 / 50 µg) 1 (5) 8 (33) 4 (12) 
LTRA’s     
Montelukast (10 mg) 1 (5) 5 (21)  
Monoclonal antibody    
Omalizumab (150 – 375 mg / month)  6 (25)  
Anticholinergics     
Ipratropium bromide (20 – 500 µg) 1 (5) 2 (8) 3 (9) 
Tiotropium bromide (18 µg)  2 (8) 8 (24) 
Xanthines      
Theophylline (200 – 400 mg)  8 (33) 1 (3) 
Mucolytics    
Carbocisteine (375 – 1500 mg)  1 (4) 4 (12) 
Erdosteine (300 mg)   1 (3) 
Results are presented as number and (% of group) 
*Percentages of each treatment are a proportion of the number of patients on that treatment in that 
group.  
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ICS’s = inhaled corticosteroids 
OCS’s = oral corticosteroids 
SABA’s = short acting β2-agonists 
LABA’s = long acting β2-agonists 
LTRA’s = leukotriene receptor antagonists 
 
4.3.2 Forced spirometry 
Table 4.3 shows the forced spirometry results and where appropriate, 
identifies significant differences in the measures between the groups. Qualitatively 
as expected, spirometry confirmed lower levels of lung function in obstructive lung 
disease patients compared to healthy subjects. FEV1 decreased with disease 
severity as observed between both asthma groups. The COPD group had worse 
spirometric lung function among patient groups, such that for absolute values FEV1 
(L) in COPD patients was (1.67) compared to the healthy group (3.18), smokers 
(2.76), mild-moderate asthmatics (3.03) and severe asthmatics (2.32). In terms of 
percentage of predicted values, similar trends were seen; FEV1 (% pred) was lower 
in COPD (68.5) compared with healthy group (105.0), smokers (97.1), mild-moderate 
asthma (84.0) and severe asthma (78.0). 
 
FVC (L) was lower in COPD (3.33) compared to healthy group (4.23) and 
mild-moderate asthma (4.49). FVC (% pred) was similar between groups. The 
Tiffeneau-Pinelli index, the ratio of FEV1 / FVC (%) was lower in COPD (51.12) 
compared to healthy group (75.65), smokers (72.87), mild-moderate asthma (67.62) 
and severe asthma (61.83).  
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The MMEF values are usually considered a surrogate marker of small airways 
disease. With respect to absolute values, MMEF75/25 (L/s) was lower in COPD (0.53) 
compared to healthy group (2.48), smokers (1.90), mild-moderate asthma (2.01) and 
severe asthma (1.34) and in severe asthma compared to healthy group. Similar 
trends were observed with percentage of predicted values where MMEF75/25 (% 
pred) was lower in COPD (18.3) compared to healthy group (68.5), smokers (54.9), 
mild-moderate asthma (47.1) and severe asthma (37.0).  As can also be observed, 
MMEF75/25 (% pred) was lower in both asthma groups compared to healthy group 
and in severe asthma compared to smokers.  
 
Table 4.3: Forced spirometry results at baseline  
 Healthy  Healthy 
smokers 
Mild-moderate 
asthma 
Severe  
asthma 
COPD 
 
FEV1 (L) 3.18 
c d  
(0.79) 
2.76 
g  
(0.73) 
3.03 
h i    
(0.80) 
2.32 
j  
(0.88) 
1.67 
(0.44) 
FEV1 (% pred) 105.0 
b c d  
(10.0) 
97.1 
f g  
(12.2) 
84.0 
i
 
(13.7) 
78.0 
(20.7) 
68.5 
(15.3) 
FVC (L) 4.23 
d  
(1.12) 
3.82 
(1.12) 
4.49 
i  
(1.02) 
3.72 
(0.97) 
3.33 
(0.77) 
FVC (% pred) 116.0 
(13.6) 
111.1 
(18.5) 
104.3 
(15.2) 
106.5 
(16.7) 
109.1 
(17.6) 
FEV1 / FVC (%) 75.65 
c d  
(6.45) 
72.87 
f g  
(7.23) 
67.62 
i  
(9.37) 
61.83 
j  
(15.21) 
51.12 
(11.43) 
MMEF75/25 (L/s) 2.48 
c d  
(0.88) 
1.90 
g  
(0.88) 
2.01 
i  
(0.97) 
1.34 
j  
(0.96) 
0.53 
(0.29) 
MMEF75/25 (% pred) 68.5 
b c d  
(17.2) 
54.9 
f g  
(19.8) 
47.1 
i  
(16.9) 
37.0 
j  
(22.8) 
18.3 
(9.8) 
Results are presented as mean (± SD) 
 
151 
 
b 
(p < 0.05 healthy compared with mild-moderate asthma)
 
c 
(p < 0.05 healthy compared with severe asthma) 
d 
(p < 0.05 healthy compared with COPD)
 
f 
(p < 0.05 healthy smokers compared with severe asthma) 
g 
(p < 0.05 healthy smokers compared with COPD)
 
h 
(p < 0.05 mild-moderate asthma compared with severe asthma)
 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
j 
(p < 0.05 severe asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
 
 
4.3.3 Lung volumes  
Parameters associated with gas trapping (hyperinflation) were elevated in 
COPD, a physiological hallmark of this condition and often signifying distal airways 
disease. Table 4.4 displays results for lung volumes and where appropriate, 
identifies significant differences in the measures between the groups.  
 
The RV (L) was larger in COPD (3.14) compared to healthy group (2.03), 
smokers (2.20), mild-moderate asthma (2.37) and severe asthma (2.32). The RV (% 
pred) was larger in the COPD (146.0) compared to healthy group (104.9), smokers 
(110.7) and severe asthma (121.0). The TLC (% pred) was larger in COPD (116.8) 
compared to healthy smokers (105.1). The RV: TLC (%) was larger in COPD (49.12) 
compared to healthy group (32.48), smokers (37.33), mild-moderate asthma (35.11) 
and severe asthma (38.59). The RV: TLC (% pred) was larger in the mild-moderate 
asthma (113.6), severe asthma (108.0), and COPD (120.6) compared to healthy 
group (93.6).  RV: TLC (% pred) was larger in COPD compared to smokers (101.6).  
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The FRCpleth (L) was larger in COPD (4.02) compared to healthy group (3.15), 
smokers (3.21) and severe asthma (3.19). FRCpleth (% pred) was larger in COPD 
(133.2) compared to healthy group (103.2), smokers (106.2), mild-moderate asthma 
(111.5) and severe asthma (107.7). 
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Table 4.4: Lung volumes results at baseline 
 Healthy Healthy  
Smokers 
Mild-moderate  
asthma 
Severe 
asthma 
COPD 
 
RV (L) 2.03 
d 
(0.50) 
2.20 
g 
(0.49) 
2.37 
i 
(0.69) 
2.32 
j 
(0.83) 
3.14 
(0.66) 
RV (% pred) 104.9 
d 
(18.3) 
110.7 
g 
(18.7) 
125.0 
(23.2) 
121.0 
j 
(36.6) 
146.0 
(34.1) 
TLC (L) 6.34 
(1.35) 
6.00 
(1.36) 
6.76 
(1.12) 
6.02 
(1.27) 
6.43 
(1.14) 
TLC (% pred) 108.0 
(10.5) 
105.1 
g
 
(14.4) 
105.3 
(12.8) 
107.3 
(17.4) 
116.8 
(15.8) 
RV: TLC (%) 32.48 
d 
(7.24) 
37.33 
g 
(7.14) 
35.11 
i 
(7.88) 
38.59 
j 
(9.99) 
49.12 
(7.94) 
RV: TLC (% pred) 93.6 
b c d  
(14.5) 
101.6 
g 
(13.2) 
113.6 
(16.5) 
108.0 
(22.5) 
120.6 
(19.1) 
FRCpleth (L) 3.15 
d 
(0.66) 
3.21 
g 
(0.96) 
3.55 
(0.79) 
3.19 
j 
(0.89) 
4.02 
(0.82) 
FRCpleth (% pred) 103.2 
d 
(16.2) 
106.2 
g 
(24.3) 
111.5 
i 
(23.2) 
107.7 
j 
(27.2) 
133.2 
(23.4) 
Results are presented as mean (± SD) 
 
b 
(p < 0.05 healthy compared with mild-moderate asthma)
 
c 
(p < 0.05 healthy compared with severe asthma) 
d 
(p < 0.05 healthy compared with COPD)
 
g 
(p < 0.05 healthy smokers compared with COPD)
 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
j 
(p < 0.05 severe asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
4.3.4 Airways resistance and specific airways conductance  
Patients with obstructive lung disease had poorer expiratory airways resistance 
and specific airways conductance. Raw EX (kPa/L/s) was larger in severe asthma (0.66) 
and COPD (0.90) compared to healthy group (0.35). Raw EX was larger in COPD 
compared to smokers (0.40) and mild-moderate asthma (0.50).  
 
SGaw EX (kPa/L/s/L) was lower in mild-moderate asthma (0.68), severe asthma 
(0.71) and COPD (0.43) compared to healthy group (1.00). SGaw EX (kPa/L/s/L) was 
lower in COPD compared to smokers (0.88) and both asthma groups. Table 4.5 
displays results for expiratory airway resistance and specific airway conductance.  
 
Table 4.5: Expiratory airway resistance and specific airway conductance results at baseline 
 Healthy  Healthy 
smokers 
Mild-moderate 
asthma 
Severe  
asthma 
COPD 
 
Raw EX (kPa/L/s) 0.35 
c d  
(0.11) 
0.40 
g 
(0.13) 
0.50 
i
 
(0.20) 
0.66 
(0.43) 
0.90 
(0.61) 
SGaw EX (kPa/L/s/L) 1.00 
b c d  
(0.30) 
0.88 
g  
(0.23) 
0.68 
i 
 
(0.29) 
0.71 
j 
 
(0.41) 
0.43 
(0.28) 
Results are presented as mean (± SD) 
 
b 
(p < 0.05 healthy compared with mild-moderate asthma)
 
c 
(p < 0.05 healthy compared with severe asthma) 
d 
(p < 0.05 healthy compared with COPD)
 
g 
(p < 0.05 healthy smokers compared with COPD)
 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
j 
(p < 0.05 severe asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
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4.3.5 Single-breath transfer factor test 
Pulmonary diffusion capacity assesses the integrity of the alveolar-capillary 
interface in the acinar compartment and therefore an indirect maker of terminal small 
airways dysfunction.  Pulmonary diffusion capacity (TLCOc) was reduced in COPD due 
to emphysema and in smokers due to smoking induced inflammatory damage. TLCOc 
(mmol/min/kPa) was lower in COPD (5.14) compared to healthy group (8.15), mild-
moderate asthma (9.14) and severe asthma (7.62). TLCOc was lower in smokers (6.32) 
compared to healthy group and mild-moderate asthma. TLCOc (% pred) was lower in 
COPD (66.2) compared to healthy group (89.9), mild-moderate asthma (88.1) and 
severe asthma (86.4). TLCOc (% pred) was lower in smokers (72.9) compared to 
healthy group and both asthma groups.  
 
The transfer coefficient kCOc is the value of the transfer factor (TLCOc) divided by 
the alveolar volume (VA) and is an expression of the gas transfer ability per unit volume 
of lung. kCOc (mmol/min/kPa/L) was lower in COPD (1.04) compared to healthy group 
(1.47), mild-moderate asthma (1.55) and severe asthma (1.52). The kCOc was lower in 
smokers (1.24) compared to heathy group and both asthma groups. The kCOc (% pred) 
was lower in COPD (74.8) compared to healthy group (94.9), mild-moderate asthma 
(97.4) and severe asthma (96.2). The kCOc (% pred) was lower in smokers (81.0) 
compared with healthy group and both asthma groups.  
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The alveolar volume VA (L) was larger in mild-moderate asthma (5.86) compared 
to COPD (4.93) and VA (% pred) was similar between groups. Table 4.6 displays results 
for single-breath transfer factor tests.  
 
Table 4.6: Single-breath transfer factor results at baseline  
 Healthy  Healthy  
smokers 
Mild-moderate 
asthma 
Severe  
Asthma 
COPD 
 
TLCOc (mmol/min/kPa) 8.15 
a d 
(1.92) 
6.32 
e 
 (1.50) 
9.14 
i 
(2.08) 
7.62 
j 
(1.77) 
5.14 
(1.60) 
TLCOc (% pred) 89.9 
a d 
(13.0) 
72.9 
e f 
(12.3) 
88.1 
i 
(10.4) 
86.4 
j 
(14.9) 
66.2 
(18.1) 
kCOc (mmol/min/kPa/L) 1.47 
a d 
(0.23) 
1.24 
e f  
(0.30) 
1.55 
i 
(0.22) 
1.52 
j 
(0.27) 
1.04 
(0.24) 
kCOc (% pred) 94.9 
a d 
(13.8) 
81.0 
e f  
(16.1) 
97.4 
i 
(13.5) 
96.2 
j 
(13.9) 
74.8 
(18.4) 
VA (L) 5.56 
(1.22) 
5.20 
(1.12) 
5.86 
i  
(0.92) 
5.08 
(1.05) 
4.93 
(0.93) 
VA (% pred) 97.8 
(9.51) 
93.6 
(11.8) 
93.7 
(11.5) 
92.9 
(13.3) 
91.1 
(12.0) 
Results are presented as mean (± SD) 
 
a 
(p < 0.05 healthy compared with healthy smokers)
 
d 
(p < 0.05 healthy compared with COPD)
 
e 
(p < 0.05 healthy smokers compared with mild-moderate asthma)
 
f 
(p < 0.05 healthy smokers compared with severe asthma) 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
j 
(p < 0.05 severe asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
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4.3.6 Multiple flow exhaled nitric oxide 
Airway inflammation increases exhaled nitric oxide production. FENO50 (ppb) was 
increased in mild-moderate asthma (48.6) compared to heathy group (26.6), smokers 
(14.9), severe asthma (27.0) and COPD (24.1). Inflammation from the large airways 
(J’awNO (nl/s)) was increased in mild-moderate asthma (140.0) compared to healthy 
group (76.6), smokers (36.0), severe asthma (79.2) and COPD (64.3). This finding may 
be explained by the observation that mild-moderate asthmatics reported using less 
ICS’s (Table 4.2).  
 
Inflammation from the smaller peripheral airways and alveoli ((CalvNO (ppb)) was 
similar between all groups. Table 4.7 displays results for multiple flow exhaled nitric 
oxide.  
 
Table 4.7: Multiple flow exhaled nitric oxide results at baseline 
 Healthy  Healthy 
smokers 
Mild-moderate 
asthma 
Severe  
asthma 
COPD 
 
FENO50 (ppb) 26.6 
b 
(15.7) 
14.9 
e  
(7.0) 
48.6 
h i   
(28.9) 
27.0 
(20.2) 
24.1 
(15.5) 
J’awNO (manual) 
(nl/s) 
76.6 
b 
(46.3) 
36.0 
e  
(21.1) 
140.0 
h i  
(83.6) 
79.2 
(63.2) 
64.3 
(49.5) 
CalvNO (manual) 
(ppb) 
0.1 
(0.1 – 0.2) 
0.2 
(0.2 – 0.2) 
0.2 
(0.2 – 0.3) 
0.2 
(0.1 – 0.2) 
0.2 
(0.1 – 0.3) 
Results are presented as mean (± SD) and median (± IQR).  
b 
(p < 0.05 healthy compared with mild-moderate asthma)
 
e 
(p < 0.05 healthy smokers compared with mild-moderate asthma)
 
h 
(p < 0.05 mild-moderate asthma compared with severe asthma)
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i 
(p < 0.05 mild-moderate asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
 
4.3.7 Multi-breath nitrogen washout  
Ventilation heterogeneity increases with airflow limitation and gas trapping. 
Ventilation heterogeneity in acinar airways ((Sacin (/L)) was larger in COPD (0.481) 
compared to healthy group (0.089), smokers (0.150), mild-moderate asthma (0.122) 
and severe asthma (0.214). Ventilation heterogeneity in conducting airways ((Scond (/L)) 
was larger in smokers (0.068) compared to healthy group (0.041) and mild-moderate 
asthma (0.045).  
 
The LCI a generalised marker of ventilation heterogeneity was increased in 
COPD (8.30) compared to the healthy group (5.65), smokers (6.51), mild-moderate 
asthma (6.11) and severe asthma (6.70) groups. The LCI was increased in smokers 
and severe asthmatics compared to the healthy group. Table 4.8 displays results for 
multi-breath nitrogen washout tests.  
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Table 4.8: Multi-breath nitrogen washout results at baseline 
 Healthy Healthy smokers Mild-moderate 
asthma 
Severe 
asthma 
COPD 
 
Sacin (/L) 0.089 
d  
(0.051) 
0.150
 g  
(0.084) 
0.122 
i  
(0.094) 
0.214 
j  
(0.194) 
0.481 
(0.297) 
Scond (/L) 0.041 
a   
(0.016) 
0.068 
e
 
(0.027) 
0.045 
(0.015) 
0.057 
(0.026) 
0.057 
(0.020) 
LCI  5.65 
a c d 
(0.60) 
6.51 
g  
(0.77) 
6.11 
i  
(0.49) 
6.70 
j  
(1.06) 
8.30 
(1.23) 
Results are presented as mean (± SD) 
 
a 
(p < 0.05 healthy compared with healthy smokers)
 
c 
(p < 0.05 healthy compared with severe asthma) 
d 
(p < 0.05 healthy compared with COPD)
 
e 
(p < 0.05 healthy smokers compared with mild-moderate asthma)
 
g 
(p < 0.05 healthy smokers compared with COPD)
 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
j 
(p < 0.05 severe asthma compared with COPD) 
all other comparisons between groups were non-significant (p >0.05) 
 
4.3.8 Impulse oscillometry 
The resistance (R) and reactance (X) of large and small airways can be indirectly 
determined by impulse oscillometry, where higher frequencies suggest large airways 
dysfunction and lower frequencies relate to small airways dysfunction (Goldman et al, 
2005). Expiratory resistance and reactance worsen with progressive airflow limitation. 
R5 EX (kPa/L/s) was larger in COPD (0.66) compared to healthy group (0.45). R20 EX 
was similar between groups. R5 - R20 EX (kPa/L/s), considered a marker of small 
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airways dysfunction, was larger in COPD (0.28) compared to healthy group (0.09), 
smokers (0.11) and mild-moderate asthma (0.13). Rcentral (kPa/L/s) was larger in severe 
asthma (0.30) and COPD (0.30) compared to healthy group (0.23). Rperipheral (kPa/L/s) 
was larger in severe asthma (0.49) and COPD (0.56) compared to healthy group (0.29). 
Rperipheral was larger in COPD compared to healthy smokers (0.35) and mild moderate 
asthma (0.36).  
 
With respect to the reactance (X) values, X5 EX (kPa/L/s) was more negative in 
COPD (-0.38) compared to healthy group (-0.12), smokers (-0.16), and mild-moderate 
asthma (-0.17).  AXEX was larger in severe asthma (1.12) and COPD (2.29) compared 
to healthy group (0.29) and in COPD compared to smokers (0.47). Additionally, AX was 
larger in severe asthma (1.01) and COPD (1.78) compared to healthy group (0.39) and 
in COPD compared to smokers (0.45). 
 
The fres (1/L) was increased in COPD (22.50) compared to healthy group 
(13.46), smokers (15.70) and mild-moderate asthma (16.00) and in severe asthma 
(19.45) compared to healthy group. Table 4.9 displays results for impulse oscillometry. 
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Table 4.9: Impulse oscillometry results at baseline  
 Healthy Healthy 
smokers 
Mild-moderate 
asthma 
Severe 
Asthma 
COPD 
 
R5 EX (kPa/L/s) 0.45 
d  
(0.16) 
0.50
 
(0.25) 
0.50 
(0.17) 
0.59 
(0.21) 
0.66 
(0.24) 
R20 EX (kPa/L/s) 0.36 
(0.12) 
0.39 
(0.15) 
0.37 
(0.09) 
0.41 
(0.11) 
0.38  
(0.08) 
R5 - R20 EX (kPa/L/s) 0.09 
d  
(0.10) 
0.11 
g  
(0.12) 
0.13 
i   
(0.11) 
0.19 
(0.15) 
0.28 
(0.20) 
Rcentral (kPa/L/s) 0.23 
c d  
(0.09) 
0.27 
(0.11) 
0.27 
(0.06) 
0.30 
(0.06) 
0.30 
(0.06) 
Rperipheral (kPa/L/s) 0.29 
c d  
(0.13) 
0.35 
g 
(0.16) 
0.36 
i
 
(0.15) 
0.49 
(0.24) 
0.56 
(0.27) 
X5 EX (kPa/L/s) -0.12 
d 
(0.07) 
-0.16 
g  
(0.11) 
-0.17 
i
 
(0.09) 
-0.28 
(0.29) 
-0.38 
(0.28) 
AXEX (kPa/L) 0.29 
c d  
(0.09 – 1.16) 
0.47 
g  
(0.35 – 1.39) 
0.78 
(0.33 – 1.79) 
1.12 
(0.45 – 2.78) 
2.29 
(1.57 – 5.37) 
AX (kPa/L) 0.39 
c d  
(0.15 – 0.73) 
0.45 
g  
(0.31 – 1.09) 
0.57 
(0.33 – 1.51) 
1.01 
(0.48 – 2.53) 
1.78 
(1.07 – 3.36) 
fres (1/L) 13.46 
c d  
(5.03) 
15.70 
g  
(5.30) 
16.00 
i  
(6.85) 
19.45 
(7.92) 
22.50 
(6.10) 
Results are presented as mean (± IQR) and median (± IQR). 
 
c 
(p < 0.05 healthy compared with severe asthma) 
d 
(p < 0.05 healthy compared with COPD)
 
g 
(p < 0.05 healthy smokers compared with COPD)
 
i 
(p < 0.05 mild-moderate asthma compared with COPD)
 
all other comparisons between groups were non-significant (p >0.05) 
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4.4 DISCUSSION 
 
To my knowledge, this is the first study to measure and compare respiratory 
function and inflammation of both the large and small airways using a group of three 
advanced physiological parameters for small airways dysfunction (CalvNO, Sacin and R5-
R20 EX) in these five patient groups. The results of this study are discussed in terms of 
actual values and percent predicted according to patient groups and then summarised 
according to the tests of small versus large airways dysfunction.  
 
4.4.1 COPD  
In COPD patients, the airflow limitation is progressive and only partially reversible 
(Global Initiative for Chronic Obstructive Disease, 2009). Airflow limitation was greatest 
in this group as demonstrated by reduced spirometry, reduced airway conductance and 
increased airways resistance. These stage I to III patients had significant airflow 
limitation based on FEV1, FEV1 / FVC, and MMEF75/25.  
 
The FVC during spirometry in COPD patients is often lower than relaxed 
measures of vital capacity due to dynamic compression of the airways during forced 
expiration (Elad and Einav, 1989). This group continued their medications as normal 
which may have stabilised their FVC to 100% of predicted, close to their IVC’s 
measured during lung volumes and single-breath tests (not included here).  
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This group demonstrated poor expiratory resistance and conductance which 
would be indicative of fixed small airway obstruction through fibrosis (Hogg et al, 2004). 
Indeed, it is being increasingly recognised in patients with COPD that lung fibrosis 
(usually causing a ‘restrictive’ pattern in lung physiology) can complicate their 
emphysematous ‘obstructive’ lung disease (Lin and Jiang, 2015. During inspiration the 
airways do not dilate sufficiently and collapse early during expiration. This could be 
demonstrated during normal tidal breathing where R5 EX, X5 EX, AXEX, AX, and 
Rperipheral showed impairment of small airway calibre. Resistance in the large airways (as 
determined by R20 EX) was similar across groups however the difference between small 
and large airways (R5-R20 EX) was greater for COPD highlighting that small airways 
disease is a major lesion in this condition. Impulse oscillometry doesn’t require any 
special breathing manoeuvre and may be more reflective of daily changes in airway 
calibre than spirometry.  
 
Narrowing of the small airways during expiration and their inability to dilate during 
inspiration, physiologically compromises gas exchange, which is the primary aim of the 
respiratory system and Gaver and colleagues (1990) have shown that airway closure 
can also lead to local hypoventilation. Gas exchange occurs by convection in larger 
conducting airways proximal to the diffusion front. The ventilation heterogeneity within 
these airways (Scond) was increased (0.057 /L) compared to healthy subjects (0.041 /L). 
Verbanck et al (1998; 2004) yielded comparable results for Scond in two studies on 
COPD patients where medication was withdrawn. The results from three separate 
groups which included (i) a standard COPD group, (ii) COPD (FEV1 / FVC <70% pred 
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and TLCOc ≥ 70% pred), and (iii) COPD (FEV1 / FVC <70% pred and TLCOc < 60% 
pred), were respectively, 0.085 (/L), 0.064 (/L), and 0.068 (/L). 
 
In the smaller acinar airways, gas exchange occurs predominantly by diffusion 
and partially by convection and when these airways that are distal to the diffusion front 
get obstructed, ventilation heterogeneity (a mismatch between ventilation in different 
lung units, airways and regions) increases. This was demonstrated by Sacin which was 
more than four times higher (0.481 /L) than the healthy subjects (0.089 /L) and what we 
(Verbanck et al, 2012) recently observed in a larger cohort of healthy subjects (0.089 
/L). In the studies by Verbanck et al (1998; 2004) the results for Sacin for the three COPD 
groups described above were respectively, 0.430 (/L), 0.295 (/L), and 0.444 (/L). 
Similarly the LCI, a marker of ventilation heterogeneity, was elevated in COPD 
compared to healthy subjects in this and our larger cohort study (6.00) (Verbanck et al, 
2012). These MBNW parameters increase due to ventilation heterogeneity within the 
acinar zone which compromises gas exchange and the importance of ventilation 
heterogeneity has recently been shown to be a physiological ‘biomarker’ of exercise 
impairment in patients with COPD (Neder et al, 2015).  
 
During single-breath transfer tests patients had to inhale the tracer gas (CO) fast 
and deep. These patients could perform this manoeuvre therefore the TLCOc and kCO 
would not be reduced due to lung volume recruitment but due to emphysema and co-
existent fibrosis. It has been demonstrated that Sacin tends to increase as TLCOc and 
kCOc decrease (Verbanck et al, 1998). Increased airflow limitation and ventilation 
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heterogeneity caused lung hyperinflation as demonstrated by elevated RV, FRCpleth, 
RV: TLC compared to healthy subjects.  
 
The application of the mathematical model by Tsoakias and George (1998) has 
made it possible to calculate nitric oxide arising from bronchial (J’awNO) and alveolar 
compartments (CalvNO). The data show that, multiple flow exhaled nitric oxide results 
were comparable to healthy subjects and this is most likely due to type of inflammation 
in COPD which is predominantly neutrophilic and therefore undetectable by exhaled 
nitric oxide (Postmat al, 2014). Although recently, Chou and colleagues (2014) have 
shown the utility of exhaled nitric oxide in identifying  patients with COPD that have 
eosinophilic  inflammation, where they analysed sputum from patients with COPD for 
the presence of eosinophilia and correlated this to measures of exhaled nitric oxide. The 
possible importance of this is that this subtype of COPD patient may be responsive to 
corticosteroid therapy and in an outpatient study of 200 patients diagnosed with COPD, 
Donohue and colleagues (2014) saw elevated level of exhaled nitric oxide particularly in 
those patients who had previously been diagnosed with both COPD and asthma. 
 
4.4.2 Severe asthma  
In patients with severe asthma, airflow limitation can be fully reversible or 
partially reversible when remodelling occurs (GINA, 2009). Airflow limitation measured 
by spirometry was similar to mild-moderate asthmatics and better than COPD. Similarly 
to COPD patients, this group continued medications which helped reduce airflow 
limitation and maintain their FVC’s at 100% predicted.  
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Airways conductance and resistance were slightly higher and lower respectively 
to COPD patients, but not significantly different. Results from impulse oscillometry for 
R5, X5, AX at 5 Hz and Rperipheral were similar to COPD highlighting small airway 
involvement in asthma. Qi and colleagues (2013) studied impulse oscillometry in 
healthy subjects and patients with mild, moderate and severe asthma and showed that 
R5-R20 worsened with worsening severity of asthma, suggesting greater presence of 
small airways dysfunction, and that R5-R20 together with R5 and fres were reliable IOS 
parameters for classifying airway obstruction in patients with asthma as determined 
using conventional spirometric measures. Large airway resistance was similar between 
groups. However R20 EX (0.41 kPa/L/s) and Rcentral (0.30 kPa/L/s) were higher than in 
healthy group demonstrating large airway involvement even when medication is taken. 
This observation was also reported by the study by Qi and colleagues (2013), where 
abnormities in R20 were observed in severe asthmatic patents, suggesting both large 
and small airways abnormality, which would be in keeping with the pathology of asthma 
which involves both the large and small airways. Ventilation heterogeneity in the 
conducting zone (Scond) was similar to COPD (0.057 /L).  Ventilation heterogeneity in the 
small airways (Sacin) and LCI were increased but not as high as COPD. Thompson and 
colleagues (2013) have specifically assessed measures of small airways dysfunction 
using ventilation heterogeneity indices in patients with acute severe asthma and shown 
abnormalities in both the conducting (Scond) and acinar (Sacin) regions, supporting both 
large and small airway involvement. Importantly, they reported that only the more distal 
airway marker of Sacin showed a direct correlation with airflow obstruction and the need 
for more intensive treatment in patients with severe unstable asthma. 
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Emphysema and lung hyperinflation can occur in patients with severe asthma, as 
Gupta and colleagues (2009) showed using HRCT scans of 185 patients with severe 
asthma that ~8% had the presence of emphysema, however our data did not 
demonstrate gas trapping by way of abnormal lung volumes in patients with severe 
asthma. Indeed, physiologically we could expect abnormal lung volumes as Sorkness et 
al (2008) recently showed that RV:TLC (% pred) was markedly increased in severe 
asthmatic patients compared to non-severe asthmatics as part of a large cohort (~300) 
of patients with severe asthma (SARP).  
 
Transfer factor results (TLCOc and kCO) were within normal limits and as 
expected, better compared to COPD. The surface area available for gas exchange (VA) 
was also normal.  
 
Multiple flow exhaled nitric oxide results were comparable to healthy subjects 
and this is probably due to the use of OCS’s and combined ICS’s and LABA’s in this 
group, that may have been controlling the underlying airway eosinophilic inflammation 
and hence suppressing the exhaled nitric oxide signal, as exhaled nitric oxide is 
sensitive to the  suppressive effects of ICS’s (Jatakanon et al, 2000). Indeed, Berry and 
colleagues (2005) showed that alveolar nitric oxide levels were elevated in patients with 
severe asthma and that these levels correlated with elevated eosinophil counts in 
bronchoalveolar lavage fluid, but treating these patients with oral corticosteroids for 2 
weeks reduced the levels of alveolar nitric comparable to those of patients with mild 
asthma.  
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4.4.3 Mild-moderate asthma  
Airflow limitation in mild-moderate asthma is often fully reversible following β2-
agonist therapy (GINA, 2015). Spirometry was overall slightly better than in patients with 
severe asthma and significantly better for FEV1. Percent predicted FEV1 and MMEF75/25 
were still lower compared to healthy group. Spirometry, Sacin and LCI were better 
compared to COPD.  
 
The use of medication, in particular corticosteroid therapy (Table 4.2)  was less in 
this group compared to severe asthma and this would have influenced the physiological 
outputs measured by improving airflow limitation and maintain their FVC’s at 100% 
predicted. Expiratory airways conductance and resistance were similar to severe 
asthma but better than patients with COPD. Expiratory conductance was lower 
compared to healthy subjects. Resistance and reactance measured by impulse 
oscillometry was comparable to severe asthma, while R5-R20 EX, Rperipheral, X5 EX, and 
fres were lower compared to COPD. The results for R5, (0.42 kPa/L/s), R20 (0.34 
kPa/L/s), R5-R20 (0.08 kPa/L/s) and AX (0.57 kPa/L) were similar to those in a study by 
Yamaguchi et al (2009) in mild-moderate asthmatics that reported 0.42, 0.34, 0.08 and 
0.63 respectively. However, the data reported here showed a difference in IOS 
measures between asthma and COPD patients and this is different to results previously 
reported in our laboratory where IOS measures were similar between these two patient 
groups (Paredi et al, 2009). This may be a reflection of differences in the disease 
severity of the patients, where  the disease severity of COPD patients in the current 
study was milder to that of Paredi et al (2010), FEV1 68% predicted and 59% predicted 
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respectively, and similarly the mild-moderate asthmatics were milder, FEV1 84% 
predicted and 69% predicted, respectively. Differences in study population and 
prescribed treatment are also the main reasons why the data here also did not show a 
difference between disease severity in patients with asthma (that is compared to severe 
asthmatics), unlike that of Qi and colleagues (2013), as described above.    
 
Ventilation heterogeneity results were comparable to severe asthma and healthy 
subjects and Sacin and LCI were better compared to COPD. King (2011) suggested that 
Scond appears to be more affected in asthma, however, the use of medication in this 
study would have normalised ventilation heterogeneity in the conducting airways. We 
(Biddiscombe et al, 2010) previously measured Scond in a group of mild-moderate 
asthmatics where medication was withdrawn and the result was higher (0.080 /L). The 
results though show that Sacin is worse in COPD patients than mild asthmatics 
suggesting more acinar damage in patients with COPD, and these data are in keeping 
with that reported in the seminal paper by Verbanck and colleagues (1999) who 
compared Sacin and Scond in patients with COPD and asthma. 
 
The results for TLCOc and kCOc were similar to severe asthma and better than 
COPD. The VA significantly bigger compared to COPD because the mild-moderate 
asthma group were taller. However, no difference in percent predicted VA. Lung 
volumes were similar to severe asthma. The RV, RV:TLC, and FRCpleth (% pred) were 
smaller compared to COPD.  
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Multiple flow exhaled nitric oxide results revealed that FENO50 and bronchial NO 
(J’awNO) were highest in this group compared to severe asthma, COPD, and healthy 
group. The high results in this group of FENO (49ppb) suggests ongoing underlying 
airways inflammation that clinical practice guidelines on nitric oxide suggest needs to be 
controlled by increased anti-inflammatory medication, but could also suggest poor 
adherence to inhaler use, or persistent allergen exposure (Dweik et al, 2011). Table 4.2 
shows that overall the mild-moderate asthmatic patients studied were probably more 
mild (as also reflected in the FEV1% predicted of 84%) and on limited use of OCS’s and 
not very high doses of ICS monotherapy or combination ICS/LABA therapy. Alveolar 
NO (CalvNO) was not elevated in this group and was similar across groups, and this is 
similar to the observation by Berry and colleagues noted similar levels of CalvNO 
between patients with mild asthma and healthy subjects, and that CalvNO levels in 
severe asthmatics were markedly elevated compared to mild asthmatics and healthy 
subjects (Berry et al, 2005 .   
 
4.4.4 Healthy smokers 
Cigarette smoke is toxic to the airways with pro-inflammatory (Thompson et al, 
2003), that results in an increase neutrophils in the airways (Bosken et al, 1992; Lams 
et al, 1998). The smoking history of the group studied was greater than 10 pack years 
(1 pack year = 20 cigarettes a day for one year).  
 
Spirometry was overall lower than healthy subjects but there were no significant 
differences in the parameters measured. Loss of lung function as measured by 
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spirometry has been shown to reduce by up to 50 mls per year in smokers (Anthonisen 
et al, 2002; James et al, 2005). Verbanck et al (2004) investigated smokers who were 
classified according to pack years. Smokers with 10 – 20 and 20 – 30 pack years had 
FEV1’s (% pred) of 114.0 and 108.0, respectively. Smokers with a longer pack history 
(32 years) had an FEV1 (% pred) of 107.0% (Verbanck et al, 2006). Comparing the 
result of 10 – 20 pack years FEV1 (% pred) was slightly larger than observed in the 
present study, FEV1 97.1 (% pred) and this may be that the data of Verbanck (2006) 
had patients with greater pack towards 20 years. The MMEF75/25 (% pred) was lower in 
this study (54.9%) compared to 98.0% and 86.0% in smokers with 10 – 20 and 20 – 30 
pack years.  
 
Cigarette smoking is common with about 20% of asthmatics being regular 
smokers (Althuis et al, 1999; Walsh et al, 1999) and asthmatics who smoke have been 
reported to have more severe symptoms than non-smoking asthmatics (Althuis et al, 
1999; Siroux et al, 2000). Boulet et al (2006) looked at smoking in mild-moderate 
asthma and found that asthmatics who smoked (14 pack years) had lower FEV1 / FVC, 
MMEF75/25, TLCOc (% pred), kCO (% pred), and increased airways resistance (% pred) 
and FRCpleth (% pred) compared to non-smoking asthmatics.  
  
Airways conductance and resistance followed the same trend as spirometry and 
was not significantly different to healthy subjects. Impulse oscillometry failed to 
discriminate smokers from healthy subjects. 
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Alternative methods to spirometry have been previously used to detect the 
effects of smoking on the small airways (Brand et al, 1994; Buist et al, 1976; Buist et al, 
1979). Cosio et al (1978) and Marco and Minette (1976) demonstrated that single-
breath nitrogen washout test was able to detect structural changes in the small airways 
earlier than spirometry possibility at a point when structural changes are possibly 
reversible.  
 
Ventilation heterogeneity was increased within the large conducting airways as 
demonstrated by Scond (0.068 /L) and LCI (6.51 /L). Decreased expiratory flow in 
smokers with a longer smoking history may be indicative of more progressive 
deterioration in the small airways. The studies described above by Verbanck et al 
(2004; 2006) yielded lower results for Scond in smokers with 10 – 20, 20 – 30, and 32 
pack years and were 0.040 (/L), 0.049 (/L)  and 0.047 (/L). In this study, Sacin (0.150 /L) 
was increased in smokers but not significantly when compared to healthy subjects 
(0.089 /L). The studies by Verbanck et al (2004; 2006) provided comparable results for 
Sacin in smokers with 10 – 20, 20 – 30, and 32 pack years and were 0.100 (/L), 0.124 
(/L), and 0.126 (L/). Pinkerton et al (2000) stated that the transitory zone around the 
acinar entrance is vulnerable to accumulation of particulate matter and airway wall 
thickening opposed to the conducting airways and this may account for the increase 
observed in Sacin.  
 
Results from single-breath tests revealed that TLCOc, TLCOc (% pred), kCO, 
and kCO (% pred) were lower in smokers compared to healthy subjects. The studies by 
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Verbanck et al (2004; 2006) yielded slightly better results for TLCO (% pred) in smokers 
with 10 – 20, 20 – 30, and 32 pack years and were 85.0%, 81.0% and 80.0%. Again the 
actual values for TLCO were not reported and it is not known if TLCO was corrected for 
by haemoglobin in these studies by Verbanck et al (2004; 2006) therefore no 
comparison can be made. Additionally, Verbanck et al (2004; 2006) may have used 
different predicted equations yielding slightly different results.  
 
Exhaled NO has limitations as an inflammatory marker in smokers as it is 
suppressed by smoking (Malinovschi et al, 2006). FENO50 and J’awNO were lowest in 
this group compared to all other groups. Hogman et al (2002) found that following four 
weeks of smoking cessation that abnormally low J’awNO returned to normal values with 
no change in alveolar NO (CalvNO). Smoking has also been shown to impair the efficacy 
of short-term OCS’s (Chaudhuri et al, 2003) and low dose ICS’s (Tomlinson et al, 2005).  
  
The impact of smoking on small and large airways in asthma warrants further 
investigation. From the studies of Verbanck (2004, 2006) it seems likely that ventilation 
heterogeneity and large and small airways calibre decrease faster. This would be due to 
both structural changes and the effect smoking has on therapy.  
 
4.4.5 Healthy subjects 
The healthy subjects had results for spirometry, lung volumes, single-breath 
transfer factor tests that lay within predicted limits. Airways conductance and resistance, 
impulse oscillometry, multi-breath nitrogen washout and multiple flow exhaled nitric 
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oxide results were normal.  From the discussion above, comparison of the parameters 
for small airways (CalvNO, Sacin and R5-R20 EX, see section 4.2.2) as the primary 
endpoint analysis showed small airways physiological dysfunction markers of Sacin and 
R5-R20 EX were elevated in all groups compared to healthy subjects, but there was no 
difference in the small airways inflammation marker of CalvNO.  
 
4.4.6 Small versus large airways tests 
 
4.4.6.1 Multiple flow exhaled nitric oxide 
Elevated exhaled NO is caused primarily from eosinophilic inflammation that 
occurs in asthma. By performing the test at multiple expiratory flows larger central 
airway (J’awNO) and smaller airway and alveolar (CalvNO) nitric oxide was measured. At 
the same time FENO50 is measured which is an overall biomarker of inflammation 
arising from the larger central airways and has been advocated to be used as a 
biomarker in patients with asthma in clinical practice (Dweik et al, 2011). J’awNO and 
FENO50 both increase in the presence of airway inflammation and therefore it would be 
simpler to perform FENO50 to determine inflammation in this large airway compartment.  
 
CalvNO was similar across groups and did not discriminate the degree of alveolar 
inflammation between both asthma groups. These tests were performed while patients 
were treated with corticosteroids which were used more in severe asthma. Excluding 
corticosteroids would have allowed multiple flow exhaled nitric oxide tests to 
discriminate disease severity. Additionally this test could be used to monitor the small 
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airway / alveolar response in patients receiving long term corticosteroid, as was noted in 
the study by Berry and colleagues (2005) where patients with severe asthma once 
treated with OCS has significant reductions in their CalvNO levels.  
 
Both parameters that represent inflammation arising from large (J’awNO) and 
small (CalvNO) airway compartments were not useful for the assessment of airway 
inflammation in COPD and smoking. However, this test may provide evidence that 
individuals are continuing to smoke since J’awNO (and FENO50) were lowest in smokers. 
An artificially low J’awNO in smoking asthmatics may be a sign of other inflammatory 
processes occurring in bronchial airways.  
 
4.4.6.2 Multi-breath nitrogen washout 
Increased ventilation heterogeneity was measured in the larger conducting 
(Scond) and smaller acinar (Sacin) airway compartments. As airflow limitation increases in 
one or both compartments a corresponding increase in Scond and Sacin was expected. 
Smoking induced damage was detected by an elevated Scond and Sacin. COPD patients 
also had high Scond and Sacin values due to severe air flow limitation from long term 
smoking. Airflow limitation is progressive and largely affects the small airways in COPD 
and Sacin can be expected to increase with disease severity faster than Scond. Therefore 
Sacin can be used to measure disease progression. Asthma is characterised by variable 
airflow limitation that affects all airways. Sacin detected small airway dysfunction with 
disease severity as it was increased in severe asthma versus mild-moderate asthma.  
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4.4.6.3 Impulse oscillometry  
Like Sacin, small airways resistance was increased in the presence of airflow 
limitation. This increase in small airways resistance was related to the severity of airflow 
limitation. The R5 EX which represents small airways resistance was slightly larger in 
severe asthma versus mild-moderate asthma. Airflow limitation as determined by 
spirometry was worse in COPD who also had an increased R5 EX. Similarly, Rperipheral 
was elevated in severe asthma and COPD and may better reflect severity of airflow 
limitation in these airways. Reactance parameters that reflect small airway dysfunction 
(X5 EX, AXEX, AX) worsened with progressing airflow limitation as seen amongst both 
patient groups.  
 
Resistance in the large airways was measured by R20 EX and Rcentral was similar 
in both asthma groups. This could be due to the use of β-2 agonist’s which relax airway 
smooth muscle in larger airways. However, Rcentral was elevated in severe asthma and 
COPD and may better reflect severity of airflow limitation in these airways.  
 
4.4.7 Limitations of the study 
 
4.4.7.1 Biological factors 
The study aimed to match group participants based on their characteristics (table 
4.1). The ratio of men to women was greater in mild-asthma versus severe asthma. 
Men are generally taller which could have implications when comparing disease severity 
between these groups using absolute values. The COPD group were older than other 
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groups which could affect comparisons using absolute values. However height and age 
would not affect percent predicted comparisons. Childhood health wasn’t extensively 
investigated. Low birth weight and weight gain in early childhood are associated with 
reduced lung volumes and diffusing capacity (Hancox et al, 2009).  
 
Attempts were made to test participants at the same time of day due to diurnal 
variations in respiratory function however this proved unpractical due to their scheduling 
conflicts. Medarov et al (2008) recently demonstrated that spirometry and diffusion 
capacity results were better at approximately 16:00 and 08:00 hours respectively in 
4756 individuals.  
 
The lifestyles and dietary habits of participants were not investigated. 
Recommendations could have been made prior to testing so that subjects avoided L-
arginine rich foods. Kharitonov et al (1995) has suggested that eating an L-arginine rich 
diet could increase exhaled nitric oxide.  
 
4.4.7.2 Non-biological factors 
Every attempt was made to have an equal number of participants per group 
however when approached smokers were reluctant to participate affecting the sample 
size of this group. In contrast, the sample size of the COPD group was greater since 
many patients had retired. Smokers were asked to refrain from smoking for several 
hours prior to tests however it is unknown if they adhered to this request. Passive 
exposure to cigarette smoke was not checked at screening.    
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4.4.7.3 Adjusting for cofounders 
Factors that are not of direct interest but may have been needed to be accounted 
for were not. Certainly accounting for such  cofounders (biological and non-biological) 
would have reduced the number of study participants and the use of adjusting or not for 
certain confounders in this study may have affected the outcome. Recently de Graaf et 
al (2011) suggested that matching could be used to avoid confounding factors. However 
there was no control over some variables such as time of testing. Multiple confounders 
need to be considered when interpreting these results. Indeed, cofounders such as 
weight, racial origin, and age may have affected the results. In a similar manner that 
population data are being updated and reference values being generated for lung 
function testing (Quanjer et al, 2012), there is a real need for the techniques of multiple 
breath washout, nitric oxide and impulse oscillometry. 
 
4.5 SUMMARY 
 
With respect to the primary endpoints, the data in this Chapter partially support 
the hypothesis that small airways dysfunction is present in patients with obstructive 
airways disease when compared to healthy subjects. Sacin and R5-R20 EX were elevated 
in all groups compared to healthy subjects, but there was no difference in the small 
airways inflammation marker of CalvNO.  
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Patients with COPD were characterised by small airways dysfunction with  
increased ventilation heterogeneity within the small airways, worsening of small airway 
resistance and reactance, hyperinflation, and reduced diffusion capacity. Healthy 
smokers also demonstrated abnormalities seen in COPD, increased ventilation 
heterogeneity and a reduced diffusion capacity even when their FEV1 was normal. 
Therefore smoking induced damage was detectable by multi-breath nitrogen washout 
and transfer factor tests, but not spirometry.  
 
Multi-breath nitrogen washout and impulse oscillometry results were poorer in 
severe compared to mild-moderate asthma and demonstrated small airway dysfunction 
in the presence of normal results from routine tests. Multiple flow exhaled nitric oxide 
was only elevated in mild-moderate asthma due to the low use of corticosteroids.  
 
The data in this Chapter add to the currently topical debate on treating the small 
airways and reinforce the need to directly test the hypothesis of whether targeting the 
small airways with inhaled therapeutics to treat the observed small airways dysfunction 
translates to clinical patients benefit in the diseases of asthma and COPD (Usmani, 
2015). The next chapter looks at how the results from these tests changed longitudinal 
over a period of time (16 months).  
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CHAPTER 5: 
LONGITUDINAL ASSESSMENT OF CHANGES IN AIRWAY 
PHYSIOLOGY AND INFLAMMATION IN HEALTHY LUNGS AND 
OBSTRUCTIVE LUNG DISEASE 
 
5.1 BACKGROUND  
 
5.1.1 Longitudinal assessment of respiratory function  
Longitudinal studies provide information into the natural change or decline of 
respiratory health in both health and disease. Information from such studies can be 
used to assess the progression of the respiratory disease over the course of time, 
identify healthy individuals who may be at risk of developing disease (i.e. smokers and 
occupational lung disease), and are informative on the impact of current and new 
medications in stabilising existing disease. Certainly, repeated measurement over time 
can provide some estimate of the variability of respiratory parameters that may be more 
sensitive than spirometry in detecting early disease.  
 
5.1.2 Problem with spirometry  
Historically spirometry, has been used to monitor changes in global lung function 
over time in health and disease and in clinical trials. This is because spirometry reflects 
airway calibre and spirometers are inexpensive and portable. However, spirometry has 
limitations as the technique is highly dependent on breathing technique, requires 
subject cooperation, and is effort dependant (Faria et al, 2010; Kubota et al, 2009). 
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Spirometry is performed under conditions unreflective of normal tidal breathing. 
The technique requires a forced manoeuvre that can induce bronchoconstriction 
(Orehek et al, 1981) and can result in dynamic compression of the airways (Elshout et 
al, 1990). Respiratory breathing manoeuvres of deep inspiration and forced expiration 
have both been shown to result in alterations to airway tone (Burns and Gibson, 2002; 
Faria et al, 2010; Malmberg et al, 1993; Neild et al, 1989; Orehek et al, 1981). 
Spirometry alone may not detect abnormalities in respiratory function early in the 
manifestation of lung disease. Spirometry does not always detect the changes in 
respiratory mechanics due to smoking (Coe et al, 1989). It may take several subsequent 
tests over time before an abnormality is detected since the day to day biological 
variation can be large.  
 
In patients with COPD, pathological changes leading to COPD are usually 
progressive, starting many years before a lung function abnormality can be detected 
with spirometry or radiology imaging (Baughman et al, 2012) and, the FEV1 does not 
capture the complexity of COPD (Agusti et al, 2010). Additionally, FEV1 correlates 
poorly with patient centred outcomes such as dyspnoea, exercise capacity, and quality 
of life (Jones, 2001; Mahler and Harver, 1992). Indeed, in patients with COPD, 
dyspnoea has been demonstrated to decline while FEV1 remained stable over two 
years (Halpin, 2009).  
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5.1.3 Beyond spirometry 
Longitudinal studies looking at measurements of complete respiratory function 
and airway inflammatory changes over time are scarce in comparison to studies using 
spirometry. This is surprising since many patients with asthma and COPD (as well as 
other respiratory conditions) have previously performed (and continue to perform) more 
extensive respiratory function tests once or more annually over several years at 
specialist lung function departments. This includes lung volumes measured by body 
plethysmography (or helium dilution) and single (or rebreathing transfer factor tests). 
Together with spirometry these form the more ‘routine’ lung function tests.  
 
 In Chapter 4, I reported on advanced (specialist), lung function tests of exhaled 
nitric oxide, multiple-breath nitrogen washout and impulse oscillometry as physiological 
techniques that may be complementary to the established conventional lung function 
approaches. These tests also allow the assessment of ‘large’ and also ‘small’ airway 
calibre and the Chapter described a cross-sectional investigation of patients with 
asthma and COPD to see how respiratory function and inflammation differed across 
groups. In particular the presence of small airways dysfunction was noted using the 
advanced tests, that conventional spirometry was unable to detect. One-off 
physiological results obtained for individual patients are usually used to guide therapy 
and assess lung health, but if longitudinal data are collected from patients prospectively 
this would yield valuable information on the variation in respiratory function in patients 
stratified by disease and severity and also inform on treatment effects over time.  
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5.1.4 Aims of study 
In this Chapter a longitudinal study was performed looking at routine and 
advanced respiratory function measurements in patients with asthma and COPD, 
importantly including tests of small airways function. The aim was to assess the natural 
history of the disease and variability with respect to the large, but also small airways 
function, which may go under-recognised in patients with asthma and COPD using 
conventional lung function tests. 
  
5.1.5 Hypothesis  
The hypothesis was that during the stable clinical state, specialized tests  of 
small and large airway function and inflammation demonstrate a better signal of change 
of these compartments and variability over time, than measurements obtained from 
routine conventional lung function tests.  
 
5.2 METHODS 
 
5.2.1 Subjects and study design 
This was a longitudinal study that enrolled the same patients and healthy 
subjects from the cross sectional study (section 2.3, Chapter 2 Methods). The 
parameters of respiratory function and inflammation have been described in the 
previous Chapter (4.2.2, Chapter 4) and patients were diagnosed with asthma and 
COPD and their severity classified according to criteria as previously discussed (section 
2.3, Chapter 2 Methods ). Respiratory tests were undertaken every 8 months for a total 
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of 3 study visits. This time period was chosen to allow sufficient recruitment of subjects 
over the 30 month study period such that each subject could attend all 3 visits.  
 
Patients with lung disease continued their medications as normal during the 
study to reflect real-life practice. All asthmatic and COPD patients were in a stable 
condition (≥ 4 weeks) at study visits, all tests were tolerated with no patients requiring 
rescue medication (β2-agonists) and there were no adverse events during study visits. A 
5-item Asthma Control TestTM (ACT) (QualityMetric Incorporated, 2002) questionnaire 
was provided to measure asthma control in the asthmatic patients at each visit.  
 
5.2.2 Statistical analysis 
A repeated measures ANOVA was used to determine if results for each 
respiratory function parameter were different between the three study visits time points. 
The differences were considered statistically significant at a p value <0.01. The 
intraclass correlation coefficient (ICC) and coefficient of variation (CoV) was calculated 
for each respiratory function parameter to determine between visit variability.  
 
Parameters that were not normally distributed could not be analysed using the 
repeated measures ANOVA and are not included here (CalvNO [manual], AXEX, and AX). 
Statistical analysis was performed using SPSS statistical package (SPSS version 22 for 
Windows; SPSS Inc. Chicago, IL)   
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5.3 RESULTS 
 
5.3.1 Subject participation for each group 
Over the course of the 16 months, there were drop-outs in each of the 5 groups 
(table 5.1). In summary, there were a total of 126, 115 and 93 participants at visit 1, 2 
and 3 respectively and a total of 33 dropped out after visit 1 or 2. Figure 5.1 shows a 
consort diagram for study.  
 
Table 5.1: Number of subjects in each group at each study visit  
Number of subjects  
(Male/ Female) 
Healthy  Healthy 
smokers 
Mild-moderate 
asthma 
Severe  
asthma 
COPD 
 
Visit 1 29 (14 / 15) 20 (9 / 11) 20 (13 / 7) 23 (6 / 17) 34 (16 / 18) 
Visit 2 28 (13 / 15) 18 (7 / 11) 
 
19 (12 / 7) 19 (5 / 14) 31 (14 / 17) 
Visit 3 25 (11 / 14) 16 (5 / 11) 18 (11 / 7) 13 (3 / 10) 21 (10 / 11) 
Number dropped out since 
visit 1 (baseline) 
4 (3 / 1) 4 (4 / 0) 2 (2 / 0) 10 (3 / 7) 13 (6 / 7) 
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Figure 5.1: Consort diagram for longitudinal study. 
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5.3.2 Healthy group 
There was no significant difference in routine and specialist respiratory 
parameters between repeated visits (p = >0.01). All respiratory parameters obtained 
from routine lung function tests had a strong between visit ICC (>0.73) and low CoV 
(<12.44%). See tables 5.2 – 5.4.  
  
With respect to specialised tests of the larger airway compartment, large airway 
inflammatory parameters (FENO50 and J’awNO [manual]) had a strong between visit ICC 
(>0.72) and a low CoV (<22.93%). Resistance in the large airways (R20 EX and Rcentral) 
had a strong between visit ICC (>0.84) and low CoV (<12.23%). However, ventilation 
heterogeneity in the larger conducting airways (Scond) had a poor between visit ICC 
(0.07) and large CoV (29.71%).  
          
           In the small airways, resistance and reactance from impulse oscillometry (R5 EX, 
Rperipheral, X5 EX and fres) had a strong between visit ICC (>0.77) and a low CoV 
(<19.42%). However R5 - R20 EX which reflects small airway resistance had a fair 
between visit ICC (0.43) and very large CoV (45.82%). Ventilation heterogeneity in the 
small acinar airways (Sacin) had a moderate between visit ICC (0.65) and a large CoV 
(37.47%). LCI had a fair ICC between visit ICC (0.42) and low CoV (7.18%). This can 
be seen in table 5.5. 
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Table 5.2: Forced spirometry results in healthy group  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
FEV1 (L) 3.18 (0.79) 3.21 (0.83) 3.21 (0.90) 0.98 3.02 
FEV1 (% pred) 105.5 (10.0) 108.1 (11.3) 108.4 (11.7) 0.83 3.38 
FVC (L) 4.23 (1.12) 4.27 (1.10) 4.31 (1.20) 0.99 3.14 
FVC (% pred) 116.0 (13.6) 119.6 (15.5) 120.2 (14.5) 0.89 3.61 
FEV1 / FVC (%) 75.65 (6.45) 75.19 (6.79) 74.79 (6.23) 0.82 3.14 
MMEF75/25 (L/s) 2.48 (0.88) 2.48 (1.00) 2.46 (1.05) 0.87 12.58 
MMEF75/25 (% pred) 68.5 (17.2) 69.0 (19.3) 68.7 (22.4) 0.73 12.44 
189 
 
Table 5.3: Lung volumes and expiratory airways resistance and conductance in healthy 
group  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
Lung volumes 
RV (L) 2.03 (0.50) 2.00 (0.52) 2.04 (0.59) 0.94 6.05 
RV (% pred) 104.9 (18.3) 102.3 (17.2) 102.6 (18.8) 0.82 6.23 
TLC (L) 6.34 (1.35) 6.31 (1.37) 6.41 (1.55) 0.99 1.98 
TLC (% pred) 108.0 (10.5) 108.0 (10.8) 108.9 (11.6) 0.94 2.18 
RV: TLC (%) 32.48 (7.24) 32.17 (7.26) 32.15 (7.50) 0.94 5.03 
RV: TLC (% pred) 93.6 (14.5) 91.4 (14.4) 90.3 (11.7) 0.80 5.10 
FRCpleth (L) 3.15 (0.66) 3.21 (0.66) 3.25 (0.75) 0.91 5.76 
FRCpleth (% pred) 103.2 (16.2) 105.6 (16.7) 106.0 (17.7) 0.81 5.85 
Expiratory airways resistance and conductance  
Raw EX (kPa/L/s) 0.35 (0.11) 0.33 (0.11) 0.31 (0.12) 0.72 18.63 
SGaw EX (kPa/L/s/L) 1.00 (0.30) 1.06 (0.28) 1.18 (0.42) 0.55 17.35 
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Table 5.4: Single-breath transfer factor results in healthy group  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
TLCOc (mmol/min/kPa) 8.15 (1.92) 8.04 (1.94) 8.20 (1.90) 0.91 5.90 
TLCOc (% pred) 89.9 (13.0) 89.5 (11.7) 91.5 (11.5) 0.78 5.97 
kCOc (mmol/min/kPa/L) 1.47 (0.23) 1.45 (0.20) 1.48 (0.22) 0.84 5.13 
kCOc (% pred) 94.9 (13.8) 94.2 (11.6) 96.0 (11.6) 0.80 5.16 
VA (L) 5.56 (1.22) 5.56 (1.26) 5.60 (1.34) 0.98 2.43 
VA (% pred) 97.8 (9.5) 98.0 (9.6) 98.3 (9.3) 0.91 2.61 
191 
 
Table 5.5: Results from specialist large and small airway tests in healthy group  
Results are presented as mean ± (SD) 
            
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
Multiple flow exhaled nitric oxide 
FENO50 (ppb) 26.6 (15.7) 21.9 (10.3) 21.8 (12.0) 0.72 19.44 
J’awNO (manual) (nl/s) 76.6 (46.3) 60.8 (30.1) 59.7 (32.5) 0.72 22.93 
Multi-breath nitrogen washout 
Sacin (/L) 0.089 (0.051) 0.107 (0.072) 0.104 (0.075) 0.65 37.47 
Scond (/L) 0.041 (0.016) 0.040 (0.015) 0.042 (0.018) 0.07 29.71 
LCI  5.65 (0.60) 6.00 (0.56) 5.93 (0.36) 0.42 7.18 
Impulse oscillometry 
R5 EX (kPa/L/s) 0.45 (0.16) 0.41 (0.12) 0.42 (0.15) 0.77 11.40 
R20 EX (kPa/L/s) 0.36 (0.12) 0.34 (0.10) 0.35 (0.11) 0.84 9.07 
R5 - R20 EX (kPa/L/s) 0.09 (0.10) 0.05 (0.05) 0.06 (0.05) 0.43 45.82 
Rcentral (kPa/L/s) 0.23 (0.09) 0.23 (0.07) 0.23 (0.10) 0.86 12.23 
Rperipheral (kPa/L/s) 0.29 (0.13) 0.27 (0.12) 0.28 (0.16) 0.83 19.42 
X5 EX (kPa/L/s) -0.12 (0.07) -0.11 (0.06) -0.11 (0.07) 0.78 19.41 
fres (1/L) 13.46 (5.03) 12.38 (3.76) 12.66 (4.01) 0.86 9.23 
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5.3.3 Healthy smokers 
There was no significant difference in routine and specialist respiratory 
parameters between repeated visits (p = >0.01). All respiratory parameters obtained 
from routine lung function tests had a strong between visit ICC (>0.73) and a low CoV 
(<7.58%). See tables 5.6 – 5.8. 
 
With respect to specialised tests of the larger airway compartment, large airway 
inflammatory parameters (FENO50 and J’awNO [manual]) had a fair between visit ICC 
(>0.34) and a high CoV (<31.51%). Resistance in the large airways (R20 EX and Rcentral) 
had a strong between visit ICC (>0.82) and low CoV (<12.90%). However, ventilation 
heterogeneity in the larger conducting airways (Scond) had a poor between visit ICC 
(0.29) and high CoV (31.40%).  
          
           In the small airways, resistance and reactance (R5 EX, Rperipheral, X5 EX and fres) 
had a moderate to strong between visit ICC (>0.57) and low CoV (<21.13%). However 
R5 - R20 EX which reflects small airway resistance had a fair between visit ICC (0.44) 
and large CoV (37.88%). Ventilation heterogeneity in the small acinar airways (Sacin) 
had a strong between visit ICC (0.72) and moderate CoV (27.94%). LCI had a moderate 
between visit ICC (0.63) and low CoV (4.75%). This can be seen in Table 5.9. 
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Table 5.6: Forced spirometry results in healthy smokers  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC VoW (%) 
FEV1 (L) 2.76 (0.73) 2.65 (0.73) 2.55 (0.68) 0.98 3.19 
FEV1 (% pred) 97.1 (12.2) 99.7 (14.8) 99.4 (13.1) 0.79 4.45 
FVC (L) 3.82 (1.12) 3.79 (1.10) 3.69 (1.13) 0.99 2.92 
FVC (% pred) 111.1 (18.5) 116.1 (17.6) 118.5 (16.8) 0.92 3.79 
FEV1 / FVC (%) 72.87 (7.23) 70.35 (5.51) 69.59 (6.24) 0.84 3.18 
MMEF75/25 (L/s) 1.90 (0.88) 1.60 (0.56) 1.46 (0.51) 0.78 7.58 
MMEF75/25 (% pred) 54.9 (19.8) 48.7 (14.3) 46.4 (15.2) 0.73 7.56 
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Table 5.7: Lung volumes and expiratory airways resistance and conductance in healthy 
smokers  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC VoW (%) 
Lung volumes      
RV (L) 2.20 (0.49) 2.20 (0.62) 2.25 (0.60) 0.90 5.75 
RV (% pred) 110.7 (18.7) 110.2 (21.4) 112.8 (16.5) 0.77 5.90 
TLC (L) 6.00 (1.36) 5.95 (1.53) 5.91 (1.47) 0.98 2.23 
TLC (% pred) 105.1 (14.4) 107.3 (14.6) 109.7 (11.8) 0.94 2.28 
RV: TLC (%) 37.33 (7.14) 37.35 (6.71) 38.43 (6.12) 0.89 4.75 
RV: TLC (% pred) 101.6 (13.2) 99.2 (13.1) 100.0 (9.9) 0.80 4.85 
FRCpleth (L) 3.21 (0.96) 3.26 (1.03) 3.33 (1.01) 0.97 4.35 
FRCpleth (% pred) 106.2 (24.3) 109.8 (25.8) 113.7 (21.4) 0.93 4.39 
Expiratory airways resistance and conductance 
Raw EX (kPa/L/s) 0.40 (0.13) 0.39 (0.14) 0.37 (0.19) 0.74 16.19 
SGaw EX (kPa/L/s/L) 0.88 (0.23) 0.86 (0.29) 0.94 (0.47) 0.70 15.29 
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Table 5.8: Single-breath transfer factor results in healthy smokers  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC VoW (%) 
TLCOc (mmol/min/kPa) 6.32 (1.50) 5.99 (1.37) 5.91 (1.27) 0.88 5.54 
TLCOc (% pred) 72.9 (12.3) 71.9 (11.8) 73.4 (11.4) 0.85 5.92 
kCOc (mmol/min/kPa/L) 1.24 (0.30) 1.19 (0.29) 1.19 (0.24) 0.91 5.49 
kCOc (% pred) 81.0 (16.1) 78.3 (15.4) 78.5 (13.0) 0.83 5.54 
VA (L) 5.20 (1.12) 5.14 (1.16) 5.04 (1.07) 0.99 1.97 
VA (% pred) 93.6 (11.8) 95.6 (11.6) 96.8 (9.8) 0.95 2.06 
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Table 5.9: Results from specialist large and small airway tests in healthy smokers  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
Respiratory parameter baseline 8 months 16 months ICC CoV (%) 
Multiple flow exhaled nitric oxide 
FENO50 (ppb) 14.9 (7.0) 14.6 (4.7) 13.7 (7.5) 0.34 28.03 
J’awNO (manual) (nl/s) 36.0 (21.1) 31.3 (14.9) 31.6 (24.5) 0.36 31.51 
Multi-breath nitrogen washout 
Sacin (/L) 0.150 (0.084) 0.184 (0.107) 0.195 (0.113) 0.72 27.94 
Scond (/L) 0.068 (0.027) 0.056 (0.022) 0.062 (0.025) 0.29 31.40 
LCI  6.51 (0.77) 6.52 (0.46) 6.52 (0.67) 0.63 4.75 
Impulse oscillometry 
R5 EX (kPa/L/s) 0.50 (0.25) 0.50 (0.12) 0.49 (0.15) 0.65 11.78 
R20 EX (kPa/L/s) 0.39 (0.15) 0.40 (0.11) 0.40 (0.12) 0.82 9.30 
R5 - R20 EX (kPa/L/s) 0.11 (0.12) 0.10 (0.04) 0.09 (0.06) 0.44 37.88 
Rcentral (kPa/L/s) 0.27 (0.11) 0.29 (0.08) 0.28 (0.10) 0.85 12.90 
Rperipheral (kPa/L/s) 0.35 (0.16) 0.33 (0.12) 0.33 (0.14) 0.57 21.13 
X5 EX (kPa/L/s) -0.16 (0.11) -0.14 (0.05) -0.14 (0.06) 0.58 18.89 
fres (1/L) 15.70 (5.30) 15.14 (3.27) 14.17 (4.10) 0.65 13.38 
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5.3.4 Mild-moderate asthma  
There was no significant difference in routine and specialist respiratory 
parameters between repeated visits (p = >0.01). All respiratory parameters obtained 
from routine lung function tests had a strong between visit ICC (>0.74) and low CoV 
(<11.74%). See tables 5.10 - 5.12. 
 
Large airway inflammatory parameters (FENO50 and J’awNO [manual]) had a 
strong between visit ICC (>0.79) and moderate CoV (<24.91%). Resistance in the large 
airways (R20 EX and Rcentral) had a strong between visit ICC (>0.77) and low CoV 
(<13.76%). Ventilation heterogeneity in the larger conducting airways (Scond) had a poor 
between visit ICC (0.19) and huge CoV (45.31%).  
          
           Resistance and reactance in the small airways (R5 EX, R5 - R20 EX, Rperipheral, X5 
EX, and fres) had a moderate to strong between visit ICC (>0.56) and moderate to low 
CoV (<24.07%). Ventilation heterogeneity in the small acinar airways (Sacin) had a 
moderate between visit ICC (0.54) and large CoV (40.39%). LCI had a poor between 
visit ICC (0.28) and low CoV (7.10%). This can be seen in table 5.13. 
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Table 5.10: Forced spirometry results in mild-moderate asthmatics  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter baseline 8 months 16 months ICC CoV (%) 
FEV1 (L) 3.03 (0.80) 3.05 (0.72) 3.04 (0.77) 0.96 4.88 
FEV1 (% pred) 84.0 (13.7) 85.5 (11.8) 87.2 (12.1) 0.84 4.91 
FVC (L) 4.49 (1.02) 4.51 (1.03) 4.43 (1.01) 0.96 3.85 
FVC (% pred) 104.3 (15.2) 105.5 (15.3) 106.8 (15.8) 0.90 3.85 
FEV1 / FVC (%) 67.62 (9.37) 68.01 (8.05) 68.54 (7.64) 0.77 4.43 
MMEF75/25 (L/s) 2.01 (0.97) 1.97 (0.86) 1.99 (0.96) 0.94 11.73 
MMEF75/25 (% pred) 47.1 (16.9) 46.8 (13.9) 47.6 (16.3) 0.84 11.74 
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Table 5.11: Lung volumes and expiratory airways resistance and conductance results in 
mild-moderate asthmatics  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter baseline 8 months 16 months ICC CoV (%) 
Lung volumes  
RV (L) 2.37 (0.69) 2.35 (0.59) 2.40 (0.58) 0.86 7.76 
RV (% pred) 125.0 (23.2) 123.2 (24.3) 125.9 (23.7) 0.74 8.19 
TLC (L) 6.76 (1.12) 6.85 (1.16) 6.77 (1.14) 0.98 2.07 
TLC (% pred) 105.3 (12.8) 106.5 (12.9) 107.4 (13.3) 0.96 2.07 
RV: TLC (%) 35.11 (7.88) 34.65 (8.24) 35.86 (7.75) 0.84 7.38 
RV: TLC (% pred) 113.6 (16.5) 110.6 (20.7) 113.4 (20.9) 0.74 7.37 
FRCpleth (L) 3.55 (0.80) 3.62 (0.62) 3.62 (0.56) 0.87 6.00 
FRCpleth (% pred) 111.5 (23.2) 113.7 (19.7) 114.8 (15.9) 0.87 5.81 
Expiratory airways resistance and conductance  
Raw EX (kPa/L/s) 0.50 (0.20) 0.42 (0.16) 0.44 (0.19) 0.62 17.72 
SGaw EX (kPa/L/s/L) 0.68 (0.29) 0.75 (0.25) 0.73 (0.26) 0.72 19.03 
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Table 5.12: Single-breath transfer factor results in mild-moderate asthmatics  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter baseline 8 months 16 months ICC CoV (%) 
TLCOc (mmol/min/kPa) 9.14 (2.08) 8.97 (1.86) 8.86 (2.08) 0.93 5.31 
TLCOc (% pred) 88.1 (10.4) 87.2 (8.6) 87.8 (10.6) 0.77 5.13 
kCOc (mmol/min/kPa/L) 1.55 (0.22) 1.51 (0.24) 1.51 (0.26) 0.84 5.91 
kCOc (% pred) 97.4 (13.5) 94.9 (14.7) 95.0 (14.4) 0.80 5.91 
VA (L) 5.86 (0.92) 5.98 (0.95) 5.89 (0.95) 0.96 2.40 
VA (% pred) 93.7 (11.5) 95.3 (11.4) 95.7 (11.2) 0.94 2.43 
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Table 5.13: Results from specialist large and small airway tests in mild-moderate 
asthmatics  
Results are presented as mean ± (SD) 
 
 
 
 
 
 
Respiratory parameter baseline 8 months 16 months ICC CoV (%) 
Multiple flow exhaled nitric oxide 
FENO50 (ppb) 48.6 (28.9) 52.7 (40.8) 52.7 (43.7) 0.80 22.56 
J’awNO (manual) (nl/s) 140.0 (83.6) 154.4 (125.7) 152.9 (125.4) 0.79 24.91 
Multi-breath nitrogen washout 
Sacin (/L) 0.122 (0.094) 0.162 (0.106) 0.187 (0.124) 0.54 40.39 
Scond (/L) 0.045 (0.015) 0.070 (0.037) 0.057 (0.029) 0.19 45.31 
LCI  6.11 (0.49) 6.16 (0.80) 6.38 (0.84) 0.28 7.10 
Impulse oscillometry 
R5 EX (kPa/L/s) 0.50 (0.17) 0.47 (0.16) 0.47 (0.14) 0.84 11.83 
R20 EX (kPa/L/s) 0.37 (0.09) 0.38 (0.11) 0.37 (0.09) 0.88 7.09 
R5 - R20 EX (kPa/L/s) 0.13 (0.11) 0.09 (0.09) 0.10 (0.10) 0.80 41.26 
Rcentral (kPa/L/s) 0.27 (0.06) 0.27 (0.08) 0.26 (0.07) 0.77 13.76 
Rperipheral (kPa/L/s) 0.36 (0.15) 0.31 (0.12) 0.31 (0.14) 0.69 24.07 
X5 EX (kPa/L/s) -0.17 (0.09) -0.13 (0.06) -0.14 (0.11) 0.56 22.58 
fres (1/L) 16.00 (6.85) 15.18 (5.45) 14.98 (5.79) 0.83 14.54 
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5.3.5 Severe asthma 
There was no significant difference in routine and specialist respiratory 
parameters between repeated visits (p = >0.01). All respiratory parameters obtained 
from routine lung function tests had a strong between visit ICC (>0.76) and moderate to 
low CoV (<27.62%). See tables 5.14 – 5.16. 
 
Large airway inflammatory parameters (FENO50 and J’awNO [manual]) had a 
strong between visit ICC (>0.82) and large CoV (<35.49%). Resistance in the large 
airways (R20 EX and Rcentral) had a moderate to strong between visit ICC (>0.61) and low 
CoV (<12.17%). Ventilation heterogeneity in the larger conducting airways (Scond) had a 
poor between visit ICC (0.02) and large CoV (31.51%).  
          
           Resistance and reactance in the small airways (R5 EX, R5 - R20 EX, Rperipheral, X5 
EX, and fres) had a moderate to strong between visit ICC (>0.68) and moderate to low 
CoV (<30.72%). Ventilation heterogeneity in the small acinar airways (Sacin and LCI) had 
a strong between visit ICC (> 0.70) and low CoV (<21.50%). This can be seen in table 
5.17. 
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Table 5.14: Forced spirometry in severe asthmatics 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter  Baseline 8 months 16 months ICC CoV (%) 
FEV1 (L) 2.32 (0.88) 2.22 (0.93) 1.91 (0.92) 0.97 8.55 
FEV1 (% pred) 78.0 (20.7) 76.5 (24.7) 67.6 (22.0) 0.93 8.39 
FVC (L) 3.72 (0.97) 3.68 (1.05) 3.36 (1.07) 0.96 6.51 
FVC (% pred) 106.5 (16.7) 107.1 (19.2) 101.5 (20.2) 0.90 6.09 
FEV1 / FVC (%) 61.83 (15.21) 59.84 (17.04) 55.23 (14.23) 0.77 7.25 
MMEF75/25 (L/s) 1.34 (0.96) 1.27 (1.12) 0.93 (0.95) 0.94 27.56 
MMEF75/25 (% pred) 37.0 (22.8) 35.5 (27.0) 26.5 (21.6) 0.91 27.62 
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Table 5.15: Lung volumes and expiratory airway resistance and conductance results in 
severe asthmatics 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter  Baseline 8 months 16 months ICC CoV (%) 
Lung volumes  
RV (L) 2.32 (0.83) 2.47 (0.85) 2.72 (0.99) 0.90 9.67 
RV (% pred) 121.0 (36.6) 127.4 (37.2) 136.4 (39.8) 0.85 9.61 
TLC (L) 6.02 (1.27) 6.20 (1.24) 6.16 (1.39) 0.97 3.56 
TLC (% pred) 107.3 (17.4) 111.3 (16.4) 111.4 (17.7) 0.93 3.70 
RV: TLC (%) 38.59 (9.99) 39.92 (10.98) 44.11 (11.10) 0.88 7.54 
RV: TLC (% pred) 108.0 (22.5) 110.1 (25.9) 118.1 (25.2) 0.85 7.39 
FRCpleth (L) 3.19 (0.89) 3.47 (0.93) 3.65 (0.94) 0.94 6.20 
FRCpleth (% pred) 107.7 (27.2) 117.4 (27.8) 123.4 (25.6) 0.92 6.19 
Expiratory airways resistance and conductance  
Raw EX (kPa/L/s) 0.66 (0.43) 0.60 (0.41) 0.89 (0.75) 0.76 23.33 
SGaw EX (kPa/L/s/L) 0.71 (0.41) 0.66 (0.32) 0.50 (0.29) 0.77 24.71 
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Table 5.16: Single-breath transfer factor results in severe asthmatics 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter  Baseline 8 months 16 months ICC CoV (%) 
TLCOc (mmol/min/kPa) 7.62 (1.77) 7.24 (1.79) 7.15 (1.62) 0.90 6.41 
TLCOc (% pred) 86.4 (14.9) 83.6 (16.3) 84.7 (11.9) 0.76 6.33 
kCOc (mmol/min/kPa/L) 1.52 (0.27) 1.45 (0.27) 1.48 (0.25) 0.87 6.01 
kCOc (% pred) 96.2 (13.9) 92.8 (14.0) 96.0 (12.0) 0.77 5.92 
VA (L) 5.08 (1.05) 5.06 (1.11) 4.93 (1.11) 0.97 3.50 
VA (% pred) 92.9 (13.3) 93.2 (14.5) 91.7 (14.5) 0.94 3.43 
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Table 5.17: Results from specialist large and small airway tests in severe asthmatics 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
Multiple flow exhaled nitric oxide 
FENO50 (ppb) 27.0 (20.2) 40.1 (39.1) 40.6 (34.9) 0.82 31.52 
J’awNO (manual) (nl/s) 79.2 (63.2) 117.3 (119.5) 117.4 (108.9) 0.83 35.49 
Multiple-breath nitrogen washout 
Sacin (/L) 0.214 (0.194) 0.327 (0.282) 0.303 (0.231) 0.93 21.50 
Scond (/L) 0.057 (0.026) 0.059 (0.019) 0.083 (0.039) 0.02 31.51 
LCI  6.70 (1.06) 6.92 (1.26) 6.90 (1.16) 0.70 8.26 
Impulse oscillometry 
R5 EX (kPa/L/s) 0.59 (0.21) 0.63 (0.23) 0.72 (0.35) 0.76 15.07 
R20 EX (kPa/L/s) 0.41 (0.11) 0.42 (0.08) 0.44 (0.14) 0.85 8.27 
R5 - R20 EX (kPa/L/s) 0.19 (0.15) 0.22 (0.19) 0.28 (0.24) 0.68 30.72 
Rcentral (kPa/L/s) 0.30 (0.06) 0.30 (0.07) 0.32 (0.08) 0.61 12.17 
Rperipheral (kPa/L/s) 0.49 (0.24) 0.52 (0.34) 0.68 (0.46) 0.78 17.68 
X5 EX (kPa/L/s) -0.28 (0.29) -0.34 (0.40) -0.46 (0.44) 0.75 32.21 
fres (1/L) 19.45 (7.92) 20.47 (8.75) 23.42  (11.54) 0.82 12.77 
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5.3.6 COPD group  
There was no significant difference in routine and specialist respiratory 
parameters between repeated visits (p = >0.01). All respiratory parameters obtained 
from routine lung function tests had a strong between visit ICC (>0.70) and moderate to 
low CoV (<21.34%). See tables 5.18 – 5.20. 
 
Large airway inflammatory parameters (FENO50 and J’awNO [manual]) had a 
strong between visit ICC (>0.81) and large CoV (<36.76%). Resistance in the large 
airways (R20 EX and Rcentral) had a moderate to strong between visit ICC (>0.59) and low 
CoV (<11.03%). Ventilation heterogeneity in the larger conducting airways (Scond) had a 
poor between visit ICC (0.29) and huge CoV (36.93%).  
          
           Resistance and reactance in the small airways (R5 EX, R5 - R20 EX, Rperipheral, X5 
EX, and fres) had a moderate to strong between visit ICC (>0.67) and large to small 
CoV (<33.72%). Ventilation heterogeneity in the small acinar airways (Sacin and LCI) had 
a fair between visit ICC (>0.37) and moderate to low CoV (<29.30%). This can be seen 
in Table 5.21. 
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Table 5.18: Forced spirometry results in COPD group 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
FEV1 (L) 1.67 (0.44) 1.63 (0.43) 1.62 (0.44) 0.88 7.63 
FEV1 (% pred) 68.5 (15.3) 67.9 (13.9) 69.6 (16.9) 0.87 7.92 
FVC (L) 3.33 (0.77) 3.36 (0.80) 3.42 (0.69) 0.94 5.07 
FVC (% pred) 109.1 (17.6) 111.9 (19.3) 117.6 (18.8) 0.84 5.60 
FEV1 / FVC (%) 51.12 (11.43) 49.61 (11.14) 47.81 (10.80) 0.87 7.62 
MMEF75/25 (L/s) 0.53 (0.29) 0.48 (0.24) 0.43 (0.19) 0.70 21.34 
MMEF75/25 (% pred) 18.3 (9.85) 16.7 (8.35) 15.2 (6.04) 0.67 21.23 
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Table 5.19: Lung volumes and expiratory airway resistance and conductance in COPD 
group 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
Respiratory parameter Baseline 8 months 16 months ICC CoV (%) 
Lung volumes 
RV (L) 3.14 (0.66) 3.12 (0.71) 3.12 (0.86) 0.90 6.28 
RV (% pred) 146.0 (34.1) 144.9 (28.7) 142.8 (29.2) 0.87 6.05 
TLC (L) 6.43 (1.14) 6.49 (1.12) 6.55 (1.27) 0.95 2.83 
TLC (% pred) 116.8 (15.8) 119.0 (13.2) 120.0 (12.7) 0.89 3.13 
RV: TLC (%) 49.12 (7.94) 48.24 (7.89) 47.57 (7.38) 0.89 4.73 
RV: TLC (% pred) 120.6 (19.1) 118.0 (18.3) 115.4 (17.0) 0.89 4.70 
FRCpleth (L) 4.02 (0.82) 4.00 (0.82) 4.10 (0.97) 0.96 4.12 
FRCpleth (% pred) 133.2 (23.4) 133.4 (21.5) 135.5 (21.2) 0.92 4.02 
Expiratory airways resistance and conductance  
Raw EX (kPa/L/s) 0.90 (0.61) 0.72 (0.36) 0.72 (0.33) 0.54 27.89 
SGaw EX (kPa/L/s/L) 0.43 (0.28) 0.46 (0.27) 0.45 (0.26) 0.74 27.36 
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Table 5.20: Single-breath transfer results from routine tests in COPD group 
Results are presented as mean ± (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measurement  baseline 8 months 16 months ICC CoV (%) 
TLCOc (mmol/min/kPa) 5.14 (1.60) 5.36 (1.65) 5.15 (1.82) 0.90 8.67 
TLCOc (% pred) 66.2 (18.1) 70.1 (18.9) 67.7 (20.6) 0.86 9.02 
kCOc (mmol/min/kPa/L) 1.04 (0.24) 1.08 (0.27) 1.02 (0.28) 0.90 6.68 
kCOc (% pred) 74.8 (18.4) 76.9 (20.4) 74.0 (21.7) 0.92 6.66 
VA (L) 4.93 (0.93) 4.95 (0.86) 5.00 (0.77) 0.96 3.03 
VA (% pred) 91.1 (12.0) 94.3 (11.6) 95.0 (12.7) 0.91 3.32 
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Table 5.21: Results from specialist large and small airway tests in COPD group 
Results are presented as mean ± (SD) 
 
5.3.7 Asthma control test 
The ACT score at visit 1 (baseline), 2 and 3 was 22 in mild-moderate asthma, 
reflecting no changes in asthma control scores over the duration of the study and 
stability in the disease of this population. In severe asthma the ACT score for visit 1, 2 
and 3 was 14, 15 and 15 respectively, reflecting worse asthma status than the mild-to-
Measurement  baseline 8 months 16 months ICC CoV (%) 
Multiple exhaled nitric oxide 
FENO50 (ppb) 24.1 (15.5) 25.5 (23.3) 25.7 (17.3) 0.81 29.83 
J’awNO (manual) (nl/s) 64.3 (49.5) 63.8 (62.9) 63.4 (49.8) 0.82 36.76 
Multi-breath nitrogen washout 
Sacin (/L) 0.481 (0.297) 0.489 (0.261) 0.346 (0.139) 0.44 29.30 
Scond (/L) 0.057 (0.020) 0.061 (0.027) 0.055 (0.032) 0.29 36.93 
LCI 8.30 (1.23) 8.32 (1.42) 7.74 (1.13) 0.37 13.85 
Impulse oscillometry 
R5 EX (kPa/L/s) 0.66 (0.24) 0.66 (0.25) 0.67 (0.27) 0.77 13.98 
R20 EX (kPa/L/s) 0.38 (0.08) 0.39 (0.10) 0.40 (0.13) 0.78 9.34 
R5 - R20 EX (kPa/L/s) 0.28 (0.20) 0.27 (0.18) 0.27 (0.17) 0.75 26.14 
Rcentral (kPa/L/s) 0.30 (0.06) 0.30 (0.06) 0.30 (0.08) 0.59 11.03 
Rperipheral (kPa/L/s) 0.56 (0.27) 0.56 (0.27) 0.55 (0.28) 0.67 23.42 
X5 EX (kPa/L/s) -0.38 (0.28) -0.38 (0.30) -0.35 (0.25) 0.69 33.72 
fres (1/L) 22.50 (6.11) 22.09 (6.20) 22.47 (6.56) 0.72 11.09 
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moderate asthmatics, as would be expected, but no real change in asthma control 
scores over the duration of the study and stability in the disease of this population. 
            
5.4 DISCUSSION 
 
To date, this is the first longitudinal study to measure respiratory function of the 
large and small airways as well as airway inflammation using specialist lung function 
tests in these five patients groups collectively. Overall, no significant differences were 
found between visits for each respiratory parameter (routine and specialist) in each of 
the patient groups studied. The results of this study are discussed in terms of the  
routine and specialist respiratory  tests undertaken in the  patient groups, and their 
change and variability over the duration of the course of this study, reflecting on the 
between visit CoV. The results from this study are also discussed in relation to previous 
studies. 
 
5.4.1 Forced spirometry 
Small studies have looked at the day to day CoV in healthy adults, asthmatics 
and COPD patients who were stable over subsequent visits. In healthy subjects 
previously reported CoV’s for FEV1 were <1% (Vijayan et al, 1990), 3.1% (Gimeno et al, 
1993) and 6.4% (Elshout et al, 1990). For FVC the CoV was <1% (Vijayan et al, 1990). 
For FEV1 / FVC the CoV was 5.9% (Elshout et al, 1990). In the current study the 
smallest CoV was for FEV1 (3.02%) and largest for MEF75/25 (12.58%). In healthy 
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smokers the smallest CoV was for FVC (2.92%) and largest for MEF75/25 % pred 
(7.58%).  
 
In asthma, Elshout et al (1990) previously reported CoV’s for FEV1 and FEV1 / 
FVC  as 9.2% and 7.9%. The study by Elshout et al (1990) included 15 healthy subjects 
and 30 asthmatics tested on 3 separate visits. In the current study the smallest CoV 
was for FVC and FVC % pred (3.85%) and the largest was for MEF75/25 % pred 
(11.74%) in mild-moderate asthma. In severe asthma the smallest CoV was for FVC % 
pred (6.09%) and largest for MEF75/25 % pred (27.62%).  
 
In COPD the previously reported CoV for FEV1 was 11% (Gimeno et al, 1993). 
Gimeno et al (1993) measured the variability in healthy and COPD patients on 10 
separate visits. In the current study the smallest CoV was for FVC (5.07%) and the 
largest was for MEF75/25 (21.34%) in COPD. Figures 5.2, 5.3 and 5.4 show longitudinal 
plots for FEV1, FVC and MMEF75/25 for the five groups in this Chapter (below).  
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5.4.2 Lung volumes  
As with spirometry there are relatively few studies that have looked at the 
longitudinal changes in lung volumes. In the study by Lee et al (2013), the average 
annual change in TLC, IVC, FRCpleth, and RV were -43.7, -33.7, 6.2 and 4.9 mls per 
year respectively in COPD. The annual change in RV: TLC was 0.91% per year. The 
patients in this study were grouped according to baseline severity of airflow limitation 
(FEV1 ≥ 50% or FEV1 <50 % of pred) and there was no significant difference in the 
annual rate of change in respiratory function parameters measured between both 
groups. However, the annual rate of change was significantly greater among patients 
with severe airflow limitation for inspiratory capacity and the ratio of inspiratory capacity 
to total lung capacity. The authors stated that RV is the first volume compartment to 
increase in COPD. Pellegrino and Brusasco (1997) previously stated that increases in 
FRC and TLC then follow as a consequence of expiratory flow limitation and decreased 
elastic recoil of the lung from emphysema. Oga et al (2012) found that FRC (% 
predicted) increased annually by 1.9% per year in a five year study in COPD. FRC was 
measured by helium dilution in this study.   
 
In healthy subjects the previously reported CoV’s for TLC was <2% (Vijayan et al, 
1990), for RV <5% (Vijayan et al, 1990), for FRCpleth 10% (Pelzer and Thomson, 1966) 
and <2.5% (Vijayan et al, 1990). The findings in the current study were similar across 
groups with the smallest CoV being for TLC (<4%) and the largest for RV and RV% 
pred (<10%).  
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The study by Vijayan et al (1990) included 6 healthy South Indian adults tested 
on 3 separate visits. In the study by Pelzer and Thomson (1966) the subjects were 
tested on 3 separate visits and it is not known if any of the 8 healthy subjects included 
smokers. The time duration of these studies was not specified. Figures 5.5 and 5.6 
display longitudinal plots of RV and TLC in all 5 groups studied in this Chapter.  
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5.4.3 Airways resistance and specific airways conductance 
These measurements were performed at the same time as lung volumes using 
body plethysmography. As FRC increases with time the resistance and specific airway 
conductance increases and decreases respectively. In healthy subjects the previously 
reported CoV for Raw was 10.8% (Gimeno et al, 1993). In healthy subjects the 
previously reported CoV’s for SGaw were 28.8% (Gimeno et al, 1993) and 17.9% 
(Pelzer and Thomson, 1966). In the current study the CoV for Raw EX was 18.63% and 
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for SGaw Ex was 17.35% in this group. Figure 5.7 displays expiratory airway 
conductance in the five groups studied in this Chapter (below).  
 
 
5.4.4 Single-breath transfer factor test 
Hathaway et al (1989) measured the single-breath transfer tests in 8 healthy 
subjects over 1 year and the CoV was 9% for all results. In healthy subjects the 
previously reported CoV’s for TLCO, kCO, and VA were <2% (Vijayan et al, 1990). In the 
current study the CoV for all single-breath transfer tests parameters were <6% for 
healthy subjects, <6% for healthy smokers, <6% mild-moderate asthmatics, <6.5% for 
severe asthmatics, and <10% in COPD. Oga et al (2012) found that the annual decline 
in TLCOc (% pred) was -3.5% per year in a five year study in COPD. Figures 5.8 and 
5.9 display longitudinal plots for TLCOc and kCOc for the five groups studied in this 
Chapter (below). 
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5.4.5 Multiple flow exhaled nitric oxide 
In healthy subjects the previously reported CoV for FENO50 was 13.3% in 33 
healthy subjects (Kumor et al, 2004). The CoV for FENO50 was 32% in 72 pregnant 
asthmatic females using ICS’s (Nittner-Marszalska et al, 2013) and 33.8% in 26 
pregnant females with well controlled asthma (Dor-Wojnarowska et al, 2013). In the 
current study the CoV’s for FENO50 were <20%, <29%, <23%, <32% and <30% in 
healthy subjects, healthy smokers, mild-moderate asthma, severe asthma and COPD 
respectively. The CoV’s for J’awNO (manual) were 22.93%, 31.51%, 24.91%, 35.49% 
and 36.76 in healthy subjects, healthy smokers, mild-moderate asthma, severe asthma 
and COPD. The CoV’s for FENO50 and J’awNO (manual)  were similar between each 
other and across groups because these parameters represent NO from the larger 
central bronchial airways. While smoking effects exhaled nitric oxide and may provide 
spurious results (Barnes et al, 2010) this did not affect the CoV in smokers compared to 
the healthy group. Figures 5.10 and 5.11 display longitudinal plots for FENO50 and 
J’awNO for all five groups studies in this Chapter (below). 
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5.4.6 Multi-breath nitrogen washout 
Currently most of the available longitudinal data on the multi-breath nitrogen 
washout is limited to the LCI in the paediatric community. Previously our group 
(Biddiscombe et al, 2010) reported day to day CoV results for the multi-breath nitrogen 
washout measured on 3 separate occasions in 39 healthy subjects and 21 mild-
moderate asthmatics. The CoV for Sacin and Scond were 22.8% and 19.5% in healthy 
subjects. In the current study the CoV’s for Sacin was 37.47%, for Scond was 29.71%, and 
for LCI was 7.18%. In our previous study CoV’s for Sacin and Scond were 28.3% and 
21.5% in mild-moderate asthmatics (Biddiscombe et al, 2010). In the current study and 
for this group of patients the CoV’s for Sacin, Scond, and LCI were 40.39%, 45.31% and 
7.10%. The CoV’s for Sacin and Scond in our previous study were smaller than that 
observed in this study. This is likely to be due to the smaller time intervals between the 
three visits in that study compared to the current study. Indeed, this is an important 
consideration when assimilating and reflecting on the results of previous studies as the 
time interval between the tests performed (days, weeks, months, years) in the studies 
vary.   
 
The CoV’s were larger in mild-moderate asthma compared to severe asthma and 
COPD and this could be due to the higher use of ICS’s to stabilise respiratory function 
in severe asthma and COPD. Maintenance treatment with ICS’s attenuates the decline 
in respiratory function in asthmatics (Dijkstra et al, 2006; O’Byrne et al, 2009). 
Additionally, in severe asthma and COPD fixed airway obstruction may reduce the 
variability in Sacin and Scond. In severe asthma the CoV for Sacin, Scond and LCI were 
225 
 
21.50%, 31.51%, and 8.26% respectively. In COPD the CoV for Sacin, Scond and LCI 
were 29.30%, 36.93% and 13.85% respectively. In smokers the CoV’s for Sacin (27.94%) 
and LCI (4.75%) demonstrated that ventilation heterogeneity within the smaller acinar 
airways may vary day to day to a lesser degree than non-smokers. Figures 5.12, 5.13 
and 5.14 display longitudinal plots for Sacin, Scond and LCI for the 5 groups studied 
(below).  
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5.4.7 Impulse oscillometry  
To my knowledge this is the first study to include longitudinal data on impulse 
oscillometry. Other studies have used the forced oscillation technique and reported day 
to day CoV data. In healthy subjects previously reported CoV’s for R8, R52, resonant 
frequency, mean resistance, and mean reactance were 10.1%, 9.9%, 6.9%, 9.2% and 
14.6% (Elshout et al, 1990). Resistance at 8 and 52 Hertz reflected small and large 
airway resistance respectively. Two other previous studies reported the CoV for total 
respiratory resistance as 11.3% (Gimeno et al, 1993) and 15.9% (Rouhos et al, 2011). 
In asthmatics the CoV for R8, R52, and resonant frequency, mean resistance and mean 
reactance was 11.5%, 9.3%, 18.3%, 10.4% and 47.8% (Elshout et al, 1990). In COPD 
the CoV for total respiratory resistance was 15.7% (Gimeno et al, 1993) and 12.4% 
(Rouhos et al, 2011). Elshout et al (1990) performed the forced oscillation test in 15 
healthy controls and 30 asthmatics on three separate visits. The day to day CoV’s for R5 
EX, R20 EX, R5-R20 EX, Rcentral, Rperipheral, X5 EX and fres were <46% in the healthy 
group, <39% in smokers, <41% in mild-moderate asthma, <33% in severe asthma, and 
<34% in COPD. Figures 5.15, 5.16, 5.17 and 5.18 display longitudinal plots for R5 EX, 
R20 EX, Rcentral and Rperipheral for the 5 groups studied (below). 
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5.4.8 Limitations of the study 
There are limitations of this study that may not have detected a change in the 
respiratory function in the five patient groups. Firstly, we may have too small numbers to 
detect a change and much larger number of subjects may be needed with large cohort 
studies from multiple centres. Secondly, we studied patients with stable disease 
attending a specialised hospital centre with routine intensive follow up and treatment 
adjustment and this may have kept their disease stable. Indeed, in the asthmatic group 
the asthma control tests scores did not change between visits.  Following on from this, 
the study could be undertaken selecting patients who had exacerbated in the previous 
year (suggesting sub-optimal control) and compare them to a control group (stable 
control such as our group studied) and then assess their respiratory function 
prospectively over a similar period of time (as we studied) to assess if there were any 
changes in small or large airway function.  
 
Indeed, such as study may also be designed to assess if any of the lung function 
parameters studied could prospectively predict or be a risk factor for more unstable 
disease and a risk of disease exacerbation in either asthma or COPD. Also, our 
observation period was too short and a much longer period of time may probably have 
been needed, possibly a few years – to detect a change in the natural history of the 
disease with respect to the large and small airways lung function. Indeed, the CoV can 
also be used to measure the amount of variability observed in a parameter of 
respiratory function when ≥ 3 measurements are performed, but there are many 
biological and non-biological factors that can affect the natural variability in respiratory 
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function. The biological variability is due to factors affecting the bronchial diameter such 
as bronchomotor tone, mucosal inflammation, and mucus plugging (Elshout et al, 1990) 
particularly in asthma and COPD. Other causes of variation include diurnal variation 
related to season, weather, effort level, fatigue, weight changes, recent environmental 
or occupational exposures to pollutants, seasonal allergen exposures, medication use 
and changes in medication, all which need to be considered when interpreting the data 
over a period of time such as months and years.  
 
5.4.9 SUMMARY 
The data in this Chapter show that significant physiological changes of large and 
small airway function using specialist and routine tests were not observed in patients 
with asthma (mild-to-moderate and severe), COPD, and healthy smokers and healthy 
subjects over the duration of this study. The data do not support the hypothesis that 
during the stable clinical state, specialized tests of small and large airway function and 
inflammation demonstrate a better signal of change of these compartments and 
variability over time, than measurements obtained from routine conventional lung 
function tests. Several factors may contribute to this and the key considerations are in 
small patient numbers, the need for a longer duration for study, and the fact that 
patients were very well-controlled on their current medication.  
 
We did observe that, routine tests of respiratory function vary less with time then 
specialist tests of small and large airway calibre measured under conditions near to tidal 
breathing and it would be interesting to explore in a future prospective study whether 
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the inherent variability in certain small airway tests could predict future risk of disease 
exacerbation.  
 
Indeed, to this end, our approach on a small scale as part of this Chapter is now 
being undertaken in large multicentre centre global study with ATLANTIS (AssessmenT 
of smalL Airways involvemeNT In aSthma) (Postma et al, 2015). This study over the 
course of one year will assess 800 asthmatic subjects and 100 healthy controls at 5 
visits where they will undergoing respiratory function testing (small and large airways), 
lung imaging, induced sputum, lung biopsy, nasal sampling and asthma control 
questionnaires to determine the role of small airways dysfunction in the clinical 
manifestations of asthma.   
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CHAPTER 6: THE PHARMACOKINETICS OF INHALED FLUTICASONE 
PROPIONATE DELIVERED AS MONODISPERSE AEROSOLS 
 
6.1 INTRODUCTION 
 
6.1.1 Small airways in asthma 
Asthma is a disease of chronic airways inflammation which involves the larger 
airways (Barnes, 2008). However, pathological studies have shown that the airway 
inflammation in asthma actually affects the whole of the bronchial tree from the large 
central airways extending down to the small peripheral airways (de Magalhaes Simoes 
et al, 2005; Dolhnikoff et al, 2009). There is evidence that inflammation may be even 
more pronounced within the smaller airways (Contoli, et al; Hamid et al, 1997). Autopsy 
studies from specimens from subjects with fatal and non-fatal asthma have 
demonstrated that there are regional (large vs small) differences in the nature the 
airways inflammation (Sutherland et al, 2004), demonstrating that the small airways are 
heavily infiltrated with inflammatory cells, particularly lymphocytes and eosinophil’s 
(Corren, 2008; Hayley et al, 1998).  The small airways constitute the largest part of the 
respiratory tract and therefore the largest potential site for inflammation to occur, small 
airway dysfunction is present in patients with asthma and therefore there is a need to 
target inhaled therapy to this region.  
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6.1.2 Corticosteroids in asthma 
Corticosteroids are the most important maintenance treatment for asthma (Louis 
et al, 2012). Corticosteroids act as anti-inflammatory agents (Adcock and Lane, 2003) 
and produce long-lasting therapeutic effects (Winkler et al, 2004). Inhaled 
corticosteroids (ICS’s) are the most efficacious mono-therapy available (GINA, 2009). In 
terms of clinical efficacy, the dose-response curve for corticosteroids is relatively flat 
demonstrating that most benefit is obtained at low inhaled doses, while the dose-
response curve for systemic effects increases more drastically with increasing dosage 
(Barnes, 1998). This is particularly the case for hypothalamic pituitary adrenal axis 
suppression, osteoporosis, and growth retardation (Geddes, 1992). The response to 
ICS’s is heterogeneous, and therefore some asthmatics may require higher dosing for a 
small clinical benefit. Moderate to severe asthmatics often require higher doses of ICS’s 
for symptomatic control over extended periods of time, which can put them at risk of 
unwanted side-effects (Poon et al, 2012).  
 
6.1.3 Targeting the small airways in asthma 
Current conventional inhalers used in clinical practice do not effectively target the 
inhaled drug to reach the small airways. Berry and colleagues (2005) showed that 
severe asthma patients on Step 4 of the asthma guidelines (GINA), did not respond to 
increased high-doses of ICS with respect to markers of small airway inflammation, 
postulating that there was on-going untreated small airways inflammation, not targeted 
by coarse particle inhalers used in clinical practice (Berry et al, 2005). Untreated small 
airways inflammation may also be a contributing factor to the current levels of poor 
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asthma control which approximate ~40% of the asthma populations (Demoly et al 2010; 
Usmani, 2012b). 
  
The delivery of ICS’s to the deeper regions of the lung can be improved by 
utilising two approaches. Usmani and colleagues (2005) showed that by modifying 
particle size (smaller particles) and inhalation flow (slower flows) inhaled aerosols were 
able to preferentially target the smaller airways compared to larger aerosols inhaled at 
faster inhalation flows. Both approaches also lead to lower oral deposition and higher 
lung deposition (Usmani et al, 2005). Indeed, the last decade has seen the development 
of novel corticosteroid formulations with smaller aerosol particle sizes (HFA-pMDI 
ciclesonide, HFA-pMDI beclomethasone dipropionate, and HFA-pMDI beclomethasone 
dipropionate combined with formoterol) (Cripps et al, 2000; Leach et al, 1998; Leach et 
al, 2006; Martin, 2002; Yang et al, 2001) which improve total lung deposition and the 
proportion of the aerosol being delivered to the deeper lung region (Newman et al, 
2006; Nicolini et al, 2008).  
 
6.1.4 Fluticasone propionate  
There are several drugs in the class of ICS’s that are used to manage asthma 
and it is important to appreciate that ICS’s differ in their fate following inhalation based 
on their formulation and pharmacological properties. Figure 6.1 shows the fate of ICS’s 
following inhalation and Table 6.1 lists the properties of four commonly used ICS’s 
including their oral and pulmonary bioavailabilities.  
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Fluticasone propionate (FP) is a corticosteroid which was developed to exhibit 
improved airway selectivity (Johnson, 1998) while having minimal systemic side effects 
(Palmer, 2005). FP has been used successfully for many years for all asthma severities 
and has proved to be well tolerated (Brutsche et al, 2000). The pharmacokinetic (PK) 
characteristics of FP include a high ratio of topical to systemic activity (Crim et al, 2001), 
a high degree of lipophilicity (Crim et al, 2001), a high glucocorticoid relative receptor 
affinity (Würthwein et al, 1992), a rapid first pass metabolism (Mackie et al, 1996), and a 
low oral bioavailability (Falcoz et al, 1996). FP has a very low oral bioavailability due to 
99% first pass metabolism therefore systemic exposure may only be enhanced by 
increased absorption through the pulmonary route. The mass median aerodynamic 
diameter (MMAD) for FP particles generated from a pressurised metered dose inhaler 
(pMDI) is <3.0 µm as described later in Chapter.   
 
Figure 6.1: Fate of inhaled corticosteroids beyond the lungs (modified from Barnes, 2007). 
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Table 6.1: Properties of four commonly used ICS’s   
Feature ‘Ideal’ for ICS FP Budesonide Ciclesonide Beclomethasone 
Relative receptor affinity* 
 
High 1800 935 12 1345 
Lipophilicity Highly lipophilic Highly lipophilic Lipophilic 
 
Lipophilic Lipophilic 
 
Plasma protein binding 
 
High >99% 85% 99% 87% 
Systemic clearance rate 
(L/hours) 
High 
 
69 84 152 120 – 150 
Inhalation half-life 
(hours) 
Long 
 
10 – 14 2 – 3.5 0.4 2.7 
Oral  
bioavailability 
Low 
 
<1% 
 
11% 
 
<1% 
 
15 – 20% 
 
Pulmonary bioavailability High 29% 18% 52% 55 – 60% 
*Compared to dexamethasone (relative receptor affinity = 100) 
 
6.1.5 Small versus large particle ICS therapy  
In the context of the development of new ICS formulations with smaller particle 
size, the question has arisen whether there may be more systemic adverse pulmonary 
bioavailability as a consequence of more distal airway delivery and greater systemic 
absorption compared to larger particles, and where overall this may be to the detriment 
of the overall therapeutic index of the drug (ratio of adverse effects to clinical efficacy). 
The merit of comparing large particle ICS versus smaller particles in the same study, 
using the same delivery device would seem logical, in order to directly test the 
hypothesis of whether a smaller ICS particle is more effective or not. In this scenario, 
pharmacokinetic profiling of the drug helps in our understanding of lung deposition and 
absorption of inhaled therapeutic aerosol and pharmacokinetic techniques assess how 
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much of an inhaled drug eventually enters the blood stream after absorption through the 
lungs (Taylor, 2011). 
  
However, it is unlikely pharmaceutical companies will support such a study and 
currently there is only one ICS (beclometasone dipropionate (BDP)) present as two 
distinct particle sizes (Qvar ~1.1 µm; Clenil ~2.9 µm) using the same inhaler device 
(HFA-pMDI). Indeed studies that have compared large and small particle sizes of ICS in 
patients with asthma have used disparate drugs, devices, and doses (Usmani, 2015).  
 
6.1.6 Aims  
 The aims of this study therefore were to examine one inhaled corticosteroid (FP) 
delivered in different particle sizes (-1.5, -3 micron and 6 µm) using the same mode of 
delivery (controlled slow moving aerosol delivery) at the same drug dose (50 µg) to the 
airways of patients with asthma and investigate the PK profile and pulmonary 
bioavailability of FP.  
We wanted to determine that if, as has been shown, smaller particles translate to 
improved lung deposition and deeper lung penetration (Usmani, 2005), could they  
potentially contribute to increased systemic side effects and a detrimental therapeutic 
ratio as a result of greater pulmonary absorption (pulmonary bioavailability). We also 
aimed to compare the absorption behaviour of different aerosol particle sizes in 
asthmatics to that in healthy volunteers to observe whether diseased asthmatic lungs 
altered the pulmonary absorption of inhaled FP.  
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We also wanted to determine if clinical efficacy could be improved using sensitive 
tests of large and small respiratory physiology and inflammation (as previously 
described in Chapter 4) in order to assess any differential effects from large and smaller 
aerosol particles targeting to different lung regions.  
 
6.1.7 Hypothesis 
The main hypothesis to be tested was that small particle therapy of FP leads to 
greater pulmonary bioavailability and systemic absorption.  
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6.2 METHODS 
 
6.2.1 Subjects and study design 
Fifteen non-smoking subjects (8 males and 7 females, 35 ± 11.8 years, height 
172 ± 7.3 cm, weight 70 ± 14.3 kg, BMI kg/m2 23.23 ± 3.80) with a documented history 
of reversible asthma (FEV1 81.3 ± 12.0 % predicted) were selected. All asthmatics 
withheld inhaled therapeutic medication for 12 hours before the study visit.  
 
Fifteen healthy non-smoking, non-atopic subjects (5 males and 10 females, 35 ± 
10.5 years, height 169 ± 8.8, weight 65 ± 12.5 kg, BMI kg/m2 22.72 ± 2.80) with no 
history of respiratory disease (FEV1 100.5 ± 11.3 % predicted) were age matched and 
included for comparison to the asthma group.  
 
All subjects were free from significant cardiac, gastrointestinal, hepatic, renal, 
haematological, neurological and psychiatric disease. No subjects were taking 
medication contraindicated to receiving fluticasone propionate. All participants were 
provided with a patient information sheet, gave written informed consent and signed a 
consent form. This was a single-centre randomised, cross-over study where the PK 
effects of a single dose of inhaled FP were investigated.  
 
All subjects were administered four treatments separated by a minimum washout 
period of 7 days. At each visit subjects either inhaled, FP as a single 50 µg dose of 
either 1.5-, 3- and 6 µm particles as monodisperse (GSD <1.22) aerosol, or a single 
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dose (250 µg) from a pressurized metered dose inhaler (pMDI) (FlixotideTM, 
GlaxoSmithKline, UK) and volumatic spacer as a polydisperse (GSD>1.22) aerosol. 
Patients underwent physiological interventions and venous blood pharmacokinetic 
sampling at the times shown in the study protocol for up to 12 hours (figure 6.2). This 
study was approved by St Mary’s Research Ethics committee. Study ID: 08/H0712/63. 
ClinicalTrials.gov.Identifier: NCT00692978. Figure 6.2 (below) displays study overview.  
 
 Figure 6.2: Overview of study (asthma group performed respiratory function tests).  
 
6.2.2 Studies in subjects  
Please refer to section 2.8 in methods for details on the generation of monodisperse 
aerosols inhaled by all subjects.  
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6.2.3 Performance of respiratory function tests  
Measurements of respiratory function were performed in the following order and as 
outlined in methods: 
8. Multi-breath nitrogen washout  
(Parameters measured: Sacin, Scond and LCI) 
9. Multiple flow exhaled nitric oxide 
(Parameters measured: FENO50, J’awNO [manual] and Calv [manual]) 
10. Spirometry  
(Parameters measured: FEV1, FVC and MMEF75/25) 
 
Spirometry was performed using a Vitalograph Spirotrac® IV (Vitalograph, Buckingham, 
UK) in this study. Figure 6.2 (above) displays time points when tests were performed.  
 
6.2.4 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 (USA).  
 
6.2.4.1 Recruitment visit 
The sample size of both groups was based on feasibility and no statistical techniques 
were used to calculate sample size.  
 
The Kolmogorov-Smirnov test was used to confirm the variables below were normally 
distributed. T-tests were performed to compare normally distributed data between 
asthma and healthy group for: 
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 Age  
 Height 
 Weight  
 BMI  
 FEV1 
 FVC 
 MMEF75/25 
The differences between groups were considered statistically significant at a p value  
< 0.05.  
 
6.2.4.2 Pharmacokinetic variables 
Outputs for pharmacokinetic data were reported as the area under the curve (AUC0-12h) 
of the concentration time profile curve from 0-12 hours, the peak concentration (Cmax) 
and the time to peak concentration (tmax). Outputs for Cmax and AUC0-12h were log 
transformed.  
 
6.2.4.2.1 Within group analysis 
Analysis of variance (ANOVA) and Bonferroni (post hoc) tests were performed to 
determine if a significant difference was found between the four treatments in each 
group for the following variables: 
 Cmax 
 AUC(0-12) 
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Kruskal-Wallis and Dunn's Multiple Comparison Test (post hoc) tests were performed to 
determine if a significant difference was found between the four treatments in each 
group for the following variable: 
 tmax 
 
6.2.4.2.2 Between group analysis 
T-tests were performed to compare normally distributed data between asthma and 
healthy group for: 
 Cmax 
 AUC(0-12) 
Mann-Whitney tests were performed to compare non-normally distributed data between 
asthma and healthy group for: 
 tmax 
 
6.2.5 Respiratory function tests 
The Kolmogorov-Smirnov test was used to confirm the data from respiratory parameters 
were normally distributed. Repeated measures ANOVA and Bonferroni (post hoc) tests 
were used to determine if results for each respiratory function parameter were different 
between time points. The differences were considered statistically significant at a p 
value <0.05. 
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6.3 RESULTS 
 
6.3.1 Demographic characteristics and spirometry at screening 
All 15 asthmatics and 15 healthy volunteers that were screened fitted the study 
criteria and entered the study. Demographic data at screening was similar between both 
groups (see table 6.2). Spirometry at screening was significantly lower (p < 0.05) in 
asthma for FEV1 % pred (81.3), FEV1 / FVC ratio (70.36 %), FEV1 / FVC % pred (86.4), 
MMEF75/25 (2.15 L/s) and MMEF75/25 % pred (49.4), and PEF % pred (98.1). See table 
6.3 for spirometry results from screening visit. All treatments were well tolerated and no 
serious adverse events occurred.  
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Table 6.2: Demographic characteristics for asthma and healthy groups 
Asthma group Healthy group 
Subject Sex 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) BMI Subject Sex 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) BMI 
1 M 34 185 75 21.91 1 F 37 156 52 21.37 
2 F 57 169 51 17.86 2 M 58 169 63 22.06 
3 F 44 165 51 18.73 3 M 31 182 75 22.64 
4 F 38 170 75 25.95 4 M 32 180 75 23.15 
5 M 40 166 56 30.32 5 F 35 160 58 22.66 
6 M 31 172 75 25.35 6 F 41 155 43 17.9 
7 M 38 180 100 30.86 7 F 23 172 80 27.04 
8 F 48 167 72 25.82 8 F 35 175 60 19.59 
9 M 20 185 74 21.62 9 F 28 162 50 19.05 
10 F 25 163 60 22.58 10 M 53 179 87 27.15 
11 F 49 172 75 25.35 11 F 29 164 67 24.91 
12 M 22 180 73 22.53 12 F 23 165 65 23.88 
13 M 33 178 91 28.72 13 F 30 165 57 20.94 
14 M 19 166 64 23.23 14 M 48 178 70 22.09 
15 F 21 170 51 17.65 15 F 27 174 80 26.42 
Mean  35 172 70 23.23 Mean  35 169 65 22.72 
SD  11.8 7.3 14.3 3.80 SD  10.5 8.8 12.5 2.80 
SD (standard deviation) 
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Table 6.3: Spirometry results at screening visit 
Parameter Asthma group Healthy group 
FEV1 (L) 3.01 (0.76) 3.41 (0.71) 
FEV1 (% pred) 81.3 (12.0)" 100.5 (11.3) 
FVC (L) 4.30 (1.03) 4.18 (0.96) 
FVC (% pred) 101.5 (13.3) 103.0 (11.9) 
FEV1 / FVC (%) 70.36 (8.8)" 82.08 (5.47) 
FEV1 / FVC (% pred) 86.4 (9.7)" 98.7 (5.4) 
MMEF75/25 (L/s) 2.15 (0.80)" 3.51 (0.98) 
MMEF75/25 (% pred) 49.4 (13.0)" 88.4 (23.3) 
PEF (L/min) 559 (214) 538 (100) 
PEF (% pred) 98.1 (22.3)" 113.0 (11.9) 
Results are presented as mean and (SD) 
“ p < 0.05 lower in asthma group compared to healthy group 
 
6.3.2 Plasma FP analysis  
For up to 12 hours post treatment some plasma FP concentrations were below 
the limit of quantification in the asthmatic group (<10 pg / mL). This included 4, 1, 31, 
and 44 time points for the 1.5, 3, 6 µm monodisperse aerosols and pMDI respectively. 
In the healthy subjects this was 3, 3, 31, and 38 time points for the 1.5, 3, 6 µm 
monodisperse aerosols and pMDI respectively. This often occurred at successive time 
points in the same individuals. To avoid underestimation of the total bioavailability any 
concentrations that were undetectable were assigned a value of 0. No measurable 
concentrations of FP were excluded from the calculation of the PK parameters. Table 
6.4 shows results from PK parameters calculated. 
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Table 6.4: Fluticasone propionate pharmacokinetic parameters 
Aerosol / PK parameter Asthma group Healthy group 
1.5 µm  
Cmax (pg / ml) 424.52 (275.65 - 653.81) ° 358.56 (249.25 - 515.79) ° 
tmax (min) 8 (5 - 15) ª ° 8 (5 - 25) ª ° 
AUC (0-12h) (pg. h
 
/ ml) 923.28 (666.77 – 1278.50) ° 723.29 (522.49 – 1001.30) ° 
3 µm  
Cmax (pg / ml) 278.28 (179.62 - 431.14)  290.13 (194.66 - 432.43) ≈ 
tmax (min) 13 (10 - 180) 15 (8 – 120) 
AUC (0-12h) (pg. h
 
/ ml) 891.15 (637.01 – 1246.70) ≈ 933.25 (604.01 – 1442.00) ≈ 
6 µm  
Cmax (pg / ml) 84.99 (46.76 - 154.46) 62.72 (42.03 - 93.59) 
tmax (min) 25 (5 - 360) 15 (10 - 240) 
AUC (0-12h) (pg. h
 
/ ml) 222.08 (95.77 – 515.00) 204.99 (128.38 - 327.31) 
pMDI 
Cmax (pg / ml) 51.19 (37.29 - 70.27) *  64.44 (40.56 - 102.37) * ^ 
tmax (min) 45 (13 - 720) * ^ "  20 (5 - 180) *  
AUC (0-12h) (pg. h
 
/ ml) 182.66 (123.74 - 269.64) * ^ 199.07 (131.75 - 300.77) * ^ 
Results for Cmax and AUC are presented as geometric mean and 
(95% CI). Results for tmax are presented as median and (range). 
 
* p < 0.05 pMDI compared with 1.5 µm particle size 
^ p < 0.05 pMDI compared with 3 µm particle size 
° p < 0.05 1.5 µm compared with 6 µm particle size 
≈ p < 0.05 3 µm compared with 6 µm particle size 
ª p < 0.05 1.5 µm compared with 3 µm particle size 
" p < 0.05 pMDI compared between asthma and healthy group 
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6.3.3 Systemic exposure 
The AUC (0-12) (geometric mean) was similar between asthma (182.66 pg. h
 /ml) 
and healthy volunteers (199.07 pg. h/ml) following inhalation of 250 µg dose from a 
standard pMDI. These results were replicated at a lower inhaled dose (50 µg) delivered 
as 6 µm aerosol in asthmatics (222.08 pg. h/ml) and healthy volunteers (204.99 pg. 
h/ml). AUC (0-12) results were similar between asthma (891.15 pg. h/ml) and healthy 
volunteers (933.25 pg. h/ml) following inhalation of 50 µg dose delivered as 3 µm 
aerosol. These results were replicated at a 50 µg delivered as 1.5 µm aerosol in 
asthmatics (923.28 pg. h/ml) and healthy volunteers (723.29 pg. h/ml). Within both 
groups systemic exposure was significantly greater following inhalation of 1.5 and 3 µm 
aerosols compared to pMDI and 6 µm aerosols. Results for AUC(0-12) are displayed in 
table 6.4. No significant difference was observed between both groups for AUC(0-12).   
 
6.3.4 Pharmacokinetics 
The pharmacokinetics (PK’s) of the four treatments differed within each group. 
The 1.5 µm aerosol demonstrated faster systemic absorption (tmax) from the airways in 
asthmatics (8 mins) compared to 3 µm aerosol (13 mins), 6 µm aerosol (25 mins), and 
pMDI (45 mins). The maximum plasma concentrations (Cmax) were significantly greater 
for 1.5 µm aerosol (424.52 pg / ml) compared to 6 µm aerosol (84.99 pg / ml) and pMDI 
(51.19 pg / ml) in this group.  
 
In healthy volunteers the 1.5 µm aerosol also demonstrated a faster uptake (tmax) 
of 8 mins compared to the 3 µm aerosol (15 mins), 6 µm aerosol (15 mins), and pMDI 
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(20 mins). The tmax was similar between the 3 and 6 µm aerosols and the pMDI in this 
group. The maximum plasma concentrations (Cmax) were significantly greater for the 1.5 
µm aerosol (358.56 pg / ml) and 3 µm aerosol (290.13 pg / ml) compared to 6 µm 
aerosol (62.72 pg / ml) and pMDI (64.44 pg / ml). The tmax for the pMDI revealed faster 
systemic absorption in healthy volunteers compared to asthmatics. No significant 
difference between groups was observed for Cmax. Figures 6.3 to 6.6 display time-
concentration profiles for plasma FP over 12 hours and first hour following treatments in 
both groups. Please note the arithmetic mean was used in these graphs while the 
geometric mean was used in the statistical analysis. Results for Cmax and tmax are 
displayed in table 6.4.  
 
Visually inspecting the concentration-time profile of plasma concentration of FP 
for each treatment, the smaller 1.5 and 3 µm particles had a similar profile and the large 
6 µm had a similar profile to the pMDI over 12 hours of analysis (figures 6.3 and 6.5). All 
particle sizes and pMDI treatment achieved a similar final mean plasma concentration of 
FP at 12 hours after inhalation in asthmatics and healthy group.  
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6.3.5 Respiratory function tests 
 
6.3.5.1 Multi-breath nitrogen washout 
There were no significant improvements in multi-breath nitrogen washout 
parameters measured at baseline (time 0) and post aerosol inhalation (4 and 12 hours) 
or between post inhalation (4 versus 12 hours) for all 4 treatments. Table 6.5 displays 
results from multi-breath nitrogen tests for all treatments. Figures 6.7 – 6.9 show 
change in Sacin, Scond and LCI and for all treatments.  
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Table 6.5: Multi-breath nitrogen washout results for each treatment 
Aerosol / Parameter Time (hours) 
1.5 µm 0 4 12 
Sacin (L/sec) 0.184 (0.146) 0.144 (0.087) 0.138 (0.080) 
Scond (L/sec) 0.060 (0.028) 0.068 (0.027) 0.061 (0.024) 
LCI  6.29 (0.64) 5.97(0.52) 5.94 (0.38) 
3 µm       
Sacin (/L) 0.156 (0.106) 0.134 (0.077) 0.144 (0.073) 
Scond (/L) 0.072 (0.027) 0.068 (0.028) 0.067 (0.030) 
LCI  6.16 (0.62) 5.93 (0.39) 5.87 (0.30) 
6 µm    
Sacin (/L) 0.163 (0.143) 0.147 (0.083) 0.148 (0.129) 
Scond (/L) 0.063 (0.018) 0.059 (0.015) 0.061 (0.017) 
LCI  6.10 (0.49) 5.97 (0.42) 6.04 (0.50) 
pMDI       
Sacin (/L) 0.177 (0.172) 0.119 (0.051) 0.126 (0.070) 
Scond (/L) 0.057 (0.021) 0.065 (0.023) 0.066 (0.017) 
LCI  5.91 (0.59) 5.77 (0.48) 5.79 (0.42) 
Results are presented as mean (and SD) 
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6.3.5.2 Multiple flow exhaled nitric oxide 
There were no significant reductions in multiple flow exhaled nitric oxide 
parameters measured at baseline (time 0) and post aerosol inhalation (4 and 12 hours) 
or between post inhalation (4 versus 12 hours) for all 4 treatments. Table 6.6 displays 
results from multiple flow exhaled nitric oxide tests for all treatments. Figures 6.10 – 
6.12 show change in FENO50, J’awNO (manual) and Calv (manual) for all treatments. 
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Table 6.6: Multiple flow exhaled nitric oxide results for each treatment 
Aerosol / Parameter Time (hours) 
1.5 µm 0 4 12 
FENO50 (ppb) 58.5 (35.5) 58.6 (34.9) 51.0 (39.5) 
J’awNO (manual) (nl/s) 171.6 (100.6) 172.4 (99.5) 144.2 (89.4) 
Calv (manual) (ppb) 0.3 (0.2) 0.3 (0.2) 0.5 (0.7) 
3 µm       
FENO50 (ppb) 55.3 (19.4) 55.0 (21.4) 47.7 (19.2) 
J’awNO (manual) (nl/s) 156.7 (57.8) 164.3 (64.2) 136.8 (56.0) 
Calv (manual) (ppb) 0.3 (0.1) 0.2 (0.1) 0.3 (0.1) 
6 µm       
FENO50 (ppb) 56.3 (27.5) 55.3 (28.5) 54.6 (31.0) 
J’awNO (manual) (nl/s) 165.0 (90.4) 161.8 (90.0) 155.4 (86.0) 
Calv (manual) (ppb) 0.2 (0.1) 0.3 (0.1) 0.3 (0.1) 
pMDI       
FENO50 (ppb) 55.9 (38.2) 57.2 (36.3) 48.2 (28.4) 
J’awNO (manual) (nL) 173.2 (115.5) 181.8 (109.6) 156.0 (96.6) 
Calv (manual) (ppb) 0.4 (0.2) 0.3 (0.2) 0.2 (0.1) 
Results are presented as mean (and SD) 
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6.3.5.3 Forced spirometry 
There were no significant improvements in spirometry parameters measured at 
baseline (time 0) and post aerosol inhalation (4, 8, and 12 hours) or between post 
inhalation (4 versus 8 versus 12 hours) for all 4 treatments. Table 6.7 displays results 
from spirometry tests for all treatments. Figures 6.13 – 6.15 show change in FEV1, FVC 
and MMEF75/25 for all treatments.  
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Table 6.7: Spirometry results for each treatment 
Aerosol / Parameter Time (hours) 
1.5 µm 0 4 8 12 
FEV1 (L) 2.93 (0.69) 3.04 (0.74) 3.10 (0.76) 3.03 (0.74) 
FVC (L) 4.16 (0.97) 4.25 (0.91) 4.26 (0.94) 4.26 (0.92) 
MMEF75/25 (L/s) 2.13 (0.63) 2.27 (0.82) 2.39 (0.86) 2.26 (0.81) 
3 µm         
FEV1 (L) 2.92 (0.72) 3.05 (0.77) 3.18 (0.80) 3.06 (0.86) 
FVC (L) 4.11 (0.94) 4.22 (0.97) 4.31 (0.97) 4.22 (1.02) 
MMEF75/25 (L/s) 2.13 (0.68) 2.35 (0.80) 2.52 (0.90) 2.38 (0.90) 
6 µm         
FEV1 (L) 3.02 (0.76) 3.13 (0.77) 3.18 (0.76) 3.12 (0.85) 
FVC (L) 4.18 (0.98) 4.31 (0.99) 4.34 (0.97) 4.32 (0.96) 
MMEF75/25 (L/s) 2.27 (0.77) 2.38 (0.80) 2.49 (0.87) 2.44 (0.98) 
pMDI         
FEV1 (L) 3.04 (0.80) 3.06 (0.73) 3.18 (0.75) 3.06 (0.78) 
FVC (L) 4.24 (1.02) 4.25 (0.94) 4.32 (0.95) 4.24 (0.91) 
MMEF75/25 (L/s) 2.31 (0.87) 2.36 (0.84) 2.52 (0.87) 2.36 (0.86) 
Results are presented as mean (and SD) 
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6.4 DISCUSSION 
 
This is the first study to investigate the relationship between different inhaled 
particle sizes of the same corticosteroid (fluticasone propionate) and their 
pharmacokinetic behaviour and systemic bioavailability in asthmatic patients and 
healthy subjects. This study demonstrated that the systemic bioavailability of inhaled FP 
was related to its drug particle size, where smaller particles (1.5 µm & 3 µm) achieved 
greater systemic absorptive bioavailability compared to the larger 6 µm FP particles and 
to the pMDI aerosol (~2.8 µm) in asthmatics. The data also showed similar particle size 
effects in healthy volunteers.  
 
The study also compared the pharmacokinetics of a therapeutic dose of FP (250 
µg) delivered as a polydisperse pMDI aerosol, with that of monodisperse aerosols 
delivered at 1/5th of this standard dose (50 µg). The findings show that the bioavailability 
of a 50 µg dose of FP inhaled as 6 µm monodisperse aerosol was equivalent to a 250 
µg therapeutic dose inhaled from a polydisperse pMDI (with spacer); that is, if inhaled 
FP is delivered to the airways with narrow aerosol particle size distribution 
(monodisperse aerosol, GSD<1.22) a reduction in the inhaled dose can be achieved. 
There were no differences observed in respiratory function parameters between the 
particle sizes or pMDI treatment in asthmatics over 12 hours following a single inhaled 
dose of therapy; in particular, small particles (1.5 and 3 µm) treatment did not produce 
an improvement in small airway parameters and similarly large particle treatment did not 
produce an improvement in large airway parameters.  
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6.4.1 How the study relates to current work  
The current results build upon previous work undertaken in our laboratory. 
Usmani and colleagues (2005) imaged the total and regional lung deposition of different 
sized (1.5, 3, 6 µm) particles of monodisperse salbutamol aerosols in mild-moderate 
asthmatics and observed 1.5 µm and 3 µm monodisperse aerosols delivered a greater 
total lung dose (TLD) and also achieved greater distal airways deposition compared to 
6µm particles (table 6.8). The TLD for the 6 µm aerosol was 46%, 3 µm aerosol was 
51% and for 1.5 µm aerosol was 56%, whereas the penetration index (PI, the ability of 
an aerosol to penetrate deeper into the lungs) was greatest for the smaller aerosols; 6 
µm 0.36, 3 µm 0.60, 1.5 µm 0.79. Inferring from this imaging deposition data, this would 
suggest that the smaller 1.5 and 3 µm FP particles in the current study may deposit 
deeper into the lungs and possibly give rise to greater systemic absorption via the 
pulmonary route (pulmonary bioavailability) compared to the larger particles depositing 
more proximally in the airways 
  
However, when considering systemic exposure, the oral bioavailability 
component is important (Figure 6.1). Usmani and colleagues (2005) observed smaller 
particles had far less oropharyngeal deposition and hence, the potential for less gut 
absorption and oral bioavailability. In contrast, larger particles had greater 
oropharyngeal deposition and potentially would give rise to a greater gastrointestinal 
load (oral bioavailability) with the potential to give rise to systemic adverse effects.  In 
this respects the specific drug properties of FP need to be considered as different 
corticosteroids have inherently different physiochemical, pharmacokinetic and biological 
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properties (Swami and Shahiwala, 2013). The oral bioavailability contributing to 
systemic exposure after swallowing and absorption of FP aerosol is low (<1%) because 
of high plasma protein binding and high hepatic metabolism. Hence, plasma systemic 
exposure for inhaled FP is primarily a result of pulmonary bioavailability. In this context, 
oral bioavailability is relatively negligible as a contributor to systemic exposure and this 
study primarily assesses the biological pharmacokinetic responses as a result of 
differential regional airways targeting (as a function of particle size) on pulmonary 
bioavailability. This study is in keeping with previous studies which have shown that the 
pulmonary absorption of small particle ICS is faster and more extensive than that of 
large particles in asthmatics (Agertoft et al, 2003; Harrison et al, 1999; Harrison et al, 
2011).  
 
However our data should be directly put in context with the study of Esposito-
Festen et al (2007). The authors investigated the pharmacokinetics of beclomethasone 
dipropionate delivered as 3 monodisperse aerosols (1.5, 2.5 and 4.5 µm) in 10 mild 
asthmatics (FEV1 83% predicted). Unlike FP, beclomethasone dipropionate is an 
inactive compound that is hydrolysed to 17-beclamethasone monopropionate (17-BMP) 
by endogenous esterases in the lung. They measured plasma 17-BMP and found the 
1.5 µm aerosol gave 2-3 fold lower values for Cmax and AUC compared to 2.5 and 4.5 
µm aerosols. That is the larger particles gave higher plasma concentration. The Cmax for 
1.5, 2.5 and 4.5 µm were 475.00, 1300.00, and 1161.00 pg / ml and the AUC values 
were 825.00, 2629.00, and 2276.00 pg.h / ml respectively. Esposito-Festen et al (2007) 
suggested that the small PK results for the 1.5 µm aerosol may be a consequence of re-
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exhalation of small particles despite the 10 second breath-hold. These results contrast 
what was observed in the present study i.e. as aerosol particle size increased the Cmax 
and AUC were shown to decrease. Although they state that smaller particles may be 
exhaled more, Usmani and colleagues (2005) showed that only ~20% of 1.5 microns 
particle are exhaled in vivo in patients with asthma in contrast to the earlier in vitro work 
using modelling of experimental monodisperse aerosols (Heyder 1986) that showed 
nearly 80% of 1.5 micron particles were exhaled.  
 
It may also be that the results of Esposito-Festen (2007) are peculiar as they 
used BDP, where (i) the conversion of BDP to other metabolites in the lung may be of 
importance and (ii) the oral bioavailability of BDP is much greater (~20%) compared to 
FP (<1%). In the lung (and plasma) there is some inactivation of 17-BMP by ester 
interchange to 21-beclomethasone monopropionate (Boobis, 1998) and 
beclomethasone (Nave et al, 2007). Ninety percent of active 17-BMP is subsequently 
metabolised to pharmacologically less-active beclomethasone (Nave et al, 2004). If 
inactivation had occurred faster for the smaller sized particles (1.5 µm), and if they 
deposited more peripherally within the alveoli where the air-blood interface is small, 
possibly less 17-BMP would be present in the systemic circulation. Additionally, the 
activation of BDP in the oropharynx has been reported to be fast as similar amounts of 
BDP and 17-BMP have been detected in mouth rinsing solutions post inhalation of 1000 
µg BDP via a pMDI (Holz et al, 2004).  
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Larger particles (4.5 µm) that had impacted in the oropharynx during inhalation 
(and re-exhalation) could have been swallowed and absorbed via gastrointestinal 
absorption becoming detectable at high concentrations in the blood. Esposito-Festen et 
al (2007) report using a total of 20 g activated charcoal before and throughout most of 
the study to block gastrointestinal absorption of BDP. Agertoft et al (2003) used a total 
of 45 g of charcoal before and throughout most of their study examining the 
bioavailability of 200 µg BDP inhaled as HFA-pMDI’s in asthmatic children and reported 
small but insignificant differences in the bioavailability of 17-BMP when charcoal was 
and wasn’t used. Unlike BDP, the contribution from any swallowed FP to total 
bioavailability in the present study would be virtually zero (Table 6.1, Grahnén et al, 
1994).  
 
It would have been of interest if Esposito-Festen et al (2007) measured BDP and 
its secondary metabolites. The effect of aerosol particle size on BDP and its dynamic in 
vivo conversion to active and inactive metabolites needs further attention. Additionally, 
there may also be important methodological differences between our data and that of 
Esposito-Festen et al (2007). The authors did not report any validation work on their 
aerosol particle size and aerosol distribution, nor the dose of drug delivered in the 
inhaled volume given to patients before performing in vivo experiments and there may 
have been variability in drug dose delivery that could have affected their 
pharmacokinetic data and conclusions on BDP particle size. 
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Table: 6.8. Monodisperse aerosol lung deposition and airways distribution in asthmatic 
subjects 
Aerosol particle size 
(MMAD) 
TLDa Pb Exc OPd 
PIe  
% of total delivered dose 
1.5µm 56 25 22 15 0.79  
3µm 51 17 8 31 0.60  
6µm 46 10 2 43 0.36  
Data are adapted from Usmani et al, 2005 and shown are for salbutamol. atotal 
lung deposition; bperipheral lung deposition; cexhaled dose; doropharyngeal deposition; 
erelative penetration index ([99mTc-aerosol peripheral counts/99mTc-aerosol central 
counts] / [81mKr peripheral counts/81mKr central counts]).  
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6.4.2 Fate of the inhaled aerosol  
 In considering the pulmonary bioavailability, it is important to consider the fate of 
inhaled aerosol within the airway tree, that is, after an aerosol is inhaled in the airways, 
how does the aerosol interact with the many biological airways factors prior to it being 
absorbed into the bloodstream. Many factors need to be considered including 
mucociliary clearance, thickness of the airway epithelium, mucus barrier, absorptive 
surface area, and the bronchial versus pulmonary blood flow network. In the context of 
this study the larger particles would be more proximally deposited and therefore 
exposed to relatively more mucociliary clearance that would encourage aerosol 
transport towards the oropharyngeal cavity and contribute more to oral bioavailability 
and less to pulmonary bioavailability. Smaller particles would deposit deeper in the 
lungs and be lesser exposed to the mucociliary escalator and have greater potential for 
pulmonary bioavailability. Indeed, larger particles would also be exposed to a greater 
mucus barrier by virtue of depositing more proximally, but in the diseased asthma lungs 
with patchy mucus plugging this could also affect the smaller particles. Certainly the 
thickness of the epithelium would be a greater barrier to absorption for the larger 
particles depositing proximally in contrast to the thinner epithelium that the smaller 
particles would be exposed to.  
 
In addition, the more distal airways are supplied by the extensive vascular 
network of the pulmonary blood vessels in contrast to the proximal airway tree that is 
supplied by the relatively sparse bronchial blood vessels. By virtue of their aerosol 
characteristics smaller particles would undergo less impaction and therefore deposit 
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less in the proximal airways and have a greater chance of reaching more distal lung 
regions with potentially greater plasma concentration, in contrast to the larger particles.  
 
It is important to appreciate that the results shown here are specific for the drug 
FP as ICS’s differ in their physiochemical and pharmacokinetic properties between each 
other (Table 6.1) and different systemic exposures by the oral and pulmonary route 
could occur with particle sizes of different corticosteroids (Figure 6.1).  
 
6.4.3 Dose of drug delivered to the lungs 
 The study also shows that the bioavailability of FP delivered as 6 µm 
monodisperse aerosols could be achieved at 1/5th of a pMDI polydisperse dose and 
important factors to consider here include (i) the inhalation and breathing manoeuvre 
and (ii) aerosol and drug characteristics. Certainly, the ability to deliver drug to all areas 
of inflammation in the lungs at a much lower dose would also be of significant clinical 
benefit in terms of minimising both local and systemic side effects in the short and long 
term by decreasing upper airway (oropharyngeal) deposition and subsequent 
gastrointestinal absorption. Interestingly, Price and colleagues have shown the potential 
for the delivery of lower mean ICS doses for the same therapeutic benefit using smaller 
ICS particles (Price et al, 2010).  
 
 In vitro studies may help our understanding of the in vivo state, however, 
establishing in vitro / in vivo correlations is not straight forward (Newman and Chan, 
2008). Cripps et al (2000) performed cascade impaction studies at a constant inhalation 
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flow rate of 28 L/min using FP CFC-pMDI and HDFA-pMDI delivering a single dose of 
250 µg, as used in our study (HFA-pMDI plus spacer). They observed the mean fine 
particle mass (FPM, dose of aerosol contained <4.7 microns) without and with a spacer 
were 106 µg and 131 µg respectively, for a CFC-pMDI, and 102 µg and 111 µg, 
respectively for a HFA-pMDI. Cripps et al (2000) also reported the dose of ex-actuated 
(drug recovered; that is, the dose expelled beyond the inhaler). For a single dose of 250 
µg the mean ex-actuator doses without and with a spacer were 223 µg and 231 µg, 
respectively for a CFC-pMDI, and 206 µg and 234 µg, respectively for a HFA-pMDI. The 
data of Cripps et al (2000) suggests that less than half of the drug dose (111 µg / 250 
µg) is able to reach the lower airways as indicated by the FPM, at a controlled inhalation 
flow. They also found that the FPM was slightly improved with the use of a spacer. The 
data also show the potential loss of drug, or drug unavailable to reach the lower airways 
(234 µg - 111 µg = 123 µg / 250 µg).  
 
The large doses recovered during such in vitro cascade impaction studies may 
be more of a consequence of using a simplified metal induction port (throat) that does 
not realistically represent the in vivo human throat. The induction port does not mimic 
the anatomy of the upper airway which possesses different internal geometries, and soft 
tissue structures which increase aerosol deposition within this region thus reducing lung 
deposition. Importantly, deposition during impaction studies occurs due to inertial 
impaction whereas deposition within the lungs occurs due to additional processes 
(Newman and Chan, 2008).  
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Patients generally inhale their medications at high flows and low inspiratory 
volumes which results in impaction losses within the upper airways. Breath-holding at 
the end of inspiration is recommended but not often performed therefore drug particles 
can be re-expired or impact on the upper airways during expiration. The use of a 
volumatic spacer increases the distance between the pMDI valve outlet and mouth and 
has been shown to remove large unwanted aerosol particles. We elected to use a 
spacer with our pMDI aerosol in order to slow the velocity of the actuated aerosol in 
order to help patients breathe the inhaled drug to the airways tree. In the current study, 
the PK results for the pMDI dose demonstrated that the aerosol shared a similar fate to 
the larger 6µm monodisperse aerosols and could also be due to a reduction in the 
amount of ex-actuated drug that reached the lungs following the use of a spacer.  
 
In an in vivo study, Shrewsbury et al (2008) compared Flovent® with TempoTM 
inhaler (FP) in 12 healthy volunteers who underwent two-dimensional gamma-
scintigraphy following treatments. The aerosols were radiolabelled with 99mTc 
pertechnetate which unaltered the particle size distribution. The FP aerosols were 
inhaled at 30 L/min and a 10 second breath-hold was performed at end inspiration. For 
a 220 µg dose (2 x 110 µg) the mean whole lung deposition was 13.8% for the CFC-
pMDI and 41.5% for the TempoTM inhaler. The mean extra-thoracic deposition was 
76.8% for the CFC-pMDI and 18.3% for the TempoTM inhaler. When subjects exhaled 
post breath-holding there was evidence of aerosol being re-exhaled. The mean 
deposition of FP trapped on filters on exhalation was 0.5% for the CFC-pMDI and 1.5% 
for the TempoTM inhaler. The pulmonary bioavailability of FP is 16 – 30% depending on 
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the inhalation device used (Möllman et al, 1998). With oral inhalation, FP’s total 
systemic bioavailability results from absorption through the lungs (Lawrence et al, 
1997). During our study and for all FP treatments, every effort was made to minimise 
waste by getting the subjects to perform the breathing manoeuvre appropriately. 
Importantly we had a breath-hold pause of ten seconds in our study and this is 
important in optimising delivery of the drug to the lungs; this is a component of the real-
life patient inhalation manoeuvre that is often not accounted for or replicated in in vitro 
studies.  
 
6.5 Aerosol and drug characteristics 
 
6.5.1 Aerosol particle distribution (monodispersity) 
The average particle size (mass median aerodynamic diameter, MMAD) for FP 
particles from the above pMDI studies is <3.00 µm (2.84 µm) which is smaller than FP 
from a DPI MMAD 6 µm (Derendorf et al, 2006). If the geometric standard deviation 
(GSD) was <1.22 (monodisperse) the particle size distribution generated by a pMDI 
would be narrow and most of the drug mass would have been delivered close to 2.84 
µm aerosol particles and would have a similar bioavailability to the 3 µm monodisperse 
aerosol (or between the 1.5 µm and 3 µm monodisperse aerosol pharmacokinetic 
profiles). However, the GSD of pMDI’s are usually polydisperse (that is >1.22) indicating 
that the particle size distribution around the MMAD 2.84 µm was large. Therefore, the 
fact that the pMDI aerosol had a pharmacokinetic profile similar to the 6 µm aerosol 
suggests larger aerosol particles were generated from the pMDI. Hence, particles >6 
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µm are more likely to impact on the upper airways and are therefore not available to 
lung and in light of the low oral bioavailability of FP (<1% to systemic bioavailability), the 
lower doses reaching the lungs are reflected in the lower absorption pharmacokinetic 
profiles of the pMDI mirroring almost the 6 µm monodisperse particles.  
 
6.5.2 Lipophilicity and solubility 
With respect to aerosol characteristics, the lipophilic property of FP increases 
lung retention time reducing the drugs systemic release. It is not known if this property 
will be counteracted when the MMAD is small enough for the aerosol particles to be 
delivered towards the lung periphery and translocated systemically, as a result of the 
very thin epithelium. FP is poorly soluble in water and dissolves slowly in sputum. Its 
mean absorption time after inhalation is longer compared with more soluble ICS such as 
budesonide. The slow dissolution of FP and long lung retention means that it is more 
likely to be cleared by mucociliary transport before it can enter the systemic circulation 
(Brutsche et al, 2000). This would again have affected those particles that had a greater 
tendency to deposit in the mucociliary escalator region (larger particles) and hence lead 
to less drug being absorbed via the lungs.  
 
6.5.3 Clinical parameters 
In addition to investigating the PK’s of FP delivered as monodisperse aerosols 
this study wanted to see if clinical efficacy could be achieved at one fifth the dose of a 
standard FP pMDI and whether changes could be observed in parameters that 
distinguish large and small airway improvements compared to conventional spirometry.  
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This is the first study looking at PK’s of inhaled FP as a function of particle size 
and physiological change in small and large airways. The study did not observe an 
improvement from baseline for multi-breath nitrogen washout, multiple flow exhaled 
nitric oxide, or spirometry parameters following any of the four FP treatments. This is 
unsurprising and likely to be a consequence of single-treatment doses of FP. 
Unfortunately, it was not possible to deliver chronic (7 day) treatment with 
monodisperse aerosols generated from the STAG as the apparatus needs to undergo 
daily maintenance following drug delivery. Nevertheless, if another drug delivery system 
was able to generate  monodisperse aerosols reliably on a daily (or even twice daily) 
scale, then it would be interesting to see if a definitive association could be made 
between aerosol particle size and small and large airway calibre. Theoretically, if the 
airway inflammation arising from the bronchial and alveolar compartments is reduced 
(multiple flow exhaled nitric oxide) and consequently the airway lumen diameter 
increases, then improvements in ventilation heterogeneity with the airways (multi-breath 
nitrogen washout) may be observed. With improved ventilation heterogeneity the vital 
capacity and expiratory flows would also be expected to improve.  
 
Previous studies on FP where spirometry and multiple flow exhaled nitric oxide 
were investigated, have used higher FP doses for longer periods. Lehtimäki et al (2001) 
compared bronchial (J’awNO) and alveolar (CalvNO) in 16 asthmatics before and during 
treatment with Flixotide Diskus for 8 weeks. 500 µg was taken twice daily over weeks 1 
- 4 and 250 µg was taken twice daily weeks 5 - 8. J’awNO before and after treatment 
significantly decreased 3.6 to 0.7 (nl/s). CalvNO before and after treatment was identical 
281 
 
1.2 (ppb). FEV1 % predicted increased from 85.0 to 93.0. van Rensen et al (1999) 
compared exhaled NO in 25 mild asthmatics before and after treatment with 500 µg FP 
taken twice daily for 4 weeks. Exhaled NO (ppb) before and after treatment significantly 
decreased 6.30 to 1.43.  
 
6.5.4 Therapeutic ratio 
 In the study we tried to infer whether the therapeutic ratio (the ratio of unwanted 
adverse effects to beneficial clinical effects) was altered, with smaller particle sizes, 
although this was not formally biologically measured or statistically tested in our clinical 
study design. For all three particle sizes, there were equal changes in clinical outcome 
measures. With the smaller 1.5 and 3 µm particles we observed a higher Cmax 
compared to the larger 6 µm particles, which could suggest the potential for a worse 
therapeutic ratio.   
 
The corticosteroid FP is active in the systemic circulation and has been shown to 
affect the hypothalamic-pituitary-adrenal (HPA) axis in doses as low as 250 µg with 
cortisol suppression (Grahnén, 1994). Cortisol suppression has been used as an 
indirect surrogate as a predictor of systemic effects. However, in the current study, and 
during the course of 12 hours monitoring, none of the monodisperse aerosols caused 
an increase in plasma FP near the threshold of 1250 pg.h / ml,  a concentration in the 
systemic circulation that reduces plasma cortisol by 20% (Falcoz et al, 2000; Mackie 
and Bye, 2000). It would have been useful to have undertaken blood sampling for 
cortisol analysis.  
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It should also be noted that genetic factors may alter responses to ICS’s include 
polymorphism of the oxidative enzymes responsible for clearing the drugs systemically 
and polymorphisms in the glucocorticoid receptor; the receptor to which corticosteroids 
bind to (DeRijk et al, 2002; Kozower et al, 1974). Inflammation in the airways also 
reduces the binding affinity of the glucocorticoid receptors for exogenous 
corticosteroids, so it is interesting to note that overall there were no significant 
difference in the primary pharmacokinetic outputs and pharmacokinetic profiles between 
asthmatic lungs and those of healthy subjects. 
 
6.5.5 Chronic ICS dosing, small airways and particle size effects 
Studies comparing FP with another ICS have also used higher doses for longer 
periods than in the present study, and although not ideal as discussed previously 
(different compounds, drug doses, inhalers, inhalation flows) they may give us some 
insight to support the concept of the importance of particle size, particularly studies that 
included multiple flow exhaled nitric oxide and multi-breath nitrogen washout tests to 
assess the small airways regions. In a double-blind and double-dummy study where 37 
subjects were treated with ciclesonide and fluticasone, Cohen et al (2011) investigated 
the effects of these ICS’s on preventing a drop in FEV1 following adenosine 
monophosphate (AMP) provocation challenges (PC20) using small (1.06 µm) and large 
(9.9 µm) particle sized aerosols.  Ciclesonide improved small particle PC20 while 
fluticasone improved large particle PC20 i.e. had a preventative effect on FEV1 drop. 
Ciclesonide is a small-particle ICS (~1.1. microns) which has shown good clinical 
efficacy at low doses in asthma (Leung et al, 2005; Taylor et al, 1999; Wilson et al, 
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2006; Zietkowski et al, 2006). In an earlier study, where 7 subjects received placebo 
and 9 received ciclesonide, Cohen et al (2008) found that ciclesonide reduced CalvNO.  
  
Zietkowski et al (2006) compared the effect of 100 µg FP taken twice daily with 
80 or 160 µg ciclesonide taken once daily on exhaled NO in 35 patients with mild 
allergic asthma over 12 weeks. From baseline to 12 weeks after study the median 
FENO50 (ppb) decreased in 200 µg FP group (82.4 to 50.9), 80 µg ciclesonide group 
(76.8 to 33.5), and 160 µg ciclesonide group (104.7 to 31.7). From baseline to 12 weeks 
after study FEV1 % pred increased in 200 µg FP group (79.30 to 101.80), 80 µg 
ciclesonide group (78.66 to 96.72), and 160 µg ciclesonide group (73.00 to 93.10). The 
decrease in FENO50 from baseline was significant in ciclesonide groups compared to 
FP group but there was no difference between the two ciclesonide dose (160 µg and 80 
µg) groups. The increase in FEV1 (L) and FEV1 % pred was significant from baseline but 
no difference was observed between groups. This data shows that small particle 
ciclesonide was able to alter an inflammatory measure (FENO) more effectively than 
large particle FP, and this was possible at a smaller ciclesonide dose (80 µg). 
 
Verbanck et al (2006) compared budesonide (DPI) and BDP (HFA-pMDI) inhaled 
at 100% and 50% dose equivalents of budesonide in 30 asthmatics with varying 
disease severity. Patient treatment with budesonide, and the 2 dose equivalents as 
BDP lasted 6 weeks. Sacin (/L) for budesonide, 100% equivalent dose as BDP and 50% 
equivalent dose as BDP were 0.181, 0.157 and 0.148. Sacin for the 50% equivalent dose 
as BDP was significantly reduced versus budesonide. Scond (/L) for budesonide (0.065), 
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100% equivalent dose as BDP (0.063), and 50% equivalent dose as BDP (0.066) were 
not significantly different. FEV1 % pred for budesonide (75.1), the equivalent dose as 
BDP (76.8), and 50% of the equivalent dose as BDP (77.3) were not significantly 
different. Mean FEF25-75 % predicted for budesonide (47.1), the equivalent dose as BDP 
(48.3), and 50% of the equivalent dose as BDP (46.3) were not significantly different. 
This study by Verbanck and colleagues (2006) demonstrated that stable asthmatics with 
small airway (acinar) dysfunction have the potential to improve some small airway 
calibre from ultrafine steroid aerosols.  
 
Downie et al (2007) investigated the clinical response in 18 mild asthma patients 
treated for 12 weeks with clinically equivalent doses of ICS’s (twice daily CFC-BDP 750 
µg or HFA-BDP 400 µg). FENO (ppb) decreased 14.1 to 8.0, Scond (/L) decreased 0.067 
to 0.052, Sacin  (/L) decreased 0.159 to 0.142, LCI decreased 8.54 to 7.78, FEV1 % pred 
increased 80.1 to 85.9, and FEV1 / FVC (%) increased 73.0 to 75.0. These results 
demonstrate an improvement in both the large and small airway compartments following 
treatment with ICS’s.  
 
These studies provide some insight into the bioequivalence of two different ICS’s, 
their particle sizes and their impact on large and small airway improvements, however, 
this is still an under-researched area and more definitive data is needed on whether 
altering  the particle size of ICS (to a smaller particle size) really leads to an added 
advantage in terms of patient related outcome measures such as symptoms and or 
asthma control (Usmani, 2015).   
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6.6 Limitations of study 
 This study is novel and likely to have an important impact when published.  This 
chapter has endeavoured to highlight its strengths. However, it is also important to 
mention the limitations. The main limitations of the study are that a single dose is given 
and therefore it is not possible to observe the effect of multiple doses of drug delivered 
at different particle sizes of aerosols. Only one ICS was studied and cortisol levels were 
not measured. Future work could repeat the study with other ICS. Ideally the drug would 
be radiolabelled, as was the case for Usmani et al (2005), so that deposition patterns 
could be compared to the PK parameters using gamma-scintigraphy. However, this was 
not possible for this study due to the difficulty in radiolabelling this particular formulation.   
 
6.7 SUMMARY 
 
 This Chapter has shown that the systemic bioavailability of inhaled FP is related 
to drug particle size and is a function of lung dose and regional airways deposition. The 
data support our hypothesis that smaller monodisperse particles (1.5 µm & 3 µm) 
achieve greater systemic bioavailability compared to large monodisperse particles (6 
µm) and to a polydisperse pMDI and spacer. By altering aerosol particle size 
distributions to a narrower aerosol distribution (monodisperse), such aerosols allow a 
reduction in the dose of inhaled  drug ~1/5th dose of conventional polydisperse inhalers. 
The important caveat is that this data is unique to FP and each ICS will interact 
differently within the lungs. 
  
286 
 
These data are novel and may guide the future development of inhaled 
formulations, particularly generic inhaler devices of FP treatment. However, there is a 
delicate balance between a clinically efficacious lung dose and dose delivered to 
systemic circulation and when formulating drugs in either large or small particle aerosols 
consideration should be given to the therapeutic ratio. 
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CHAPTER 7.0 GENERAL DISCUSSION 
 
The underpinning aim of this thesis was to advance knowledge in inhalation 
science and a need to investigate, evaluate, and answer how aerosol particle size 
influences deposition in the upper and lower airways to better target aerosolized drugs 
to patients with obstructive lung disease. The work in this thesis was challenging to 
address and link distinct hypotheses related to inhaled drug delivery in three lung 
compartments; the (i) upper airways (Chapter 3), (ii) lower airways (Chapters 4 and 5) 
and (iii) lung-vascular region (Chapter 6) in order to further our understanding of the fate 
of an inhaled drug.  
 
Key findings from each of the Chapters are presented and discussed in the 
context of how they contribute to our current knowledge. This is followed by reflection 
upon and critique of each Chapter with respect to the main limitations and finally, a 
forward thinking approach on future direction that work arising from this thesis could 
follow. 
 
7.1 Deposition of monodisperse aerosols in the upper airway 
The main aim of Chapter 3 was to investigate the effect of aerosol particle size, 
flow rate, and flow direction on upper airway deposition by using three separate 
monodisperse aerosols (1.5, 3 and 6 µm). These sizes were chosen as they cover the 
spread of particles contained within the ‘respirable’ range (2 - 6 µm); that is, have good 
potential to reach the lungs. By performing deposition studies in an upper airway 
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experimental model during an ‘inspiratory mode’ it was hoped that the findings could be 
used to relate and predict what happens in the human upper airway. Additional studies 
in upper airway models were performed during an ‘expiratory mode’ to investigate the 
deposition of ‘re-expired' particles from the monodisperse aerosols.  
 
It was observed that total deposition in the upper airway models was similar for 
each combination of aerosol particle size (3 and 6 µm) and flow rate (30 and 60 L/min), 
and was unaffected by flow direction. The key finding was that as aerosol particle size 
and flow rate increased so did deposition and this is a reflection of relatively greater 
inertial impaction with the larger and faster particles in comparison to the smaller and 
slower particles.  
 
Deposition was then investigated in the four regions of interest (ROI) in the upper 
airways. In the model studies and during the inspiratory mode, oral deposition was less 
when the particle size was small (3 µm) and inspired flow rate was low (30 L/min). Oral 
deposition increased when the particle size was large (6 µm) and the flow rate was high 
(60 L/min). The key finding was that smaller sized aerosol particles travel further distally 
towards the trachea and could potentially reach the lungs while larger particles were 
retained proximally in the mouth.  
 
Deposition in patients demonstrated similar findings to model studies and 
incorporated a smaller sized particle (1.5 µm). The addition of a smaller, almost sub-
micron sized aerosol particle yielded extra information on the deposition of particles 
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below the ideal respirable range. In patients, smaller sized aerosol particles travel 
further distally towards the trachea and could potentially reach the lungs and this was 
regardless of flow rate. The key finding in the patient studies was that particle size 
influenced deposition more than inspiratory flow rate.  
 
The aim was also to understand if there were any particular patterns of 
deposition based on aerosol particle size and flow profile within the upper airway model 
and comparisons between the models and patient studies demonstrated that 
pharyngeal deposition, and to some extent laryngeal deposition, during inspiration was 
similar regardless of particle size (3 and 6 µm) and that the models could be used to 
predict deposition in humans, however there was disparity with respect to the tracheal 
and oral cavity deposition.  
 
Chapter 3 also examined  how to mimic the re-exhalation of aerosol particles in 
humans. This was  a novel part of the Chapter as most researchers have focused on 
the deposition of therapeutic aerosols during the inspiratory phase, with the deposition 
of re-exhaled aerosol particles in the upper airway receiving very little attention. In the 
model studies and during the expiratory mode aerosol deposition was greatest in the 
pharyngeal region. Pharyngeal deposition was slightly greater when the aerosol particle 
size was large (6 µm) and the flow rate was high flow (60 L/min) in comparison to when 
the aerosol particle size was small (3 µm) and expiratory flow rate was low (30 L/min). 
The key finding was that during the expiratory mode aerosol deposition does indeed 
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occur in the upper airway and is within the pharyngeal region which is contrary to 
previous beliefs. 
 
Other investigators have looked at quantities and concentrations of drug re-
exhaled and collected on total trap filters during drug deposition studies involving 
human subjects. The re-exhalation of inspired aerosol demonstrated that even when 
protocols are designed to maximise lung deposition during inhalation the re-exhalation 
of some aerosol in unavoidable. Due to practicalities in using subjects it was not 
possible to measure the amount of aerosol which could deposit in the human upper 
airway during exhalation, but it seems likely to be more than the amount of exhaled drug 
collected on filters. This is because as the drug is carried in the exhaled air it would 
have to bypass the curvature in the oropharyngeal region where impaction losses occur 
regardless of flow direction. Therefore, it is probable that the re-exhalation of aerosol 
collected on filters would be lower than the quantity retained in the upper airway.   
 
Aerosol particles of different sizes can deposit throughout the airways but this 
distribution is not uniform and is a consequence of the interaction between particle size 
and inhalation flow. Importantly if the particles are too large or small they will not come 
into contact with sites within the lungs where they are required to elicit their therapeutic 
benefit. To transport aerosol particles via the upper airway and towards the lungs 
aerosol particles of micron size should be within the ‘respirable’ range. Additionally, a 
slower inhalation is more favourable to traverse the oropharynx and deposit more 
distally compared to a faster inhalation.  The results from Chapter 3 demonstrated that 
291 
 
the smaller the aerosol particle size is, within this range, the likelihood of it reaching the 
lungs increases.  
 
7.2 Small and large airway respiratory function in obstructive lung disease  
 The second major part of this thesis was to utilise a panel of novel physiological 
tests that detect large and small airway function in healthy subjects and patients with 
obstructive lung disease and in particular, determine if small airways dysfunction was 
present (Chapter 4, cross-sectional study) and if so, whether this changed with time 
(Chapter 5, longitudinal study).  
 
The key driver of these Chapters was the appreciation in the last decade of the 
potential impact of the small airways and their contribution to lung disease and hence, 
the need to answer the question of whether targeting inhaled therapeutic drug to this 
region is beneficial in patients with obstructive lung disease. In order to ascertain this, 
accurate assessments are needed of this region, which has been elusive as 
conventional lung function tests are unable to assess the small airways (hence the term 
the ‘quiet’ zone). However, advanced physiological tests have been developed over the 
last few years that have the potential of assessing this region to determine small 
airways dysfunction.   
 
So, in Chapters 4 and 5, I investigated novel tests of small airways and 
conventional tests of large airways in a cross-sectional and longitudinal (over 16 
months) fashion in 5 groups including healthy non-smoking volunteers, healthy 
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smokers, mild-moderate asthmatics, severe asthmatics, and COPD (stage I – III). Both 
asthma groups and COPD group continued their medications as normal.   
 
In the COPD group airflow limitation was progressive and significantly worse than 
age matched healthy individuals even when medication was taken routinely. Because of 
the significant airflow limitation caused by this condition spirometry and expiratory 
specific airways conductance were low while expiratory airways resistance was high. 
Emphysema in conjunction with airflow limitation caused abnormalities in the small 
airway tests through physiological hyperinflation which was demonstrated by increased 
lung volumes, ventilation heterogeneity as determined by the multi-breath nitrogen 
washout and a significant reduction in the transfer factor for carbon monoxide.  
 
The severe asthma group demonstrated the presence of small airways 
dysfunction and indeed, the small airway function results were similar to those observed 
in COPD.  There was greater evidence of larger central airway obstruction and this 
observation is in keeping with the pathology of asthma, which affects all of the airways 
where COPD affects mainly the smaller peripheral airways. It was expected that 
measurements of exhaled nitric oxide (NO) would have been higher in the asthma 
group; however, due to the high use of inhaled corticosteroids in severe asthma, the 
exhaled NO was suppressed. In contrast, the mild-moderate asthma group had higher 
exhaled NO results most probably due to the lower use of inhaled corticosteroids. 
Spirometry was slightly better in mild-moderate asthmatics than in the severe asthma 
group, which would be expected, while single-breath transfer factor results were the 
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same. Lung volumes were similar between both asthma groups and there was no 
evidence of gas trapping in the asthmatics, as was seen in the COPD patients.  
 
Healthy smokers had results for spirometry, expiratory airway resistance and 
conductance that were worse than the healthy non-smoking group. This airflow 
limitation was associated with gas trapping within the lungs of the smoker and elevated 
ventilation heterogeneity in both conducting and acinar airways, suggesting the signs of 
early small airways dysfunction.  
 
Having determined the presence of small airways abnormalities in the patient 
groups, the longitudinal study in Chapter 5 demonstrated that all respiratory parameters 
remained stable over the 16 month period in all five groups; in particular, small airways 
dysfunction did not worsen over time. However, the parameters from tests where a vital 
capacity manoeuvre was required (forced spirometry, lung volumes and single-breath 
transfer factor) had a lower between visit variability, coefficient of variation (CoV), over 
the 16 months. In contrast, the parameters from tests where a vital capacity manoeuvre 
were not required (airway resistance, specific airway conductance, multi-breath nitrogen 
washout, impulse oscillometry, multiple expiratory flow nitric oxide) had a larger 
variability, between visit CoV, over the 16 months study period. So although there was 
no significant change in small (and large) airways tests over this period of time studied, 
there was greater variability in the small airways tests. Whether this represents 
underlying labile disease or a function of the test itself will require further study and is 
discussed next.   
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7.2.1 So, which test is best? 
It is really important to distinguish between the various tests of respiratory 
function (and inflammation) involving a vital capacity maneuver and those obtained 
during tidal breathing. Having monitored the respiratory function of adults with and 
without obstructive lung disease there still remains a need to evaluate the benefits of 
each test. Tests involving a vital capacity maneuver will not detect abnormalities that 
manifest early in lung disease. While the multi-breath nitrogen washout and impulse 
oscillometry may detect dysfunction arising from large and small airways, the best test 
has yet to be determined. Unlike spirometry further standardization of multi-breath 
washout tests are needed. However, since the original submission of this thesis a 
Consensus statement has been published (Robinson et al, 2013). No such consensus 
statement exists for impulse oscillometry. For this reason individual laboratories should 
generate their own data. Additionally studies comparing different types of equipment are 
warranted before multi-center studies are conducted. Recently Gonem et al (2014) also 
studied the variability of small and large airways parameters from multi-breath washout 
tests (using sulphur hexafluoride) and impulse oscillometry in asthmatics. They found 
that parameters from impulse oscillometry were more stable over time and between 
visits in comparison to multi-breath washout parameters. Horsley et al (2008) also found 
that Scond had poor within-visit test repeatability.  
 
The ideal test should be easy to perform, have a short duration of measurement, 
have low variability between differing equipment set ups and laboratories, and reliable 
predicted values should be available. The equipment shouldn’t be costly and should be 
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easy to operate. The outcome parameter(s) should be reproducible, have a low within-
test CoV, a low between test CoV, low inter-subject variability, and be related to the 
outcome of interest. 
 
7.3 Deposition of monodisperse aerosols in the lower airways; pharmacokinetics 
and small airway responses 
 
The final part of this thesis involved investigating how aerosol particle size of the 
inhaled corticosteroid, fluticasone propionate, affected drug deposition in the lungs of 
asthmatics through pharmacokinetics, together with an assessment of small airway 
response. The main aim of this Chapter was to determine if using smaller drug particles 
to target the deeper lung regions, could  potentially contribute to increased systemic 
side effects and a detrimental therapeutic ratio as a result of greater pulmonary 
absorption (pulmonary bioavailability).  
 
 Clinical studies investigating inhaled therapeutic drugs involve the physiological 
assessment of drug efficacy. Most of these physiological tests center on the large 
airways and most inhalers deposit drug within these large airways. Once inhaled 
aerosols have reached the lungs they may have a different fate dependent on 
characteristics such as particle size, inhalation flow, and the region of the lung in which 
they deposit. That is, smaller particles may result in increased plasma concentrations of 
the drug quicker than larger particles.  
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The results in Chapter 3 showed that smaller particles increased deposition 
distally down the airway towards the lung. This was observed in the models and 
asthmatics following inhalation. The final study in Chapter 6 was a continuation of the 
findings from Chapter 3. In this study asthmatics and healthy subjects inhaled a 
corticosteroid delivered as three separate monodisperse aerosols of the same particle 
sizes (1.5, 3, and 6 µm), as in the upper airway studies.  
 
Fluticasone propionate (FP) is a potent inhaled corticosteroid used in asthma and 
the pharmacokinetics of a therapeutic dose of 250 µg from a pMDI and a 50 µg dose 
from monodisperse aerosols was studied. The aerosol particle size was directly related 
to the increase of drug concentration in the plasma, in that the smaller the particle size 
of the aerosol the earlier it was detected in the plasma and the higher the peak 
concentration. The pMDI generated aerosols had  a wide particle size distribution 
(polydisperse spread of particles)  and it’s concentration-time profile curve almost 
matched that of the large 6 µm particles despite the differences in inhalation doses 
suggesting the aerosol behavior of the polydisperse pMDI was indeed like that of larger 
particles even though its MMAD (mass median aerodynamic diameter was ~2.8 
microns). That is the pMDI and larger particles would preferentially deposit in the larger 
airways and due to the low oral bioavailability of FP (~ <1%), the quantity of drug 
reaching the lungs would be lower than the actual ex-actuated dose. The bioavailability 
of FP became greater as particle size decreased.  
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Additionally in Chapter 6, tests of respiratory function and inflammation (that 
were investigated in Chapters 4 and 5) were performed at baseline and post treatment 
with FP. Multiple expiratory flow nitric oxide (NO) was used do differentiate airway 
inflammation arising from the larger airways (J’awNO) and smaller alveolar compartment 
(CalvNO). None of the particles had an effect on reducing inflammation, as measured by 
large and small airway compartment nitric oxide in the lung.  
 
Further work is required to establish a link between particle size and effects on 
inflammation arising from bronchial and alveolar airway compartments; specifically daily 
chronic treatment with these monodisperse aerosols or commercial inhalers, as 
opposed to single-dose therapy as undertaken in this study, could have resulted in 
reductions in exhaled NO and altered the pharmacokinetic concentration-time profiles. 
Importantly, such studies would also allow an assessment of the therapeutic ratio. 
Theoretically, a reduction in airway inflammation could increase the airway lumen and 
improve ventilation heterogeneity following chronic treatment. Improvements in 
parameters measured during the multi-breath nitrogen washout, particularly Sacin and 
Scond could then be linked to aerosol particle size. If ventilation heterogeneity becomes 
more uniform then the vital capacity and expiratory flow could increase. Establishing 
definitive associations between aerosol particle size and improvements in parameters 
that reflect large and small airway function and inflammation would provide valuable 
information on how to target therapy appropriately.  
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7.4 Limitations of studies 
 
7.4.1 Upper airway deposition 
 The main limitation of the experiments on upper airway models was the use of a 
simplified upper airway model with no realistic internal geometry or anatomical 
structures. The main limitation of the experiments in human subjects was the use of a 
two-dimensional imaging technique. The models were based on images taken in one 
individual performing an end expiratory breath-hold in the supine position. It is not 
known how much the end-inspiratory breath hold compensates for the gravitational 
forces while in the supine position. Additionally images should have been taken during 
expiration to construct models to be used in expiratory mode. The inclusion of realistic 
anatomical structures would yield better results for comparison to human experiments. 
Using two dimensional gamma-scintigraphy to quantify deposition in the human upper 
airway was incredibly difficult because there was no way to distinguish aerosol 
deposition in the esophagus from the trachea. Therefore the interpretation of results 
reported for tracheal deposition in asthmatics should be interpreted with care.  
 
7.4.2 Small and large airway respiratory function in obstructive lung disease  
Every attempt was made to maintain an equal number of participants in each 
group for every visit. The main limitation of this study was the drop-out rate and the 
relatively small number of patients studied particularly in the longitudinal group. Despite 
making every effort to contact participants via phone or letters they would either not 
respond, had changed their contact details, or had relocated. The second limitation of 
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this study was trying to test subjects at the same time of day proved difficult and the 
influence of any biological diurnal variation in physiological could not be excluded.  Our 
subjects were also intensively followed up by their clinical teams and their airway control 
rigorously monitored and the severe asthmatics in particular were treated with either 
oral corticosteroids and or high dose inhaled steroids that both have the ability to reach 
the small airways through systemic effects and as such, no change in small airway tests 
may have resulted from this. Indeed, the mild asthmatics had very good asthma control 
scores, and this may have also influenced the relatively stability of the small (and large) 
airway tests over the longitudinal study time course. Potentially, studying patients would 
have labile disease and prone to exacerbations (those that may have experienced more 
than one exacerbation in the previous year) may be a future group to study. Indeed, to 
this end it is reassuring to see that a large multicenter center global study with 
ATLANTIS (AssessmenT of smalL Airways involvemeNT In aSthma) (Postma et al, 
2015) will study over the course of one year 800 asthmatic subjects and 100 healthy 
controls at 5 visits where they will undergoing lung function (small and large airways), 
lung imaging, induced sputum, lung biopsy, nasal sampling and asthma  control 
questionnaires to determine the role of small airways dysfunction in the clinical 
manifestations of asthma.   
 
7.4.3 Deposition of monodisperse aerosols in the lower airways; 
pharmacokinetics and small airway responses  
The main limitation of this study was the use of a single- dose of treatment and 
50 µg dose of corticosteroid. While this was sufficient for the pharmacokinetic signal no 
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physiological response could be detected with such a small dose that may have been 
present with a higher dose and therefore give insight into the therapeutic ratio. Indeed, 
daily chronic treatment with the monodisperse particles or the use of commercial 
inhalers with different particle size characteristics (and hence deposition patterns), as 
opposed to single-dose therapy as undertaken in this study, could have resulted in 
reductions in exhaled NO and altered the pharmacokinetic concentration-time profiles.  
 
7.4.4 Statistical analysis 
In this thesis, corrections for multiple comparisons were not made. For this 
reason I am being cautious in the outcome of the results and am not over interpreting 
the findings. As an example of how to correct for multiple comparisons I will use the 
data from Chapter 4. In this chapter 35 statistical tests were performed on the 35 
normally distributed respiratory function parameters. To apply a Bonferroni correction, 
the critical value (alpha) for each statistical test is found by dividing the desired p value 
(0.05) by number of tests. In this example the critical value would be: 
0.05 / 35 = 0.001429 
or 0.001 when rounded up to 3 decimal points. Therefore for a statistical difference to 
be observed for each of these 35 parameters compared between 5 groups the p value 
must be <0.001.  
 
7.5 Future work and further projects 
The work in this thesis suggests exciting future avenues and directions. From 
Chapter 3, an observation I had was how investigating the volume and hence 
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morphology of the human upper airway changes in respect to both flow rate (various 
speeds from slow to fast) and flow direction (inhalation and expiration).  Accurate 
measurement of the volume changes would help in mimicking the real-life scenario and 
support the development of realistic upper airway models. Aerosol deposition could then 
be better studied in models that contain the internal geometry in respect to a specific 
flow rate and flow direction. Alternatively instead of using static models the construction 
of a dynamic model capable of all the volume changes observed in humans would be 
the ‘optimal’ goal however, and this could be achieved with dynamic magnetic 
resonance imaging (with the advantage of no ionizing radiation unlike three-dimensional 
computed tomography) of the upper airways linked with computational fluid dynamics to 
study aerosol transport and trajectory in the oropharynx. Additionally, the models could 
be refined to contain realistic anatomic features as these affect the internal volume and 
affect aerosol deposition, such as the larynx, vocal cords and epiglottis, and investigate 
how they change with direction of flow and whether this affects aerosol transport 
through the oropharynx into the lungs.  
 
Additional work was also started to explore commercial devices that generate 
aerosols with a smaller particle size and the physiological response in the large and 
small airways was investigated, to continue to investigate whether regional (large 
versus small) airways drug delivery as a function of particle size is important.  
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7.5.1 The effects of formoterol fumarate dihydrate versus salmeterol xinafoate on 
small airways parameters in chronic obstructive pulmonary disease  
From Chapters 4 and 5, having acquired the technical ability to use advanced 
physiological tests to assess small (and large) airways function, the natural progression 
would be to use these tests to see if they could distinguish effects between inhaled 
particles of different sizes. A study was started (Study ID: CCD-0901-PR-0012. 
ClinicalTrials.gov.Identifier: NCT01344655 and approved by the National Research 
Ethics Committee) comparing the effects of long-acting β2-agonists formoterol fumurate 
(Foradil) versus salmeterol xinafoate (Serevent) on small airway parameters in COPD, 
where long-acting inhaled β2-agonists were used as effective bronchodilation for 
controlling the symptoms of patients with COPD.  
 
Twelve COPD patients (stage I – III) were recruited and completed the study. 
Each patient attended a screening visit then three subsequent study visits where they 
were treated in a double-dummy fashion with either formoterol and placebo, salmeterol 
and placebo, or placebo and placebo. Vital signs, lungs volumes, airways resistance, 
impulse oscillometry, multi-breath nitrogen washout, and multiple expiratory flow nitric 
oxide were performed at baseline and up to 12 hours following treatments. The study 
has completed and the data is now being collated prior to analysis. 
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7.5.2 The clinical effect of inhaled fluticasone propionate delivered as 
monodisperse aerosols in asthma  
From Chapter 6, the question arose as to the pharmacodynamic effects of the 
different particle sizes of FP and specifically whether FP had the effect of reducing 
airway inflammation. In this respect a study was started (Study ID: CRO1694. 
ClinicalTrials.gov.Identifier: NCT01662778 and approved by the National Research 
Ethics Committee) to assess the preventative effect of FP (anti-inflammatory) on the 
airway exposure to the bronchoconstricting agent, adenosine monophosphate (AMP). 
The concentration of AMP required to provoke a drop in FEV1 by 20% (PC20) was used 
as the primary outcome.  
 
A single dose (50 micrograms) of FP from three separate monodisperse aerosols 
(1.5 and 6 µm) were delivered and a standard (250 microgram dose from a pMDI to 
assess the effect on the AMP challenge in patients with mild-moderate asthma. 
Simultaneously, pharmacokinetic assessments were also undertaken in this patient 
group together with markers of small airways inflammation. The study has completed 
and the data is now being collated prior to analysis.  
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